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1 Summary 
According to the World Health Organization (WHO) bacterial resistance to antibiotic drug therapy is 
emerging as a major public health problem around the world. Infectious diseases seriously threaten 
the health and economy of all countries. Hence, the preservation of the effectiveness of antibiotics is 
a world wide priority. The key to preserving the power of antibiotics lies in maintaining their diversity. 
Many microorganisms are capable of producing these bioactive products, the so called antibiotics. 
Specifically in microorganisms, polyketide synthases (PKS) and non-ribosomal peptide synthases 
(NRPS) produce these natural bioactive compounds. Besides being used as antibiotics these non-
ribosomal peptides and polyketides display an even broader spectrum of biological activities, e.g. as 
antivirals, immunosuppressants or in antitumor therapy. The wide functional spectrum of the peptides 
and ketides is due to their structural diversity. Mostly they are cyclic or branched cyclic compounds, 
containing non-proteinogenic amino acids, small heterocyclic rings and other unusual modifications 
such as epimerization, methylation, N‐formylation or heterocyclization. It is has been shown that these 
modifications are important for biological activity, but little is known about their biosynthetic origin. 
PKS and NRPS are multidomain protein assembly lines which function by sequentially elongating a 
growing polyketide or peptide chain by incorporating acyl units or amino acids, respectively. The 
growing product is attached via a thioester linkage to the 4’-phosphopantetheine (4’-Ppant) arm of a 
holo acyl carrier protein (ACP) in PKSs or holo peptidyl carrier protein (PCP) in NRPSs and is passed 
from one module to another along the chain of reaction centers. The modular arrangement makes 
PKS and NRPS systems an interesting target for protein engineering. More than 200 novel polyketide 
compounds have already been created by module swapping, gene deletion or other specific 
manipulations. Unfortunately, however, engineered PKS often fail to produce significant amounts of 
the desired products. Structural studies may faciliate yield improvement from engineered systems by 
providing a more complete understanding of the interface between the different domains. While some 
information about domain-domain interactions, involving the most common enzymatic modules, 
ketosynthase and acyltransferase, is starting to emerge, little is known about the interaction of ACP 
domains with other modifying enzymes such as methyltransferases, epimerases or halogenases. 
To further improve the understanding of domain-domain interactions this work focuses on the 
curacin A assembly line. Curacin A, which exhibits anti-mitotic activity, is from the marine 
cyanobacterium Lyngbya majuscula. This outstanding natural product contains a cyclopropane ring, a 
thiazoline ring, an internal cis double bond and a terminal alkene. The biosynthesis of curacin A is 
performed by a 2.2 Mega Dalton (MDa) hybrid PKS-NRPS cluster. A 10-enzyme assembly catalyzes 
the formation of the cyclopropane moiety as the first building block of the final product. Interestingly, 
for these enzymes the substrate is presented by an unusual cluster of three consecutive ACPs 
(ACPI,II,III). Little is known about the function of multiple ACPs which are supposed to increase the 
overall flux for enhanced production of secondary metabolites.  Summary 
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The first task in this work was to elucidate the structural effect of the triplet ACP repetition by 
nuclear magnetic resonance (NMR). The initial data show that the excised ACPI, ACPII or ACPIII 
proteins resulted in [
15N, 
1H]-TROSY spectra with strong chemical shift perturbations (CSPs), 
suggesting an effect on the structure. The triplet ACP domains display a high sequence identity (93- 
100%) making structural investigation using usual NMR techniques due to high peak overlap 
impossible. To enable the investigation of the triplet ACP in its native composition we developed a 
powerful method, the three fragment ligation. Segmental labeling allows incorporating isotopes into 
one single domain in its multidomain context. As a result we could prepare the triplet ACP with only 
one domain isotopically labeled and therefore assign the full length protein. In this way our method 
paved the way to study the structural effects of the triplet ACP repetition. We could show 
unexpectedly, that, despite the fact that the triplet repeat of CurA ACPI,II,III has a synergistic effect in 
the biosynthesis of CurA, the domains are structurally independent. 
In the second part of this work, we studied the structure of the isolated ACPI domain. Our results 
show that the CurA ACPI undergoes no major conformational changes upon activation via 
phosphopantetheinylation and therefore contradicts the conformational switching model which has 
been proposed for PCPs. Further we report the NMR solution structures of holo-ACPI and 3-hydroxyl-
3-methylglutaryl (HMG)-ACPI. Data obtained from filtered nuclear overhauser effect (NOE) 
experiments indicate that the substrate HMG is not sequestered but presented on the ACP surface.  
In the third part of this work we focussed on the protein-protein interactions of the isolated ACPI 
with its  cognate interaction  partners. We were especially interested in the interaction with the 
halogenase (Cur Hal), the first enzyme within the curacin A sub-cluster, acting on the initial hydroxyl-
methyl-glutaryl (HMG) attached to ACPI. Primarily we studied the interaction using NMR titration and 
fluorescence anisotropy measurements. Surprisingly no complex between ACPI and Cur Hal could be 
detected. The combination of an activity assay using matrix-assisted laser desorption/ionization 
(MALDI) mass spectroscopy and mutational analysis revealed several amino acids of ACPI that 
strongly decrease the activity of CurA Hal. Mapping these mutations according to their effect on the 
Cur Hal activity onto the structure of HMG-ACPI displays that these amino acids surround the 
substrate and form a consecutive surface. These results suggest that this surface is important for Cur 
Hal recognition and selectivity. Our research presented herein is an excellent example for protein-
protein interactions in PKS systems underlying a specific recognition process. Zusammenfassung 
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2 Zusammenfassung 
 
„Strukturelle und funktionelle Charakterisierung des dreifachen „Acyl Carrier Proteins“ in 
Curacin A sowie dessen Protein-Protein Interaktionen“ 
 
Ziel dieser Arbeit ist es, die strukturelle Bedeutung einer ungewöhnlichen dreifachen Wiederholung 
von Acyl Träger Proteinen (von englisch acyl carrier Protein, ACP) am C-Terminus des Proteins CurA 
zu beschreiben. Auf der Basis dieser strukturellen Studie wurden des Weiteren die molekularen 
Mechanismen untersucht, die den Interaktionen zwischen den ACPs sowie deren Proteininteraktionen 
mit anderen Proteinen zugrunde liegen.  
 
Nach Angaben der Weltgesundheitsorganisation (WHO) ist die steigende Resistenz von 
Krankheitserregern  gegenüber Antibiotika ein zunehmendes Problem. Infektiöse Krankheiten sind 
eine Gefahr für die Gesundheit der Bevölkerung, zusätzlich ist zu Bedenken, dass durch die 
Behandlung und Bekämpfung dieser infektiösen Krankheiten nicht zu vernachlässigende Kosten 
entstehen. Aus diesem Grund ist es von großer Bedeutung, die Wirksamkeit von Antibiotika zu 
erhalten. Der Schlüssel zum Erhalt der Wirksamkeit liegt in der Vielfalt der auf dem Markt 
existierenden Antibiotika. Viele Mikroorganismen sind fähig, diese niedermolekularen 
Stoffwechselprodukte, wie Peptide oder Polyketide, herzustellen. Die Biosynthese wird von 
Megasynthetasen durchgeführt, genauer gesagt von nichtribosomalen Peptidsynthetasen (NRPS) 
oder Polyketidsynthetasen (PKS). Die entstehenden Moleküle besitzen oftmals neben ihrer anti-
bakteriellen auch antivirale oder immununterdrückende Wirkung. Des Weiteren konnten einige dieser 
Peptide oder Polyketide, da sie die unkontrollierte Zellteilung hemmen, als potentielle Medikamente in 
der Krebstherapie gehandelt werden. Das große Wirkungsspektrum dieser biologischen Substanzen 
lässt sich durch ihre strukturelle Vielfalt erklären. Überwiegend sind diese Substanzen zyklisch oder 
besitzen Verzweigungen mit zyklischen Komponenten. Hinzu kommt, dass sie eine Vielzahl 
ungewöhnlicher und nichtproteinogener Aminosäuren synthetisieren und einbauen können. Viele 
dieser Peptide oder Ketide werden zusätzlich modifiziert. So finden zum Beispiel Epimerisierungen, 
Methylierungen, N-Formylierung und Heterozyklisierungen statt. Es wurde gezeigt, dass 
insbesondere diese ungewöhnlichen Modifizierungen oftmals für die Wirkung verantwortlich sind. 
Nichtribosomale Peptidsynthetasen (NRPS) sowie Polyketidsynthetasen (PKS) sind lange 
Produktionsmaschinerien, die aus verschiedenen katalytischen Domänen zusammengesetzt sind. 
Dabei ergeben mehrere Domänen ein Modul, welches für den Einbau einer Aminosäure im Falle der 
NRPS beziehungsweise kurzkettiger Carbonsäuren bei den PKS zuständig ist. Das spätere Produkt 
wird so nach und nach iterativ zusammengesetzt. Im Zentrum dieser Synthese steht das Peptid 
Träger Protein (aus dem englischen peptidyl carrier Protein, PCP) bei nichtribosomalen Zusammenfassung 
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Peptidsynthetasen oder das ACP bei Polyketidsynthetasen. An dieses kleine Protein (10 kilo Dalton 
(kDa)) ist das wachsende Syntheseprodukt über einen Thioester an den Kofaktor 
4’-Phosphopantethein kovalent gebunden. Das mit dem Kofaktor beladene ACP oder PCP wird als 
holo ACP/PCP bezeichnet und die mit Substrat beladenen Proteine als Acyl-ACP oder Peptidyl-PCP. 
Durch die Bindung des Substrates an den Kofaktor ist das wachsende Peptid oder Polyketid für 
andere Proteine leichter zugänglich und kann den jeweils aktiven Zentren der verschiedenen Enzyme 
für Modifizierungen oder zur Kettenverlängerung präsentiert werden. Das ACP übernimmt hierbei 
vermutlich die räumliche und zeitliche Koordination der Protein-Protein-/Substrat-Interaktion. Der 
modulare Aufbau von nichtribosomalen Peptid- und Polyketid-Synthetasen macht sie zu höchst 
interessanten Zielen für das Chemieingenieurwesen. Mehr als 200 neue Moleküle konnten bisher 
hergestellt werden, indem Module entfernt, ausgetauscht oder auf andere Art und Weise verändert 
wurden. Dennoch scheitert die Produktion dieser gewünschten Substanzen im großen Maßstab 
oftmals an der geringen Ausbeute. Aus diesem Grund ist es von großem Interesse, die von ACPs 
eingegangenen Protein-Protein Interaktionen, die der Biosynthese zu Grunde liegen, zu verstehen. 
Erst durch dieses Verständnis wird eine künstliche Veränderung der bestehenden Megasynthetasen, 
die dessen Produktivität erhöhen könnte, ermöglicht. In den letzten Jahren lieferten biochemische und 
strukturelle Untersuchungen immer mehr Erkenntnisse über die Funktionsweise und gegenseitige 
Erkennung verschiedener katalytischer Domänen in NRPS und PKS. Dazu gehören erste 
Erkenntnisse über die Interaktionen von ACPs mit den häufigsten Interaktionspartnern wie 
Acyltransferasen und Ketosynthetasen, beziehungsweise deren Pendants in den nichtribosomalen 
Peptidsynthetasen. Dennoch ist bis jetzt nur wenig bekannt über Protein Interaktionen mit den 
selteneren aber wichtigen Enzymen wie Methyltransferasen, Epimerasen oder Halogenasen, die 
essentielle Veränderungen vornehmen.  
 
Um gerade diese Interaktionen besser zu verstehen, wurde in dieser Arbeit eine NRPS/PKS 
Hybrid-Megasynthetase untersucht, die Curacin A herstellt. Curacin A ist eine biologische Substanz, 
die aus dem maritimen Cyanobakterium Lyngbya majuscula gewonnen wurde. In Experimenten 
zeigte diese Substanz die Inhibition von ungehemmter Zellteilung, eine Aktivität, die Curacin A zu 
einem potentiellen Krebsmittel macht. Die Wirkweise von Curacin A ist auf einige besondere 
strukturelle Eigenarten wie den Cyclopropanring, den Thiazolinring, eine interne Cis-C-C-
Doppelbinding sowie ein terminales Alken zurückzuführen. Zu Beginn der Biosynthese von Curacin A 
stehen 10 verschiedene Enzyme, die für die Herstellung des Cyclopropanrings in Curacin A 
verantwortlich sind. Diese 10 Enzyme sind in den Proteinen CurA bis CurF präsent. Je nach 
katalytischer Funktion können sie in drei Untergruppen unterteilt werden. Die Erste Gruppe besteht 
aus der Halogenase Cur Hal, welche in das Protein CurA eingebettet ist. Die zweite Gruppe ist die 
Hydroxymethyl-glutaryl (HMG) Kassette und umfasst eine dreifache ACP Widerholung am 
C-terminalen Ende von CurA (ACPI,II,III), ein einzelstehendes ACP (CurB), ein Ketosynthetase (KS) Zusammenfassung 
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ähnliches Enmzym bezeichnet als CurC, ein HMG-Synthetase-(HCS) ähnliches Enzym CurD, die 
Dehydratase ECH1 (CurE) und eine Decarboxylase ECH2 am C-terminalen Ende von CurF. Der letzte 
Schritt der Cyclopropanbildung wird durch die als drittes zu benennende Komponente, die Enoyl-
Reductase (ER), eingebettet in CurF katalysiert. Interessanterweise agieren all diese Enzyme, 
während das Substrat an die ungewöhnliche dreifach Wiederholung von ACPs am C-terminus von 
CurA gebunden (ACPI,II,III) ist. Bisher ist wenig über solche multiplen ACPs bekannt, jedoch wurde 
kürzlich gezeigt, dass sie die Effizienz der aneinandergekoppelten enzymatischen Schritte zur 
Cyclopropanbildung erhöhen. 
  
Im ersten Teil dieser Doktorarbeit wurde untersucht, welchen strukturellen Einfluss die ACPs 
innerhalb der dreifachen Wiederholung (ACPI,II,III) gegenseitig auf sich ausüben. Zu diesem Zweck 
wurden zunächst [
1H,
15N]-TROSY-HSQC Spektren von ACPI,II,III sowie den isolierten ACPs 
aufgenommen. Die Isolierung jeder Domäne, ob ACPI, ACPII oder ACPIII hatte starke Veränderungen 
der chemischen Verschiebungen in den HSQC Spektren zur Folge. Solche chemischen 
Verschiebungen können auf eine Veränderung der Struktur hindeuten. Dadurch, dass die dreifachen 
ACPs sich in ihrer Sequenz nahezu identisch sind (95-100%), wurde eine strukturelle Untersuchung 
des nativen, dreifachen ACPs mit den gängigen Kernspinresonanz-Methoden (von engl. nuclear 
magnetic resonance, NMR) aufgrund des ausgeprägten Signalüberlapps unmöglich. Aus diesem 
Grund wurde im Rahmen dieser Arbeit mit der segmentellen Isotopenmarkierung (aus dem 
englischen von segmental labeling) eine neue Methode entwickelt, die es ermöglicht, die dreifachen 
ACPs in ihrer natürlichen Umgebung zu untersuchen. Die segmentelle Isotopenmarkierung erlaubt 
es, Isotope in nur ein Segment, zum Beispiel eine Domäne eines Proteins, einzubauen. Dies 
geschieht, indem man das Zielprotein in zwei Fragmente teilt. Jedes Fragment wird mit einem Intein 
fusioniert. Die so entstandenen Proteinkonstrukte können getrennt exprimiert und unterschiedlich 
markiert werden. Wenn man die so erhaltenen Proteine nun wieder zusammenfügt erkennen sich die 
Inteinesequenzen und schneiden sich selbst, unter der Ausbildung eines natürlichen Peptidbindung, 
autokatalytisch herraus. Bisher wurde die segmentelle Isotopenmarkierung nur auf Proteine mit zwei 
Domänen angewendet. In dieser Arbeit wurde das Protokoll auf Proteine mit drei Domänen 
ausgeweitet. Das entwickelte Protokoll ermöglichte es uns, jedes ACP der dreifachen ACP 
Widerholung (ACPI,II,III) einzeln mit Isotopen zu kennzeichnen, ohne es aus seinem native 
Zusammenhang zu isolieren. Auf diese Art und Weise konnte letztendlich ACPI,II,III trotz der zuvor 
hohen Signalüberlappung, zugeordnet werden. Durch diese Zuordnung wurde es möglich zu 
erkennen, dass die starken chemischen Verschiebungen, die mit der Isolierung einer Domäne 
einhergehen, sich nur auf den N- und C-Terminus beschränken und nicht wie zunächst angenommen 
eine Veränderung der ACP Struktur indizieren.  Unerwarteter Weise konnten wir auf diese Art zeigen, 
dass, obwohl die ACPs einen synergistischen Effekt haben, sie sich dennoch strukturell voneinander 
unabhängig verhalten. Zusammenfassung 
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Durch die Tatsache das sich die ACPs voneinander unabhängig verhalten, konnten wir unsere 
strukturellen Studien im zweiten Teil dieser Arbeit auf ein ACP (ACPI) als Repräsentanten 
fokussieren. Zunächst wurde die de novo Struktur von holo-ACPI mit NMR bestimmt. Von der Frage 
getrieben, ob das ACP durch die Aktivierung mit dem 4’-Phosphopantethein-Arm einen 
konformationelle Veränderung durchläuft, wurden Kern-Overhauser-Effekt (engl. nuclear Overhauser 
effect, NOE) Messungen von apo ACP und holo ACP durchgeführt. Der Vergleich der beiden 
Spektren zeigt, dass das Protein keine strukturellen Veränderungen durch die Aktivierung durchläuft. 
Somit ist das Modell der strukturellen Veränderung, welches besagt, dass mit der Aktivierung des 
ACPs einhergehende konformationelle Veränderungen neue Protein-Protein-Interaktionen 
begünstigen, nicht auf die hier untersuchten ACPs anwendbar. Um die Lokalisierung des Substrats zu 
bestimmen, wurde 
15N/
13C-isotopenmarkiertes ACPI  in vitro mit dem unmarkierten Substrat 
Hydroxymethyl-glutaryl (HMG) beladen. Durch verschiedene NOE Filterexperimente konnten 
Distanzinformationen für das Substrat erhalten werden und ermöglichten so eine Strukturberechnung 
von HMG-ACPI. Die Ergebnisse zeigen, dass das Substrat HMG nicht in einer hydrophoben Tasche 
gebunden sondern auf der Oberfläche des ACP präsentiert wird. 
 
Der letzte Teil dieser Arbeit befasst sich tiefgehender mit den verschiedenen 
Proteininteraktionen, die CurA ACPI ausübt. Die verschiedenen Enzyme (AT-KS Didomäne (CurA), 
Cur Hal (CurA), ACP (CurB), KS (CurC), HCS (CurD), ECH1(CurE) und ECH2 (CurF)) wurden 
exprimiert und im Falle von geringer Löslichkeit umkloniert und so mit Löslichkeit verstärkenden 
Proteinen (Ubiquitin (Ub), Maltose bindendes Protein (MBP)) fusioniert. Daraus resultierend stand uns 
ECH1 für biochemische Studien und Cur Hal und ECH2 für strukturelle und biochemische Studien zur 
Verfügung. Weder in NMR-Titrationen noch in Fluoreszenzanisotropiemessungen von ACPI mit ECH2 
war eine spezifische Bindung der Proteine detektierbar. Im weiteren Verlauf der Protein-Protein-
Interaktionsstudien lag insbesondere der Fokus auf der Interaktion zwischen ACPI und der 
Halogenase Cur Hal. Cur Hal katalysiert die Chlorierung von 3-Hydroxy-3-Methyl-Glutaryl (HMG) 
welches eine der Ersten von einer Folge von Enzymreaktionen katalysiert, die zur Bildung des 
Cyclopropanrings führen. Es wurde bewiesen, dass Cur Hal nur die Chlorierung von HMG katalysiert, 
wenn dieses an eins der ACPs im Trippel ACP gebunden ist.  Zunächst wurde in dieser Arbeit diese 
Interaktion mit NMR und Fluoreszenz Anisotropie untersucht. Allerdings konnte auf diese Art und 
Weise keine Komplexbildung zwischen den Proteinen festgestellt werden. Die Kombination eines 
Aktivitätstests zusammen mit Massenspektrometrie-Untersuchungen ermöglichte es zu zeigen, dass 
Cur Hal in der Tat keine Chlorierung von HMG vornimmt, wenn dieses an CurB ACP oder TycB1 PCP 
gebunden ist, sondern nur, wenn es von einem ACP des Trippel ACP (ACPI,II,III) präsentiert wird. 
Darauf folgend wurden verschiedene Mutanten von ACPI hergestellt, um die Interaktionsfläche der 
beiden Proteine zu bestimmen. Mittels Massenspektrometrie konnten mehrere ACPI Mutanten Zusammenfassung 
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gefunden werden, die die Aktivität der Halogenase (Cur Hal) stark beeinträchtigen. Die Ergebnisse 
zeigen, dass in erster Linie Helix II sowie Helix III von ACPI für dessen Erkennung durch Cur Hal 
wichtig sind.Bei der Kennzeichnung dieser Mutationen auf der zuvor gelösten Struktur von HMG-
ACPI, zeigte sich, dass das Substrat zusammen mit den für die Interaktion wichtigen Aminosäuren 
eine gemeinsame Oberfläche bildet. Zusätzlich konnte gezeigt werden, dass die mangelnde 
Interaktion nicht durch eine veränderte Lokalisierung des Substrats, sondern tatsächlich durch die 
Veränderung der Oberfläche ausgelöst wird. 
 
Zusammengefasst konnte in dieser Arbeit zum Einen ein erfolgreiches Protokoll für die 
segmentelle Dreifragment Isotopenmarkierung erstellt werden, einer Methode, die es ermöglicht, 
auch andere Proteine in ihrer nativen Umgebung zu studieren. Des Weiteren war es uns möglich zu 
zeigen, dass die Oberfläche des ACPs zusammen mit dem Substrat HMG ist für die Erkennung durch 
Cur Hal wichtig ist. Die in dieser Arbeit gewonnenen Daten zeigen, dass die HMG-ACPI/Hal 
Interaktion in der Curacin A Synthetase auf der Basis von spezifischen Erkennungsprozessen 
stattfindet. Dies ist ein weiteres Beispiel dafür, dass die Protein-Protein Interaktionen in PKS und 
NRPS sehr komplexen und spezifischen Erkennungsprozessen unterliegen.  
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3 Abbreviations 
°     degree 
∞     forever 
µ     micro 
α     alpha 
A     ampère 
Ǻ     angstrom,  1  Ǻ = 100pm= 1×10
-10 m 
aa     amino  acid(s) 
AcP     acetyl  phosphate 
ACP      acetyl carrier protein 
ACPS    acetyl carrier protein synthase 
App.     appendix 
APS     ammoniumperoxodisulfate 
AT     acyl  transferase 
ATP     adenosine  triphosphate 
bp     base  pairs 
β     beta 
BSA      bovine serum albumin 
c     concentration 
C     celsius 
CD     circular  dichroism 
CE-CF   continuous-exchange  cell-free 
CF     cell-free 
CoA     coenzymeA 
CV     column  volume 
Da     dalton 
DEBS  6-deoxyerythronolide  B  synthase 
DH     dehydratase 
DMSO   dimethyl  sulfoxide 
DNA     desoxyribonucleinacid 
dNTP    desoxyribonucleitriphosphate 
DTT     dithiothreitol 
E. coli  Escherischia coli 
ECH1     dehydratase 
ECH2     decarboxylase 
EDTA  ethylenediaminetetraacetic  acid 
e.g.     for  example 
EM     electron  microscopy 
ER     enoylreductase 
ESI     electrospray  ionisation 
et al.     and others 
EtBr     ethidium  bromide 
FAS      fatty acid synthases 
Ferene S     3-(2-pyridyl)-5,6-bis(2-(5-furyl sulfonicacid))-1,2,4-triazine 
FM     feeding  mix 
FPLC      fast performance liquid chromatography 
Frct.     fraction 
g     gram 
h     hour(s) 
Hal     halogenase 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic  acid 
HMG     3-hydroxy-3-methylglutaryl coenzymeA 
HPLC    high performance liquid chromatography 
HSQC    heteronuclear single quantum coherence Abbreviations 
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IDA     iminodiacetic  acid 
IMAC     immobilized metal affinity chromatography 
IPTG     isopropyl-β-D-thiogalactopyranosid 
α-KG     alpha-ketoglutarate 
KS     ketosynthase 
L     liter(s) 
LB     Luria-Bertani 
m     milli 
M     molar  (mol/L) 
MALS    multi angle light scattering 
MALDI    matrix-assisted laser desorption/ ionization  
MBP     maltose binding protein 
MS     mass  spectrometry 
mdeg     millidegree 
mg     milligram(s) 
min     minute 
mL     milliliter(s) 
MW     molecular  weight 
MWCO    molecular weight cut-off 
n     nano 
Ni-NTA   nickel-nitrilotriacetic  acid 
nL     nanoliter(s) 
nm     nanometer 
NMR     nuclear magnetic resonance 
NRP     non ribosomal peptide 
NRPS    non ribosomal peptide synthases 
NTP     nucleotide  triphosphate 
ON     over  night 
PPT     pellet 
PAGE    polyacrylamide gel electrophoresis 
PCR     polymerase chain reaction 
PEP     phosphoenol  pyruvate 
PK     polyketide 
PKS     polyketide  sunthetase 
RM     reaction  mix 
RNA     ribonucleic acid 
4’- Ppant    4’- phosphopanthetheinyl 
ppm      parts per million 
PPTase   phosphopantetheineyl  transferase 
PK     polyketide 
PKS     polyketidesynthetases 
rpm      round per minute 
RT     room  temperature 
s     second 
S     supernatant 
SEC      size exlusion chromatography 
SDS     sodium  dodecylsulfate 
SNT     supernatant 
Srf     surfactin 
ST     sulfotransferase 
T      thiolation domain stands for ACPs and PCPs 
T7RNAP    T7 RNA polymerase 
TCEP  tris-(2-carboxyethyl)phosphine  hydrochloride 
TE     thioesterase 
TE II     thioesterase II 
Tris     tris-(hydroxymethyl)methylamine Abbreviations 
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Triton X-100  polyethylene-glycol P-1,1,3,3- tetra-methyl-butylphenyl-ether 
tRNA     transfer RNA 
Tween 20    polyoxyethylene-sorbitane-monolaurate 20 
Tyc     tyrocidin 
Ub     ubiquitin 
Ulp1      ubiquitin-like protein specific protease 1 
WHO     world health organization 
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4 Introduction 
Bacterial resistance to antibiotic drug therapy is emerging as a major public health problem 
around the world. Hence infectious diseases seriously threaten the health and economy of all 
countries, the preservation of the effectiveness of antibiotics is a world wide priority [2, 3]. The 
key to preserve the power of antibiotics lies in maintaining their diversity. The ability to 
synthesize such nonribosomal or polyketide compounds is widely spread among 
microorganisms and these small bioactive compounds find application in modern medicine. As 
broad as the spectrum of biological activities, is the structural diversity of these peptides and 
ketides (Fig. 1), which are mostly cyclic or branched cyclic compounds, containing non-
proteinogenic amino acids, small heterocyclic rings and other unusual modifications such as 
epimerization, methylation, N‐formylation. 
 
Fig. 1: Polyketide compounds and their function (picture from http://linux1.nii.res.in/~pksdb/polyketide.html). 
These bioactive compounds are synthesized using polyketide synthases (PKSs) and 
nonribosomal peptide synthases (NRPSs). In these enzymes that are organized in large 
modular assembly lines each module incorporates a given monomer unit into the growing chain. 
This modular architecture is ideally suited for creating new assembly lines, producing new 
complex molecules with potential antibiotic, anti-cancer or anti-inflammatory functions. Actually, 
over two hundred novel polyketide compounds have been created by modul swapping, gene 
deletion or other specific manipulations; unfortunately engineered polyketide synthases (PKS) 
or nonribosomal peptide synthases (NRPSs) often fail to produce significant amounts of the 
desired products [4-6]. These results show that reengineering requires a detailed knowledge of 
the interaction between the individual domains. Recent investigations suppose that dynamic Introduction 
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processes and conformational switches play important roles for the communication between 
domains in nonribosomal pepdide synthases (NRPS) [7]. 
Decreasing effectiveness of antibiotics-  The introduction of antibiotics into medical 
practice in the 1940s revolutionized human’s ability to cure infectious diseases. Since their 
discovery, antibiotics have been extensively used for more than half a century in human and 
animal therapy and as animal growth promoters. Because each application of antibiotics 
inevitably selects for resistant bacteria, insensitive strains become more and more of a problem, 
especially pathogenic germs acquiring multiple resistances. Resistant strains were found 
against several antibiotics that are commonly used. According to the world health organization 
(WHO), in the last quarter of the last century organisms including Haemophilus influenzae and 
agents of sexually-transmitted infections, such as Neisseria gonorrhoeae, have emerged as 
worldwide multidrug-resistant threats. In the struggle of raising resistance, some antibiotics like 
vancomycin were regarded as last-resort antibiotics being efficient against already resistant 
pathogens like methicillin resistant Staphylococcus aureus strains. But the appearance of 
vancomycin-resistant  Staphylococcus aureus in 1986 has raised concerns that even 
industrialized countries may be losing this antibiotic of last resort [8]. The only possibility to 
overcome the increasing number of resistant strains is the development of new agents with 
combinatorial diversity. Nevertheless, the number of new antibiotics introduced on the market 
decreased dramatically [9, 10]. Both trends: the increasing pathogen resistance and the decline 
in new agents necessarily require reinforced efforts to discover and develop new antibiotics. 
Natural antibiotics, important elements of modern medicine- The ability to synthesize 
polyketides (PK) and nonribosomal peptides (NRP) that find application in modern medicine is 
widely spread among microorganisms. In organic chemistry these biosynthetic reactions are 
either too difficult, with low efficiency or too expansive to realize. To conclude: naturally 
occurring antibiotics have benefits due to structural features rarely found in synthetic libraries. 
Biochemical and genetic studies have unveiled the key principles of those nonribosomal peptide 
synthases (NRPS) and polyketide synthases (PKS). The modular organization of NRPSs and 
PKSs offers possibilities for a rearrangement of the biosynthetic pathways and therefore the 
possibility of new antibiotic biosynthesis [11]. Introduction 
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4.1  The polyketide synthases (PKS) 
4.1.1 Definition PKS I, II and III 
The main domains in the PKS systems are the acyl carrier protein (ACP) or also called 
thiolation (T) domain, the acyl transferase domain (AT domain) and the ketosynthase domain 
(KS domain) which compose all together one minimal module and are responsible for the 
elongation of the growing acyl chain by one acylunit per module [12]. The mechanism and 
function of each domain will be described in detail later on (4.1.3). In the Type I PKS system 
these domains are connected in cis, the 6-deoxyerythronolide B synthethase (DEBS) is one of 
the best studied examples for the PKS I system. PKS I systems typically have one module for 
each round of chain elongation and modification. According to this definition, all so far 
characterised NRPS systems can be classified into Type I [13]. The Type II PKS systems have 
catalytic domains and carrier proteins on separate units, they interact in trans. Furthermore, 
there exists only one acyl carrier protein (ACP), one acyl transferase (AT) domain, and one 
ketosynthase (KS) domain which catalyze the elongation of the substrate in consecutive rounds. 
The chain grows then by two or three carbons in each cycle, tethered to the same ACP. KS and 
AT act then iteratively [14]. Some Type II PKSs in Streptomyces species are for example: 
actinorhodin, oxytetracycline, granaticin, frenolocin B [15]. Historically, those free standing 
ACPs were first detected in bacterial type II FAS (e.g. Escherichia Coli). Type III PKSs differ 
from Type I and II by their choice of substrate. They use acyl-coenzymeAs (acyl-CoAs) as 
activated monomers rather than acyl-S-pantetheinyl-ACP [16]. One example of a Type III PKS 
is the enzyme DpgA, which uses four malonyl-CoA molecules to produce 
3,5-dihydroxyphenylacetyl-CoA (DPA-CoA) in the biosynthetic pathway to 
3,5-dihydroxyphenylglycine (3,5-Dpg) for chloroeremomycin assembly [17]. This work focuses 
especially on the PKS I system. 
4.1.2 General mechanism of biosynthesis 
PKS are multimodular enzymatic assembly lines of a remarkable size up to 2 MDa [18]. Among 
several characterized PKSs, the 6-deoxyerythronolide B synthase (DEBS) has provided the 
paradigm for understanding the structure and function of the PKSs that are responsible for 
assembling complex polyketides [19]. In the PKS I assembly line each module incorporates one 
acyl unit into the growing acyl chain. Therefore the modules are also called extender modules. 
6-deoxyerythronolide B synthase (DEBS) catalyzes the formation of 6-deoxyerythronolide 
(6-dEB). It consists of six of these extender modules. They are organized in doublets of 
extender modules in three large subunits with molecular weights above 300 kDa, called DEBS1, 
DEBS2 and DEBS3 (Fig. 2). Each extender module contains at least three essential domains: 
the 45 kDa ketosynthethase (KS) domain, the 50 kDa acyl transferase (AT) domain and the Introduction 
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10 kDa acyl carrier protein (ACP) also called thiolation (T) domain. The acyl transferase (AT) 
and ketosynthethase (KS) domains are the two catalytically active core domains. The AT 
domain selects the acyl units (either malonyl-CoA or methylmalonyl-CoA) as substrate and 
transfers the C3 or C4 acyl group to the ACP domain [20] (Fig. 2). 
 
Fig. 2: Illustration of the 6-deoxyerythronolide B synthase (DEBS) PKS from the erythromycin biosynthetic 
pathway. DEBS is responsible for generation of the aglycone 6-deoxyerythronolide B (6-DEB). The domains are 
labeled according to the following abbreviations: Loading domain (LDD), Acytranferase (AT), Ketosynthase (KS), 
Acetyl Carrier Protein (ACP), Ketoreductase (KR), Dehydratase (DH), Enoylreductase (ER) and Thioesterase (TE) 
(from [21]).  
The ACP needs to be post-translationally modified to be activated. Therefore the 
phosphopantetheinyl transferase (PPTase) attaches the cofactor 4’-phosphopantetheinyl 
(4’-Ppant) – which derives from coenzymeA (CoA) - to a highly conserved serine. After 
modification the ACP is transformed from its inactive “apo” to its active “holo” form [22] (Fig. 3). 
 
Fig. 3: Posttranslational modification of the ACP by the phosphopantetheineyltransferase (PPTase). Enzymes 
of this family transfer the phosphopantetheine (4’-Ppant) from coenzyme A (CoA) to a conserved serine of the ACP 
domain [22] (picture from [12]).  
Substrates and intermediate acyl chains are then covalently linked to the thiolgroup of the 
4’-phosphopantetheinyl (4’-Ppant) arm of the holo ACP, a reaction catalyzed by the AT domain. Introduction 
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The KS forms the C-C bond between the acyl groups bound to the up- and downstream located 
ACP. Therefore it elongates the growing acyl chain by two or three carbons [12]. 
4.1.3 Mechanism 
The chain elongation 
Polketides display a remarkable structural and functional diversity with respect to just a few 
simple building blocks: acyl-coenzymeA (acyl-CoA) thioesters such as acetyl-CoA, 
malonyl-CoA, methylmalonyl-CoA that derive from the pool of primary metabolites. The 
information for the polyketide product is encoded in the number, identity, and order of protein 
modules in the assembly line. The modules determine the monomers that are incorporated and 
the order in which they are condensed. The AT domain selects the appropriate carbon extender 
unit and transfers the units from acyl-CoA onto the phosphopantetheine (4’-Ppant) arm of the 
ACP (Fig. 4). This transthiolation step activates the substrate and is essential before any 
condensation can occur. Only starter units differ from the basic extender units, they can be as 
well the thioesters of propionyl-, and benzoyl-CoAs, or structural variants, such as malonamyl-
CoA or methoxymalonyl-CoA [12].  
 
Fig. 4: The acyltransfer (AT) domain activity. During PK biosynthesis, the acyltransferase (AT) selects the 
appropriate acyl unit and transfers it to the ACP domain, leading to acyl-S-ACP (adapted from [12]). 
The KS has two neighboring ACP domains, one upstream and one downstream. The acyl chain 
from the upstream located ACP domain gets transferred to a conserved serine of the KS 
domain [12, 23]. In the mean time the KS decarboxylates the (methyl)-malonyl thioester of the 
downstream ACP to yield the stabilized C2-carbanion (thioester enolate). The carbanion then 
attacks as a nucleophile in a claisen condensation the acyl-S-group which is bound via the 
serine-thiol to the KS (Fig. 5). The timed decarboxylation of the (methyl)-malonyl 
C3-carboxylate renders the C-C bondforming step irreversible. In this way in PKS the chain 
elongation is performed [12].  
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Fig. 5: The ketosynthase (KS) domain activity. During PK biosynthesis, decarboxylation of the downstream 
(methyl)-malonyl-S-ACP yields a nucleophilic thioester enolate. This attacks the upstream acyl-S-ACP thioester in a 
claisen condensation to form a C-C bond (adapted from [12]).  
Further modifying enzymes 
A deeper look at the DEBS (Fig. 2) biosynthesis uncovers further optional tailoring domains, 
including ketoreductases (KRs), dehydratases (DHs), and enoyl reductases (ERs). These 
domains act in the well established order KR  DH  ER. The tandem action of these three 
domains can perform the four electron reduction of β-C=O to the β-CH2. The individual steps 
are the processing of the extender unit from a β-ketoacyl-S-ACP to yield a 
β-hydroxyacyl-S-ACP (KR action), followed by hydration to α, β-enoyl-S-ACP (DH action) and 
further on reducing to a acyl-S-ACP group (ER action) (Fig. 6) [20], [12].  
 
Fig. 6: Auxiliary PKS domains mediating ketoreduction (KR), dehydration (DH) and and enoylacyl reduction 
(ER) (adapted from [24] and [12]) 
These domains are unalterable in Type I and II fatty acid synthases (FAS) but can be mutated, 
unfunctional or deleted in Type I and II PKSs. In this case we obtain incomplete reduction giving 
raise to diverse chemical functionality and chemical reactivity [12]. Type I PKS systems contain 
starter units, so called initiation module and termination modules, which differ from the standard 
elongation modul and will be presented in the following. 
Initiation module 
Polyketide chain initiation is catalyzed by a “loading module” that, in all characterized type I 
PKSs, shares high similarity with the minimal extension module. A loading acyltransferase 
domain (ATL) uses an acyl-CoA substrate to load an adjacent ACP domain (ACPL). Typically, 
the ATL substrate is α-carboxylated acyl-CoA (e.g.: malonyl-CoA), like the substrate for chain 
extension, and acyl transfer (e.g: actinorhodin PKS and tetracenomycin PKS) other systems 
might have preferences for methyl-malonyl. Substrate loading is followed by a decarboxylation Introduction 
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via a mutated “KSQ” domain, which is catalytically inactive for condensation [25],[26],[27]. 
Alternatively, the KS domain may be missing entirely from the initiation/loading module at the 
N-terminus of the assembly line, like in the erythromycin PKS [25]. In that case, an acyl-CoA 
(propionyl- instead of malonyl- or methyl-malonyl-CoA) is selected by the initiating ATL domain 
and loaded on the first ACPL domain [20]. 
Termination module 
The last module of a Type I PKS assembly line is responsible for the release of the full-length 
acyl chain from covalent tethering on the final ACP domain. This process of chain termination is 
typically catalyzed by a 35  kDa thioesterase (TE) domain, which can catalyze hydrolysis, 
generating the free acid (e.g. during β-lactam biosynthesis, or intramolecular capture by one of 
the –OH groups in the polyketide chain, generating a cyclic lactone) [28]. 
4.1.4 Structural insights 
The ketosynthase (KS) and acyltranferase (AT) domain 
As the model system of modular PKSs, DEBS has been studied genetically and biochemically 
over the past two decades. The crystal structure of a 194 kDa homodimeric fragment of the 
KS-AT didomain of DEBS module five has been determined by Chaitan Khosla’s group at 
Stanford University [29]. This high resolution X-ray structure is the first didomain structure of a 
PKS module. It provides insights into the complex structural organization of the modular 
polyketide synthases machinery. The 194 kDa homodimeric fragment contains the full-length 
KS and AT domains as well as three flanking linkers: the N-terminal linker, an intervening 
KS-to-AT linker, and post-AT linker. The linker regions have been crucial for protein stability 
contrary to previous expectations that linkers only have a minor role and are mostly unfolded 
(Fig. 7) [29]. 
 
Fig. 7: X-Ray crystal structure of the ketosynthase and acyltransferase (KS-AT) didomain from DEBS module 
5. The KS–AT protein forms a homodimer. In orange: N-terminal coiled coil linker domain; in blue: ketosynthase (KS) 
domain; in green, acyl transferase (AT) domain; in yellow: KS–to–AT linker; in red: post-AT linker peptide. The 
residues 458–465 lacked electron density and were therefore modeled and shown in gray. (C,D) Side view (Picture 
from  [29]) Introduction 
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The structure reveals that the KS domain adopts a αβαβα fold, the AT domain contains an 
α,β-hydrolase like core domain and an appended smaller ferredoxin like subdomain. The three 
linkers are also structurally well defined [29]. The KS-to-AT linker is formed by a three stranded 
β-sheet packed against two α-helices on one side, the post-AT linker wraps back over both the 
AT domain and the KS-to-AT linker so as to interact specifically with the KS domain. The 
N-terminal linker forms a coiled-coil structure. The crystal structure also reveals that the active 
site Cys199 residue of the KS domain is more than 80 Å away from the active site Ser642 
residue of the AT domain. This distance is too large to be covered by the 
4’-phosphopantetheine arm (4’ Ppant) of the ACP domain measuring 18 Å, too large even when 
the 4’-Ppant arm is alternatively positioned and flexible. Thus, for domain-domain interaction, 
reorganization may be necessary for the ACP to interact successively with both the AT and the 
KS domains of this polyketide synthase module [21]. The overall structure is consistent with the 
4.5 Å structure of the mammalian fatty acid synthase [29]. Similar to the SrfA-C structure of an 
NRPS system [30] these findings give a great insight into the overall domain structure; it also 
emphasizes the crucial role of non-conserved but structurally well defined linkers. But these 
findings do not give any insights into domain-domain interactions; those would be only possible 
if large interdomain movements would take place. 
The acyl carrier protein (ACP) 
General structure: The ACPs consist of 60-100 amino acids, their family is characterized by a 
four α-helices fold (I–IV) [31][32]. Each carrier protein has a conserved serine residue at the 
N-terminus of helix II within the conserved Asp-Ser-Leu (DSL) motife (Fig. 8). The four-helix 
bundle fold is conserved among ACPs from fatty acid synthases and polyketide synthases (Fig. 
9). Nevertheless detailed comparison revealed that ACPs from polyketide biosynthetic 
pathways are more related to each other in tertiary fold than to their homologues from fatty acid 
biosynthetic pathways. PCPs and ACPs are known to share the same fold but they differ in their 
surface charge, ACPs are more acidic proteins [13]. 
 
Fig. 8: Sequential alignment of acyl carrier proteins. The sequential alignment of ACPs with an averaged size of 
80 amino acid residues from different organisms like the erythronolide ACP (DEBS) from Saccharopolyspora 
erythraea, the frenolicin ACP from Streptomyces roseofulvus, the  oxatetracycline PKS ACP from Streptomyces 
rimosus. In red are indicated the highly conserved amino acid residues containing the conserved DSL motif. The 
alignment was generated with clustalW.  Introduction 
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In nature the conserved serine residue in the DSL motife is subject to post-translational 
modification by acetyl carrier protein synthases (ACPS) [22]. ACPS belongs to the 
phosphopantetheinetransferases (PPtases) which transfer a 4’-Ppant moiety from coenzyme A 
(CoA) to the active site serine (Fig. 3). The activity of ACP depends on this conversion from the 
inactive apo to the active holo form. During the PKS biosynthesis different substrates are 
tethered to the thiolgroup of the 4’-Ppant arm. Studying the PKS and NRPS system means to 
understand the structural and functional relationship.  The most prominent questions related to 
the ACP structure are as follows. 
a) Is there a conformational switch between apo and holo form? 
b) How do different substrates loaded on the 4’-Ppant arm modulate the ACP structures? 
c) Is the ACP in the different states static or dynamic? 
d) What is the impact on protein-protein interactions of the aspects mentioned above? 
Reviewing the literature in the ACP field shows, that the answers to these questions strongly 
depend on the respective system. The individual questions will be discussed in detail in the 
following paragraph. 
Conformational switch between apo and holo form-  Evans et al. investigated the 
actinorhodin (act) ACP of Streptomyces coelicolor [33]. They solved high quality NMR structures 
of the holo and apo version. For the holo ACP chemical shift perturbations (CSPs) were 
observed in the 2D [
1H,
15N]-HSQC spectra for 10% of the peaks located on helix III and II- near 
to the 4’-Ppant attachment site. High resolution structures were calculated for the holo and the 
apo form and showed that the overall fold is the same.  
 
Fig. 9: The actinorhodin (act) ACP of Streptomyces coelicolor in its apo and holo state. (a) Cartoon view of 
holo act ACP from Streptomyces coelicolor (pdb: 2K0X). The phophopantheinyl arm (4’-Ppant) is presented in sticks. 
(b) Superimposition of the holo form (red) and the apo form (light blue; pdb: 2K0Y) which indicates the same overall 
fold. (c) Magnification of helix II and III of the superimposed structures with the detailed view of Asp41, Leu43, Glu53, 
and Asp62, indicating that helix III moves towards helix II for the holo form as Evan and colleagues acclaim (adapted 
from [33]).  Introduction 
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Evans states that the difference between both structures is the movement of helix III towards 
helix II for the holo form which constricts the hydrophobic cleft [33](Fig. 9). Studies of the NMR 
holo ACP structures of the FAS ACP of Bacillus subtillis [34], FAS ACP of Escherichia coli [35] 
and the ACP of Type II FAS Mycobacterium tuberculosis [36] are in accordance with the act 
ACP studies in the fact that the prosthetic group is localized transiently at a hydrophobic pocket 
between helix II and helix III. But in all three ACP structural investigations NOE pattern did not 
reveal that the conformations of apo ACP and holo ACP would be different. Furthermore, in 
these cases no NOEs were found for the prosthetic group. This supposes that in case of any 
interactions of the 4’-Ppant with the vicinity, this being too transient for NMR detection. The 
researchers coincide that the 4’-Ppant arm has no strong interactions with the protein surface 
and switches back and forth between protein association and solvent exposure. Relaxation data 
for the E. coli FAS ACP support that the ACP conformation itself is quite flexible [35]. 
ACP structure modulation upon substrates loading- Previous NMR studies of different 
holo ACPs (FAS and PKS) such as: FAS ACP of Bacillus subtillis [34], FAS ACP of Escherichia 
coli  [35], the ACP of Type II FAS Mycobacterium tuberculosis [36] and the PKS ACP of 
Streptomyces coelicolor [33] have shown that there are no strong interactions of the 4’-Ppant 
arm and the protein surface. No NOE’s are observed which could precisely locate the 4’-Ppant 
arm.  Roujeinikova and colleagues as well as Evans and colleagues, both studied ACPs in 
different ligand bound states. Interestingly both got slightly different results which might be 
related to the different systems which were studied and the different techniques used. 
Roujeinikova and colleagues studied by X-ray the E. coli FAS ACP in its buturyl bound state 
[37] and in its hexanoyl-, heptanoyl- and decanoyl-ACP bound states [38]. Interestingly for the 
buturyl ligand the electron density was quite weak and discontinous, which suggests that this 
part has only weak or no interactions with the ACP or that it is poorly ordered [37]. This is in a 
good agreement with Evans et al. For the acetyl, malonyl, 3-oxobutyl and 3,5-dioxohexyl ACP 
(PKS, Streptomyces coelicolor) they could only observe minimal or no interactions with the ACP 
[39]. This leads in both cases to the conclusion, that these kind of short length substrates are 
exposed to the solvent and in this way exposed to the interaction partners. Furthermore, the 
attachments of these short chain substrates do not affect the overall structure in both cases, for 
the E. coli ACP and for the Streptomyces coelicolor ACP.  But helix II and III are slightly affected 
in their conformation. These effects are even more pronounced and different for the studied 
PKS and FAS ACPs for a growing chain length of the substrate.  
For the FAS hexanoyl-, heptanoyl- and decanoyl-ACP of E. coli the analysis of the crystal 
structures reveal how the protein stabilizes the growing fatty acyl chain. For all these substrates 
the aliphatic head and the β-mercaptoethylamine moiety of the 4’-Ppant group is sequestered 
into the hydrophobic cavity in the core of the four-helix bundle. This results in the shielding of 
the thioester bond from the solvent and presumably prevents hydrolysis. The hydrophobic cavity Introduction 
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to which the substrate is bound in a linear fashion is formed like a tunnel parallel to helix αII and 
is narrowed to its end by helix IV [38] (Fig. 10 a) b)). Interestingly their analysis reveals that 
upon binding of acyl chains of up to ten carbon atoms a conformational rearrangement of three 
amino acids (Phe28, Ile54 and Ile72) occurs. This local rearrangement affects a small angular 
displacement of helix III leading to an expansion of the hydrophobic cavity. This structural 
plasticity allows a ligand-length dependant variation of the volume of the cavity of the FAS ACP 
of E. coli [38]. Studies on the spinach ACP also demonstrate that its fold undergoes only subtle 
further changes on binding of a longer (C18) acyl chain which induces large change in the size 
of the cavity (from 128 Å
3 to 305 Å
3) which can even accommodate longer acyl chains [31]. This 
was supposed not to be possible for the E. coli ACP [38]. Upon a growing acyl chain (butyryl-, 
hexanoyl-, and octanoyl-ACP) Evans and his colleagues could observe that in each case the 
acyl chain is clearly bound in a cleft which is also located between helices II and III of the PKS 
ACP. They see as well, in agreement with Roujeinikova and colleagues that the overall 
structures are superimposable for helix I, II and IV. Helix III is the only structural element which 
changes significantly, it moves away from helix II.  Interestingly this movement results in a cavity 
which runs perpendicular to that observed in FAS ACP (compare Fig. 10 a) and c) and b) and 
d)). It is also broader and more open then in the FAS ACP. The difference becomes even more 
apparent in the way the substrate is bound to the cavity, the 4’-Ppant arm remains 
predominantly solvent exposed which results in a solvent exposed thioester bond [39](Fig. 10). 
 
Fig. 10: Comparison of the substrate localization. (a) Cristal structure of the FAS hexanoyl ACP of E. coli (PDB: 
2FAC [38]) presented in the front view b) the same protein rotated by 90°. c) Presentation of the NMR structure of the 
actinorhodin polyketide synthase octanoyl-ACP from Streptomyces coelicolor (PDB: 2KGC; [39]) in the front view d) 
the same protein rotated by 90°. In the FAS hexanoyl-ACP structure the substrate is embedded in a tunnel build 
between helix II and III. The substrate aligns in parallel to helix II. In the structure of the PKS act ACP the headgroup 
is bound into a cavity created between helix II and III but the 4’-Ppant arm itself stays solvent exposed.  Introduction 
  - 30 - 
Summarizing these two investigations we can say, that the Type II FAS ACP of E. coli binds 
their fatty acyl intermediates in a narrow cleft that runs parallel with helix II and helix IV. In 
contrast the binding cleft in the Type II PKS ACP of Streptomyces coelicolor runs perpendicular 
to helix II. Three specific key amino acid substitutions between E. coli FAS and act PKS ACP, 
namely, Thr39/Leu45, Leu42/Thr48, and Ala68/Leu74, alter the size, shape, and location of this 
cavity.  This may contribute to the differential binding modes which were identified [39]. 
Dynamics of ACPs in different chemical states- Functional flexibility is often 
accommodated through conformational flexibility. This has been previously shown for the TycC3 
PCP from the NRPS system. The PCP exists in its apo form in two different states, A and A/H. 
For the holo form it exists in a new equilibrium between the A/H conformation and a new 
conformation, the H state. The interaction with the PPtase SFP specifically takes place when 
the PCP is in the A state [7]. The enzyme thioesterase II (TEII) becomes active when the PCP 
is loaded with the wrong substrate-acetyl CoA (about 80% of the CoAs are acetylated). This 
substrate locks the PCP in its H state, the conformation that has shown to be the preferred one 
for TEII interaction [40]. So far a similar conformational exchange could not be shown for ACPs. 
One exception is the FAS spinach ACP, two distinct sets of peaks could be observed in a 
[
1H,
15N]-HSQC spectra for the holo form representing presumably one folded and one unfolded 
state. It could be shown that this conformational heterogeneity is reduced upon substrate 
loading with decanoate-(10:0) and stereate-(18:0) leading only to a few, neglectable double 
peaks in a [
1H,
15N]-HSQC [31]. Furthermore a conformational exchange between a mayor state 
(85%) and a minor state (15%) could be observed as well for the 3-oxobutyl loaded act ACP 
from the PKS system of Streptomyces coelicolor. The slight differences between those 
conformations are located on helix II, helix III and the connecting loop [33]. Similar to these 
investigations are the results obtained for the holo form of the frenolicin (fren) PKS ACP. Four 
residues, located in Loop two and helix III, were identified to exchange slowly on the NMR 
timescale (kex<103 s-1). Additional relaxation studies reveal further that loop I as well as the 
4’-Ppant arm have low order parameters indicating that they undergo rapid and large amplitude 
motions [41]. A third PKS Type II example for a conformational exchange is the apo ACP from 
Streptomyces rimosus. Relaxation experiments have shown that the loop between helix I and II 
is flexible and that helix II, which is proposed as a site of protein-protein interaction, shows 
conformational exchange. These results are in agreement with the previous ones [42]. For most 
of the holo ACPs investigated, no NOE could be detected between the ACP and the 4’-Ppant 
arm. A fact which changes with the rising length of the acyl chains, longer chains lead to a 
fixation of the 4’-Ppant arm. An exception to this rule seems to be the Pf ACP from the Type II 
FAS of Plasmodium falciparum. Two conformations could be observed which are in a slow 
exchange with each other. For both conformations different NOE patterns could be derived 
exhibiting a difference in the orientation of the 4’-Ppant arm. The 4’-Ppant arm orientation is Introduction 
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accompanied by the loss of a minor helix II’ (between helix II and helix III) giving rise to a longer 
loop connecting helix II and III [43].  
ACPs and their protein-protein interactions- Many key domain-domain interactions 
involving carrier proteins are required during the production of the PKS or NRPS scaffold. For a 
typical cycle of PKS elongation, as described before, an ACP must interact with the AT domain, 
the upstream KS domain, eventually further modifying enzymes that perform tailoring of the 
resulting α-ketone and the downstream KS domain. All these events must take place in a well- 
timed manner. Leading to the question how these diverse interactions can be coordinated? How 
much of a carrier proteins surface is involved in each of these inter-domain interactions? Does 
each domain contact a separate face of the carrier domain? Is the swinging of the 4’-Ppant arm 
directed by the catalytic domains or through the carrier protein itself? It has been shown that for 
the E. coli FAS the substrate which is bound to the ACP is sequestered within the carrier. How 
does this way of transport enables individual FAS enzymes to discriminate between the different 
intermediates (e.g. β-keto, β-hydroxyl, acetoacetyl-, malonyl-ACP)?  One major factor which 
makes these studies challenging is the high amount of protein often needed for structural 
studies. Another drawback for NMR studies is the often transient and weak nature of these 
interactions, in particular those involving the ACP. Efforts to structurally characterize these 
interactions via X-ray crystallography are limited due to the highly dynamic character of those 
interactions [44]. Nevertheless much research has been done and this chapter will try to 
summarize the insights obtained by NMR, X-ray, computer simulations and docking 
experiments and results obtained via biochemical approaches.  
Phosphopantetheine transferases are essential to activate the ACPs in PKS systems and 
PCPs in NRPS systems. NMR investigations could enlighten the activation process for PCPs by 
SFPs and regeneration of misprimed PCPs by SrfTEII- all cis-acting enzymes.  The apo TycC3 
PCP exists in a conformational equilibrium called state A and A/H. SFP interactions take 
exclusively place with apo TycC3 in its A state. Titration experiments could narrow down the 
interactions to residues 30 to 55 of helix αII and the 4’-Ppant recognition site within the loop 
between helix I and II [7]. Furthermore it has been shown that the PCP interacts in its H state 
with SrfTEII. SrfTEII is a repair enzyme which removes acetyl groups from misprimed ACPs. 
This interaction could be localized on a long loop between helix II and IV. Interestingly, this loop 
can form a helix (helix III) in the inactive A/H state and after unfolding it is essential for the 
recognition by SrfTEII. The mechanism can therefore be interpreted as an allosteric regulation 
[7]. As discussed before for ACPs it was so far impossible to observe the same conformational 
plasticity [13]. Furthermore the 4’-Ppant arm is solvent exposed and flexible and not attached to 
the surface as for the TycC3 PCP [7]. It was possible to co-crystallize holo ACP from B.subtillis 
with ACPS and the result showed that the contacts between holo-ACP and ACPS are 
predominantly hydrophilic in nature with almost all of the interactions occuring between helix α1 Introduction 
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of ACPS and helix III of ACP [45]. Due to different nomenclature this helix III corresponds to 
helix II in most other ACP structures which locates the active serine on its N-terminus. 
Interestingly SFP can modulate ACPs as well as PCPs and vice versa. Nevertheless for the 
ACPS it was shown that ACPs are the better substrates, hypothetically due to the different 
surface charge and the alteration of the electrostatic interactions [46].  Based on the crystal 
structure of the KS3-AT3 didomain from DEBS module 3 from Yeast FAS a docking for ACP3 
and ACP2 was performed leading to the hypothesis that both interactions are also mediated via 
helix II [21]. In triketide lactone formation assays it could be shown that mutations on helix II of 
the different ACPs in DEBS have an effect on the specificity of the system. For example it was 
possible to change ACP2 by one single mutation (R59G) to be a bad interaction partner for KS-
AT of module 2 but a good one for KS-AT of module 6 [47]. Docking experiments with the E. coli 
FAS proposed that FabH (a β-ketoacyl-ACP Synthase III) and ACP mainly interact via helix II 
[48]. Furthermore, it was shown that helix II plays also a major role in mediating the interactions 
with β-ketoacyl-acyl carrier protein reductase (FabG) [49]. In addition there is direct evidence 
from X-ray for electrostatic interactions between helix II of dodeconyl-ACP and FabI [50]. A 
region which has shown to be especially flexible; maybe due to electrostatic repulsion (14 acidic 
and no positive residues between positions 30 and 60) [51] [52] [53]. This flexibility is thought to 
be important in facilitating rapid association and dissociation of ACP with its various partner 
enzymes. In conclusion jelix II can be called a “recognition helix” for universal enzyme 
interaction [49]. Helix II could be further confirmed to be such a “recognition helix” for 
interactions of the FAS ACP from Vibrio harveyi with holo-ACP synthase (N-terminus of helix II, 
Asp35), acyl-ACP synthase (via C-terminus of helix II) and UDP-N-acetylglucosamine acyl- 
transferase (LpxA) (also via C-terminus of helix II) [54]. Via NMR titration experiments it could 
be proven that the negatively charged helix II from the FAS ACP of Steptomyces coelicolor 
interacts with malonyl-coenzymeA-ACP transacylase (MCAT) through the negatively charged 
helix II of ACP [55]. Finally interaction studies have been performed in the NRPS cluster 
producing enterobacterin. The interaction surface on EntB-ArCP for EntF consisted of one 
residue on helix II (M249) and two residues on helix III (F264 and A268). The observations 
support a model in which the downstream recognition is mediated by helix III which might work 
due to its structural flexibility and functional ability as a conformational switch [13]. All in all the 
research on interactions in PKS, FAS and NRPS systems maps interactions on helix II, whereas 
we have shown an additional conformational hot spot on helix III within PCPs from NRPS 
systems. Additionally, many interactions seem to be transient and have been assumed not to 
alter the structure significantly [33, 35, 36, 41]. 
4.1.5 Quaternary structure and the role of docking domains 
A common feature of NRPS and PKS systems is that the modules are distributed among 
multiple protein subunits. As a consequence the intermodular transfer has to take place Introduction 
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between domains located on different polypeptides [56]. The formation of the correct product 
depends therefore not only on a specific ordering of the multienzymes, it must also prevent 
improper associations (Fig. 12)[57]. It has been shown, that the communication between 
different modules is linked to interactions between short linker regions (30-90 amino acids) 
located at the end of a module in both, NRPS and PKS systems. In NRPS systems these 
domains are called “communication domains” (COM-domains), in PKS domains these 
“interpolypeptide linkers” are called “docking domains” [57][58].  NRPS enzymes appear to be 
mostly monomeric and different polypetides associate via the COM-domains [59][58]. COM-
domains are significantly shorter than the respective C- and N-terminal docking domains of 
PKSs, approximately 15–25 in comparison to 20–30 amino acids. They exhibit little mutual 
sequence conservation. Domain swapping experiments in the tyrocidine NRPS could clearly 
demonstrate that matching pairs of COM domains are both necessary and sufficient for the 
establishment of communication between partner NRPSs in trans [58,60]. In contrast to NRPS 
proteins, PKS proteins are functional homodimers [61,62]. Their association with other subunits 
is more complex. In the DEBS system it was shown that the interpolypetide linkers- the docking 
domains- differ from the covalent linkers who link two domains with each other. The docking 
domains are hydrophobic whereas the polypeptide linkers are more hydrophilic [56]. NMR 
structural studies of the interpolypeptide linker in the erythromycin PKS system (DEBS) showed 
that these domains are α helical structured (Fig. 11). Interhelical contacts play a crucial role for 
the formation of homo and heterodimers and different recognition sequences promote the right 
positioning of each module [57]. 
 
The implementation of different docking domains assure the right positioning of the different 
subunits as drafted for the complete DEBS system (Fig. 12)[57]. With these different quaternary 
architectures for NRPS and PKS proteins, it has been unclear how molecular recognition should 
occur in mixed PKS and NRPS systems. The structural investigation of the N-terminal docking 
a)  b)  Fig. 11: Model of the 
structural basis for docking 
in modular PKS. a) 
Representation of the NMR 
solution structure of the DEBS 
docking complex. The dimeric 
C-terminal docking domain is 
shown in blue and yellow 
(three helices), while the 
dimeric N-terminal docking 
domain is shown in green and 
orange. The linker region 
between helices 2 and 3 is 
highly mobile, and therefore is 
represented as a dashed line 
in the structure. b) 
Magnification of the charged 
residues located at critical 
positions in the interface (from 
[1]). Introduction 
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domain of TubC (‘TubCdd’) from the tubulysin PKS-NRPS gives insight into a αββαα fold. These 
interactions seem to take place via a corresponding and specific electrostatic code [18][63]. 
 
Fig. 12: Schematic organization of the erythromycin polyketide synthase. a) The three DEBS subunits are 
homidimeric. The individual polypeptide linkers, so called docking domains are twisted around each other in a 
“double-helical” structure, they assure the right positioning of each subunit (from [57]).  
TubCdd is a homodimer and there is a reasonable assumption that the parent protein also 
oligomerizes. It might be that in hybrid PKS-NRPS systems also the NRPS part builds a 
homodimer, with the docking elements actively contributing to subunit self- association [18]. 
a) Introduction 
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4.2  The curacin cluster 
Curacin was originally purified as a major lipid component of the cyanobacterium Lyngbya 
majuscula, isolated in Curaçao. Curacin A has proven to be a potent inhibitor of cell growth and 
mitosis by binding rapidly and tightly at the colchicine site of tubulin. Curacin A contains a 
unique combination of functionalities in comparison to many other colchicine inhibitors including 
a cis-vinyl thiazoline heterocycle, a terminal alkene and cyclopropyl ring [64] ( 
Fig. 13).   
 
Fig. 13: The structure of curacin A. The unique combination of functionality is due to a cis-vinyl thiazoline 
heterocycle, a terminal alkene and cyclopropyl ring [65]. 
Six years later, in 2004, the first publications were made by Professor Sherman and his group 
investigating the biosynthesis of this putative cancer cell toxin. Feeding experiments allowed 
determining the metabolic origin of the different carbon atoms. Further cloning procedures of the 
64 kb operon were undertaken in order to assign structures and functions to the individual 
domains [65]. The combination of bioinformatics, enzymological studies and feeding 
experiments allowed identifying the different enzymes in the Curacin A assembly line in the 
preceeding years (Table 1 [next page]). Introduction 
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Table 1: Description of the protein sequences encoded by the curacin biosynthetic gene cluster. Proteins of 
which the structure is solved are indicated in bold (adapted and modified from [65]) 
Protein  AA  Domains  Publication 
Similar to Organism 
Id/Sim 
Accession 
CurA 2311 
GNAT, ACP, KS, AT, Hal, ACP, 
ACP, ACP PKS 
[65] 
[27] [66] 
[67] 
StiC (Stigmatella auratiaca) 50%/ 67%  CAD19087 
 
CurB 
 
79  ACP    (Bacillus subtilis) 53%/ 72%  NP570904 
 
CurC 
 
408 PksF    (Bacillus subtilis) 40%/ 56%  NP389594 
 
CurD 
 
442  HCS HMG-CoA synthase    FAB-H-like condensation 44%/63%  AAN85526 
CurE 254 
ECH1 enoyl-CoA hydratase/ 
isomerase 
 
[68] 
[69] 
enoyl-CoA hydratase/carnithine 
racemase (Nostoc punctiforme) 
35%/53% 
A48956 
 
CurF 
3195 
C- term: 
ECH2, ER, KS, AT 
N- term: 
UNK, ACP, C, A, PCP 
[68] 
[70] 
[69] 
C- term: 
mixed PKS/NRPS 
BarG (L. majuscula) 56%/71% 
N- term: UNK, ACP, C, A, PCP 
(T. erythraeum) 49%/68% 
 
AAN32981 
 
ZP00074378 
CurG  1583  KS, AT KR, DH, ACP  [71] 
CurG PKS NosB (Nostoc sp. 
GSV224)  
51%/68% 
AAF15892 
 
CurH 
 
2199  KS, AT, ER, DH, KR, ACP  [71]  StiF (Stigmatella auratiaca) 40%/56%  CAD19090 
 
CurI 
 
1656 KS,  AT,  DH, KR, ACP  [71]  StiB (Stigmatella auratiaca) 44%/60%  CAD19086 
 
CurJ 
 
2298  KS, AT, MT, DH, KR, ACP  [71]  StiC (Stigmatella auratiaca) 46%/64%  CAD19087 
 
CurK 
 
2232  KS, AT, ER, DH, KR, ACP  [71]  StiF (Stigmatella auratiaca) 40%/58%  CAD19090 
 
CurL 
 
1956  KS, AT, MT, KR, ACP    StiE (Stigmatella auratiaca) 38%/56%  CAD19089 
 
CurM 
 
2147  KS, AT, KR, ACP, ST, TE PKS/TE  [66]  StiB (Stigmatella auratiaca) 43%/60%  CAD19086 
CurN  341  Hydrolase haloalkane dehalogenase   
Hydrolase haloalkane dehalogenase 
50%/64% 
hydrolase 39%/58% 
P59336 
 
 
NP820220 Introduction 
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4.2.1 The mechanism of the curacin cluster 
Curacin became a prominent example for a mixed PKS-NRPS system. So far different steps of 
the biosynthesis have been explored biochemically and will be presented in the following 
Chapters.  
4.2.2 The initiation module  
The initiation module is a loading tridomain. Similar loading modules were found in pederin [72], 
its structural analogs onnamide and theopederin [73], myxovirescin A [74], and rhizoxin [75]. 
These chain initiation modules are a structured, N-terminal regions spanning ~180 amino acids 
which code for three domains. There is an adapter (AR) domain which does not have any 
catalytical function but increases the stability and the efficiency of the system via protein-protein 
interactions. The catalytical active domain is the GCN5-related N-acetyltransferase (GNAT) 
domain with a bifunctional decarboxylase/S-acetyltransferase function. In a first step a 
decarboxylation of malonyl-coenzyme A (malonyl-CoA) to acetyl-CoA is performed followed by 
a direct S-acetyl transfer from acetyl-CoA to load an adjacent acyl carrier protein domain 
(ACPL)- the third domain of the tridomain [27](Fig. 14). 
 
Fig. 14: Proposed mechanism of the CurA AR-GNATL-ACPL chain initiation module. Malonyl-CoA enters the 
CoA-binding tunnel (white tunnel) of the GNATL  domain (dark blue region) and GNATL catalyzes decarboxylation to 
acetyl-CoA. The AR domain (light blue circle) directs the 4’-Ppant arm of ACPL into the ACP tunnel (yellow tunnel) for 
subsequent acetyl-group transfer via trans-thioesterification (picture adapted from [27]). 
Formation of the cyclopropane moiety 
A 10-enzyme assembly catalyzes the formation of the cyclopropane moiety. These catalytic 
domains and discrete enzymes span from CurA to CurF and are grouped into three subsets: the 
(1) halogenase (Cur Hal) embedded in CurA; (2) 3-hydroxy-3-methylglutaryl (HMG) enzyme 
cassette containing a tandem acyl carrier protein (ACP) tridomain (ACPI,II,III) including ACPI, 
ACPII and ACPIII, a discrete ACP CurB, a ketosynthase-like enzymes (KS) CurC , the HMG- 
CoA synthase-like enzyme (HCS) CurD, the dehydratase (ECH1) CurE, and the decarboxylase 
(ECH2) embedded in CurF. Further on, there exists (3) the enoyl reductase domains (ERs) 
embedded in CurF. All these different catalytic domains are active when the substrate is 
tethered to the triplet ACPI,II,III [76](Fig. 15 a)). In the first steps of the biosynthesis the HMG 
cassette (malonyl-ACPIV [malonyl-CurB], KS [CurC] and HCS [CurD]) introduce a β-branching 
and leads to the formation of HMG-ACP as illustrated (Fig. 15 b)). In detail, CurB is loaded with Introduction 
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malonyl by an AT domain, CurC a KS inactive for condensation, decarboxylates malonyl and 
activates in this way the carboxyl-group. HCS (CurD) catalyzes then the condensation of the 
CurB bound acetate unit with acetoacetyl- bound to ACPI to form (S)-3-hydroxy-3-
methylglutaryl-ACP (S-HMG-ACP) [65]. 
 
Fig. 15: The 10-enzyme assembly catalyzing the cyclopropane ring formation. a) The 10 enzymes which are 
involved in the cyclopropane ring are encoded on different proteins (CurA-CurF). b) Representation of the 
Biosynthesis of the cyclopropane formation. GNATL= loading module, KS= ketosynthethase, AT= acyltransferase, 
Hal= halogenase, ACP= acetyl- carrier- protein, HCS= HMG-CoA synthase-like enzyme, ECH1= dehydratase, ECH2= 
decarboxylase, ER= enoyl- reductase (adapted and modified from [69] and [76]). 
The following reactions can be performed in different orders but as discussed by Gu and his 
colleagues the chance is quite high that the HMG formation is first followed by the chlorination 
step obtaining (S)-4-chloro-3-hydroxy-3-methylglutaryl-ACPI via Cur Hal. As shown previously; 
ECH1 catalyzes then the dehydration of 4-chloro-3-hydroxy-3-methylglutaryl-ACPI to 4-chloro-3-
methylglutaconyl-ACPI, followed by ECH2 decarboxylation to generate 4-chloro-3-
methylcrotonyl-ACPI. This is then the presumed precursor for (1R,2S)-2-methylcyclopropane-1- 
carboxyl-ACPI (Fig. 15 b)) [69, 76].  
The termination modul 
In the termination module the sulfotransferase (ST) is coupled with a thioesterase domain (TE) 
domain. The catalytic events transform the β-hydroxyl of the penultimate chain elongation 
intermediate into a β-sulfate. Β-sulfate is an excellent leaving group that is positioned chemically 
to facilitate decarboxylative elimination in the presence of the terminal carboxylate following TE-Introduction 
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mediated hydrolysis of the acylthioester. In this way the decarboxylative chain termination forms 
an unusual terminal olefin in the final product [66]. 
4.2.3 Structures of the curacin cluster 
Initiation modul- the GCN5-related N-acetyltransferase (GNAT) domain 
The crystal structures of GNATL (CurA residues 219 to 439) could be solved at 1.95 Ǻ (ligand-
free form; PDB: 2REE) and 2.75 Ǻ (acyl-CoA complex; PDB: 2REF) and is monomeric. GNATL 
has the GNAT superfamily fold and consists of a central, mostly antiparallel β-sheet, flanked by 
α-helices, and is according to Gu and his colleagues most similar to serotonin 
N-acetyltransferase [27]. Due to the difference of the acyl and the apo form it could be shown 
that there are two distinct substrate tunnels for acyl-CoA and holo-ACPL binding (Fig. 16). 
Further on it could be demonstrated by site-directed mutagenesis that His389 and Thr355, at 
the convergence of the CoA and ACP tunnels, participate in malonyl-CoA decarboxylation but 
not in acetyl-group transfer. Amino acids involved in the acetyl-group transfer could not be 
identified. These data led to a proposition for the mechanism of the biosynthesis initiation (Fig. 
16) (compare 4.2.2). 
 
Fig. 16: The GNATL domain a) Structure of GNATL domain (PDB: 2REE). b) Structure of GNAL with acetyl CoA 
tunnelling the protein (grey spheres) (PDB: 2REF). Residues Trp249, His389, Thr355, and Arg404 are 
shown (green-colored carbons). 
The dehydratase domain (ECH1) 
ECH1 is a dehydratase domain which catalyzes the formation of an α,β-double bond in the 
nascent polyketide intermediate. So far the structure of ECH1 itself could not be solved due to 
the low solubility [71]. But the crystal structures of four other dehydratase domains present in 
the curacin cluster could be solved [71](PDBs entries: CurF-DH 3KG6; CurH-DH 3KG7; CurJ-
DH 3KG8; CurK-DH 3KG9). The dehydratase domains (DH) are in solution as well as in the 
crystal structure dimers. DH domains have a double hot-dog fold in which the active site 
contains a histidine from the N-terminal hotdog and an aspartate from the C-terminal hotdog 
building together the active site [71, 77, 78](Fig. 17). Similarities between the four structures Introduction 
  - 40 - 
and the reported structure of the Ery4 DH domain suggest that loading and unloading of 
intermediates is likely facilitated by reordering of mobile elements opening the active-site tunnel. 
It is reported that ECH1 accepts HMG-CoA as substrate but has a 10* fold higher affinity 
towards the ACP bound substrate [68][69].  
 
Fig. 17: Presentation of CurJ dehydrogenase (PDB 3KG8) a) The CurJ monomer is colored according to average 
atomic temperature factor per residue (B- factor). The lowest B- factors (blue) occur in the N-terminal hotdog fold, 
which forms the dimer interface. The highest B-factors are in residues covering the active- site tunnel (the loop 
connecting helix αHD2 and strand β10, and the C-terminal 310 helix) and also in the linker connecting the two hotdog 
motifs. The substrate tunnel is colored in grey, and the active-site histidine is shown as spheres with yellow. b) 
Presentation of a surface diagram of CurJ DH monomer without the tunnel cover.  The residues with a high B-factor 
(αHD2—β10 loop and C-terminal 310 helix, shown in a) in red) were removed to allow visibility of the active site. The 
surface is colored by the structural motif (N-terminal hot dog in magenta; C-terminal hot dog in grey and the linking 
regions in brown and green). The CurJ DH substrate is modeled as sticks with yellow. Further on there is a more 
detail inset with the same orientation (Picture and description from [71]). 
The decarboxylation domain (ECH2) 
This decarboxylase is encoded at the N-terminus of CurF. The N-terminal domain is a 
multifunctional protein which catalyzes decarboxylation of 3-methylglutaconyl-ACP to 
3-methylcrotonyl-ACP. The product of the reaction is the postulated precursor of the 
cyclopropane ring of curacin A. The crystal structure of the CurF N-terminal ECH2 domain 
establishes that the protein is a crotonase superfamily member. CurF ECH2 has less than 20% 
sequence identity to identified members of the superfamily and the superfamily membership 
could only be established via the structure itself [70]. Reason is, that the crotonase superfamily 
consists of a wide variety of mechanistically diverse enzymes that exhibit various activities, such 
as hydratase [79], dehalogenase [80], decarboxylase [81][82], isomerase [82][83][84,85] (PDB 
2F6Q), hydrolase [82], and carbon-carbon bond forming [82] or cleavage activity [86,87]. Due to 
this high functional diversity the superfamily lacks conserved catalytical residues. The crystal 
structure of ECH2 is trimeric, however in solution CurF ECH2 also displays concentration 
dependent dissociation indicating a dynamic equilibrium between trimeric and lower oligomeric 
states [70] (Fig. 18).  
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Fig. 18: Structure of CurF ECH2. a) Presentation of the CurF ECH2 domain as a stereo diagram. b) Trimeric 
structure of the CurF ECH2 domain. In both representations the active site chamber is indicated by an asterisk 
(picture and subtitle from [70]). 
The backbone amides of Ala78 and Gly118 form an oxyanion hole and the hydrophobic active 
site chamber includes only three polar side chains. Mutational analysis showed that product 
formation was more than 20-fold reduced for K86A, K86Q, H240A, and H240Q variants 
compared with wild type revealing Lys86 and His240 are critical for catalytic activity but not 
Tyr82. Thus it could be concluded that Lys86 and His240 play an important role in substrate 
binding or catalysis ( 
Fig. 19). His240 is proposed to stabilize the substrate carboxylate, and Lys86 is proposed to 
donate a proton to the C-4 position of the product. The structural arrangement might be the 
explanation for the specific regiochemistry in the formation of the key isopentenyl-ACP [70].  
Further on Geders and his colleagues could show that CurF ECH2 had a 20-fold preference for 
the ACP-linked substrate- a preference which has not been reported for any other member of 
the crotonase superfamily so far [70]. 
 
Fig. 19: The proposed mechanism for CurF ECH2. During the hole mechanism is the oxyanion hole formed by the 
backbone amides of Ala78 and Gly118. His240 stabilizes the substrate carboxylate (A), and Lys86 donates a proton 
to the decarboxylated intermediate (B) to form the product (C) (Picture from [70]).  
The halogenase (Cur Hal) 
The Halogenase (Hal) is located at the C-terminus of CurA before the triplet ACP; it catalyzes a 
cryptic chlorination which leads to the cyclopropane ring formation in the synthesis of the natural 
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product curacin A. Cur Hal was originally annotated as phy due to its sequence similarity of 16% 
to the human oxygenase PhyH. Due to its function the name was changed later on. Hal is a 
nonheme Fe
2+ and α-ketoglutarate (α-KG)-dependant enzyme which catalyzes under oxidising 
conditions the chlorination of inactivated carbon centres. The functional homologues SyrB2 from 
the syrongomycin pathway and CytC3 from the armentomycin pathway show a quite low 
sequence identity (13% and 16% sequence identity). It has been shown that these enzymes are 
able to catalyze the halogenation of an inactivated aliphatic carbon through a non-heme Fe-(IV)-
O5 intermediate ((SyrB2) [88][89][90]; (barbamide) [91][92][93]; (CytC3) [94]). The role and the 
timing for the chlorination in the curacin A synthesis could be established recently [69]. Cur Hal 
is specific for (S)-HMG-ACP as a substrate, once chlorinated the product reacts sequentially 
with the CurE ECH1 dehydratase, the CurF ECH2 decarboxylase and the enoylreductase (ER). 
Then a nucleophilic displacement will take place and the production of the cyclopropane ring 
forms the endpoint of the reaction series [69]. 
Structure- The protein Cur Hal was recently crystallized and spans the residues 1600-
1919 which are designated as 1-1320 [67]. Hal is a dimer in solution as well as in the crystals. 
Crystals could be obtained for five different ligand states which are resumed in the following 
table (Table 2). All crystal structures have in common that the amino acids 319 and 320 are not 
visible (Table 2). It is to say that in the open conformation I and III (only Fe
3+) the lid region is 
not visible in the crystal structure.  
Table 2: Summary of the different ligand states which could be crystalized (data from [67]). 
Crystal Structure  I  II  III  VI 
PDB 3NNJ  3NNF 3NNL 3NNM 
Conformation Open  closed closed  open Closed 
Ligand 
State 
None 
 
Fe
3+ Fe
3+ Fe
3+   
α-KG  α-KG    
Cl
- Cl
-    
O2     
Formate     Formate 
 
All four halogenase crystal structure posses the cupin fold. The distantly related enzymes SyrB2 
and CytC3 share the same fold which consists of a barrel-like structure formed by a major anti-
parallel β-sheet ((β1, β6, β4, β8, β3, and β2). The active site is housed by the cupin barrel and 
forms specific interactions between α-KG and Fe with Cur Hal. Helices α5, α7, and α8 stabilize 
the dimer by hydrophobic interactions. The active site of each monomer is separated by 37 Å 
(not shown). Hal has with its homologues SyrB2 and CytC3 a lid in common, which is formed by Introduction 
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27 residues (Fig.20 a), amino acids 40-66 form the lid, which is indicated in red). In the different 
crystal structures two conformations can be distinguished- the open conformation with no ligand 
and the closed conformation with α-KG, Fe, Cl
-. The data suggest that the conformational switch 
between them is triggered upon α-KG binding which in turn shows dramatic differences in the lid 
region: When α-KG is bound the active site is covered by the lid and the protein is in its “closed” 
conformation, without α-KG no lid region is visible in the crystals. The lid seems to become 
disordered and opens the active site (“open” conformation). Further on the structures differ 
radically for the loop connecting helices α9 and α10 (residues 274–284) (magenta and dark blue 
in Fig.20 a)). Finally, several secondary structures are in slightly different positions, including 
strand β3 and helices α2, α4, α5, α6, α9, and α10 [67]. These structural differences clearly 
distinguish the “open” and the “closed” state of the enzyme.  
 
Fig.20: The crystal structure of the halogenase (Cur Ha)l (a) Overlay of the open (3NNJ) and closed form (3NNF) 
of Cur Hal. In the closed-form subunit (cyan), the 27 amino acid lid (colored in red) covers the active site. The α9–α10 
N- loop (dark blue) is at the periphery. In the open form (yellow), the lid (residues 40–65) is missing, and the α9–α10 
loop (magenta) is adjacent to the active site and to a 310-like helix preceding α4. Structural changes include shifts of 
β3 and helices α2, α4, α5, α6, α9, and α10. b) In the metal center (shown in sticks), iron (orange) coordinates two 
histidine side chains (cyan C), αKG (gray C), chloride (green) and formate (white C). Ligands are shown with atomic 
colors (red O, blue N) and coordination bonds in black (pictures from [67]). 
Mechanism 
The different ligand states are consistent with the mechanism in which decarboxylation of α- KG 
by iron bound dioxygen creates a ferryl-oxo (Fe4+-oxo) intermediate ( 
Fig. 21) [89, 90, 94]. Based on the mechanism proposed for SyrB2, CytC3 and the Cur Hal 
crystal structure, Khare and colleagues propose the following mechanism: The resting enzyme 
containing Fe
2+ is in the open form excluding HMG. Upon binding of α-KG the enzyme closes 
the lid and triggers S-HMG binding. The substrate binding permits then dioxygen to coordinate 
the Fe
2+ and triggers decarboxylation of α-KG by iron bound dioxygen which creates a chloro-
oxo-ferryl intermediate. In the following the substrate subtracts hydrogen and the substrate 
radical will be resolved by chlorination [67]. 
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Fig. 21: The proposed Cur Hal mechanism including the role of the conformational change. As long as the 
enzyme is in the open form, (S)-HMG-ACP is excluded. The conformational switch from the open to the closed form 
is triggered upon binding of α-KG and Cl-binding. Once Cur Hal is in its closed form (S)-HMG-ACP can bind. Due to 
the substrate binding dioxygen coordinates the iron and triggers oxidative decarboxylation of α-KG. The intermediate 
chloro-oxo-ferryl abstracts a hydrogen atom from the substrate; the substrate radical is resolved by chlorination via a 
“rebound” mechanism (Picture adapted from [67]). 
Based on modeling and alanine replacement it is supposed that the amino acids- Leu112, 
Lys48, Lys50, Lys54, Ser44, and Tyr68- are involved into the stereo-specific recognition and 
binding of S-HMG. Based on residue substitution it seems to be that Arg241 and Arg247 are 
essential for α-KG binding, Ser120 is important for Cl
-. Concerning the substrate it is important 
to say that the proximal carboxylate in HMG is a complication for Fe-dependant enzymes. 
Therefore it might be crucial to keep HMG out of the sphere of Fe
2+ until the active site is 
assembled, due to the potential of the carboxylate to be a ligand itself. Therefore it might make 
sense to exclude HMG as long α-KG and Cl
- are not bound [67]. 
4.3  Nuclear magnetic resonance on mega-synthethases 
Structural elucidation of NRPS and PKS modules is inevitable in order to get a crucial 
understanding of the structural determinants important for biosynthesis. During the last decades 
single domain architecture were determined by either X-ray or NMR structure elucidation. 
However, dissected domain structures only gave little knowledge of the mechanism underlying 
the domain interaction during NRP- and PKS-synthesis [95]. In the last years, it was possible to 
obtain high-resolution NMR and X-ray structures of didomains such as the homodimeric AT-KS 
fragment of DEBS module 5 or the SrfA-C domain [29, 30]. Both cases give an insight into the Introduction 
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structural arrangement but do not enlighten the domain-domain interactions. In both structures 
interdomain movements would be required to allow interactions of the domains with the 
4’-Ppant arm of the ACP domain. PKS and NRPS systems contain large flexible linker regions 
which make crystallization of multidomain proteins difficult. It is possible to deduce mechanisms 
or even dynamics from different structures of the proteins in case it is possible to trap it in 
different moments which worked out so far for single domains such as CurA Hal [67].  
Beside X-ray, NMR spectroscopy is a powerful tool that can be used to investigate 
structures, dynamics, and chemical kinetics and can overcome the restrictions X-ray suffers 
from. Although structure determination by NMR is limited to proteins with molecular weights less 
than 40-60 kDa new NMR techniques allow to investigate bigger proteins using for example 
stereo-array isotope labeling (SAIL) labeling [96-98] or thermophile homologues [99]. Beside 
structural investigations, NMR is an excellent tool to obtain complementary results for domain 
interactions by performing titration experiments and using fast mapping approaches for the 
domain-domain interactions [100]. Concerning the curacin triplet, a further challenge to face is 
the high symmetry of the protein leading to high overlay in the NMR spectra. One solution to 
this problem is to break the symmetry of the protein. Gaponenko and colleagues broke the 
symmetry of a dimer by attaching a paramagnetic probe resulting in improved peak distribution 
due to pseudocontact shifts [101]. In recent years, segmental labeling advanced as tool 
enabling the investigation of domain-domain interactions within the native environment and 
enabling the reduction of peak overlays of challenging proteins [129]. Introduction 
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4.4 Segmental  labeling 
The DNA level of eukaryotes is distinguishable in two major divisions, the protein-coding 
sections called exons, and nonprotein-coding sections called introns. All genes begin with the 
protein-coding sequences, the exons, and have then a variable number of exons and introns 
alternating with each other. RNA splicing is the process in which the mRNA will be produced 
which codes for the final protein [102]. Inteins are as well coded on the mRNA level and fully 
translated into a protein sequence, the non-functional protein precursor. Protein splicing is a 
post-translational process which opened with its discovery 20 years ago a new chapter of 
protein-biochemistry [103, 104]. The intervening sequence called intein divides a functional 
protein (the extein) into an N- and C-terminal part (the N- and C-intein). This “precursor” protein 
undergoes an autocatalytic process in which the intein excises itself and fuses the two adjacent 
exteins via a covalent and natural peptide bond [105] (Fig. 22). 
 
 
Fig. 22: Schematic representation of the protein splicing. 
About 100 cases of protein splicing has been found in all three domains of life, archaea, 
bacteria and eukarya [105]. Mutagenesis studies in the 90s using an in vitro system revealed 
that the splicing process is i) catalyzed due to the amino acids contained in the intein ii) a 
intramolecular process [106] iii) needs no external energy source, cofactors or auxilaury 
enzymes [107]. 
4.4.1 Splicing mechanism 
Protein splicing reaction involves four concerted steps: 1) N-S acylshift 2) trans-
thioestherification 3) Asn-cyclization 4) S-N acylshift and possibly undesired side reactions 
[108]. The first step in the splicing mechanism is the formation of a linear ester intermediate by 
N–O or N–S acyl rearrangement involving the nucleophilic amino acid residue at the N-terminal 
splice junction (Fig. 23  a)) [109]. This acylshift occurs adjascent to a serine, threonine, or 
cysteine residue. The formation of this linear ester intermediate is an essential step in protein 
splicing. Mutations of the serine or cysteine to other amino acids completely block the protein 
splicing [110][107].  The following step is the transesterification. An intramolecular nucleophilic 
attack of a nucleophilic residue at the C-terminal splice junction occurs on the linear ester 
intermediate (Fig. 23 b)).For the next step an asparagine residue adjascent to the C-terminal Introduction 
  - 47 - 
splice junction is essential. The asparagine undergoes a slow cyclization coupled with the 
cleavage of the ester intermediate resulting in an intein with an aminosuccinimide and two 
exteins with an ester bond (Fig. 23 c)). Finally the ester rearranges to a more stable amide 
bond and the aminosuccinimide spontaneous hydrolysis in uncatalyzed reactions (Fig. 23 d)).  
 
Fig. 23: The mechanism of protein splicing. The standard protein splicing mechanism is presented here with 
cysteines at both splice junctions.  The mechanism is similar if the cysteine nucleophile is replaced by a threonine or 
serine but in that case esters are generated (adapted from [111]). 
4.4.2 The nomenclature of inteins 
In nature the host proteins for inteins are quite diverse in function; they range from metabolic 
enzymes over proteases to DNA and RNA polymerases, ribonucleotide reductases, and the 
vacuolar-type ATPase. However host proteins involved in DNA repair and replication seem to 
dominate [112]. The inteins are mostly found in highly conserved regions near to the active site 
[113]. Inteins are named after the organism and gene in which they are found. The organism 
name follows the same consensus as restriction enzymes and uses a three letter genus and 
species designation, followed by a strain designation, if necessary. The organism name is 
followed by an abbreviation of the extein gene name. If more than one intein is present in an 
extein gene, the inteins are given a numerical suffix starting from 5' to 3' or in order of their 
identification [114]. The Pyrococcus furiosus ribonucleoside-diphosphate reductase α subunit 
gene for example contains two inteins. 'Pfu' abbreviates the organism; the gene has been called Introduction 
  - 48 - 
the 'RIR1' gene. Thus, these two inteins are called the Pfu RIR1- 1 intein and the Pfu RIR1- 2 
intein.  
The intein name refers to both, the gene and the intein protein. Therefore, as usual, the 
consensus is to italicize the gene name and to capitalize the first letter of the protein name 
[114]. Many inteins are bifunctional and contain an endonuclease activity; in this case the intein 
is also given a second name that follows the endonuclease naming conventions [115]. This 
name includes the prefix 'PI-', for protein insertion, the 3 letter organism abbreviation and a 
Roman numeral indicating the order of identification of the intein endonuclease in that organism. 
As a result the endonuclease names for the Pfu RIR1- 1 and Pfu RIR1- 2 inteins are PI- PfuI 
and PI- PfuII, respectively [114]. Inteins can be differentiated according to their size. The 300 to 
600 amino acid large inteins contain a self-splicing domain and an endonuclease domain. 
Interestingly the deletion of the endonuclease domain from a large intein does not affect protein 
splicing [116-118]). The endonuclease domain might be essential for the spread of the inteins 
among the kingdoms of life. Inteins missing the endonuclease are much smaller and so called 
mini-inteins. They contain only the self-splicing domain and range from 150 to 200 amino acids. 
Split inteins are mini-inteins split into two units. Inteins, such as PI-PfuI and PI-PfuII from 
Pyrococcus furious have been artificially split into two fragments in order to obtain split inteins 
that can perform trans-splicing [119-121]. Later on two naturally split inteins were identified in 
DnaE, the catalytic subunit α of DNA polymerase III, in the cyanobacteria Synechocystis sp. 
strain PCC6803 (Ssp) and Nostoc punctiforme (Npu), both are capable of protein trans-splicing 
[114, 122, 123] (Fig. 24).  
 
 
Fig. 24: Schematic presentation of the different sorts of inteins. 
4.4.3 The split intein Npu DnaE and the protein trans-splicing 
N- and C-terminal artificially split inteins can be reconstituted and promote after in vitro 
reconstitution protein splicing activity in trans [124-126]. By fusing proteins N- and C-terminally 
with inteins, a ligation of the target protein can be achieved [119, 123, 124] (Fig. 25). Limiting 
factors of the protein ligation using such artificially split inteins are the low yield and the required 
denaturating and reconstitution steps which make the procedure tedious. Further required 
denaturation and refolding protocols limit the ligation using artificially split inteins to protein 
targets which survive refolding [120, 126]. In contrast to artificially split inteins, naturally split Introduction 
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inteins such as Ssp DnaE and Npu DnaE have been used for spontaneous trans- splicing in 
vivo as well as in vitro without refolding procedures [114, 122, 127]. The usage of protein trans- 
splicing paved a way for many applications such as segmental labeling [119, 120, 126, 128, 
129], protein cyclization [122, 130-132], in vivo protein engineering [133-136], site-specific 
chemical modifications [137] [138] and activation of genes in transgenic plants [139].  
Analysis of the protein-splicing mechanism is quite complicated and the last step occurs 
spontaneously and is therefore difficult to analyze (4.4.1). Split inteins first associate (Fig. 25a)) 
and then the usual splicing mechanism takes place via trans-splicing leading to the intein on the 
one hand and the ligated protein on the other hand (4.4.1). For the application of trans-splicing it 
is important to mention that different side reactions may lead to either N- or C-terminal cleavage 
of the extein building end points of the reactions (Fig. 25 b),d)). The amount of side reactions 
depends on pH and temperature; thiol-induced cleavage depends on the intein and extein 
sequence [140].  
 
Fig. 25: The trans- splicing reaction mechanism (from [141]). 
The robust splicing activity and high efficiency of the naturally split intein of the gene DnaE from 
Nostoc punctiforme (Npu DnaE) of over 98% and its tolerance of sequence variations at the 
splicing junctions made this protein especially interesting for further engineering [127]. For a 
broad application it is of interest to have short C-terminal inteins (C-intein or IntC) which can be 
synthesized chemically. The C-terminal fragment of the naturally split Npu DnaE intein consists 
of 36 residues (NpuIntC36) (Fig. 26 I)). 36 Amino acids are too long for chemical synthesis; this 
length might disturb the solubility of the precursor fragment fused to the C-intein due to the 
relatively high hydrophobicity and the unfolded state of the C-terminal Intein. For Hideo and co-
workers it was possible to identify a functional C-intein consisting of 15 residues (NpuIntC15) 
(Fig. 26 II)) by shortening the C-intein systematically [141, 142].  Introduction 
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Fig. 26: Solution structure of the Nostoc punctiforme Intein (Npu DnaE)(PDB: 2KEQ [140]. The roman numbers 
indicate the different splicing sites I) indicates the WT natural splicing site separating the WT into the N-intein 
(NpuIntN ∆C36) and C-intein (NpuIntC36 (red, orange and yellow)) II) indicates the artificial splicing site identified by a 
systematic approach separating the Intein into the N-intein (NpuIntN∆C15) and C-intein (NpuIntC15 (orange and yellow)) 
III) shows the splicing site identified by the structural approach splitting the Intein into the N-Intein (NpuIntN ∆C6) and 
C-intein (NpuIntC6 in yellow) (Picture adapted from [140]). 
Solving the solution structure of the Npu DnaE intein and determining localizations of 
conformational exchange allowed creating a further functional intein pair with only six amino 
acids for the C-terminus (NpuIntC6) (Fig. 26 III)) [140]. Using these different Npu DnaE splicing 
variants it turned out that for the ligation of B1 domain of protein G (GB1) with itself, the intein 
pair NpuDnaE-IntN123/NpuDnaE-IntC15 shows the highest efficiency with 96%. In the same way 
different splicing variants for DnaE intein from Synechocystis sp PCC6803 (SspDnaE) were 
prepared but there, the highest yield was obtained for the wt combination SspDnaE-IntN123/ 
SspDnaE-IntC36 (67%) in case of the ligation of GB1 with chitin binding domain (CBD) and the 
new functional split inteins displayed no practical use [141]. Using the two different splicing 
variants of NpuDnaE Intein, the wt NpuDnaE-IntN102/NpuDnaE-IntC36  and the engineered 
NpuDnaE-IntN123/NpuDnaE-IntC15, it was shown that ligation by protein trans-splicing does not 
only depend on the splicing junction sequence but also on the foreign extein sequence [141] 
(Table 3).  
Table 3: The final yields of protein ligation by protein trans- splicing [141]. 
Intein  N-extein  C- extein  Yield (%) with 50mM DTT  Yield (%) with 0.5 mM TCEP 
NpuDnaE -IntN102/ IntC36 
(Wild type) 
nSH3 cSH3  n.d  n.d 
GB1  cSH3  n.d  n.d 
nSH3  GB1  77+- 10  61+- 8 
NpuDnaE -IntN123/IntC15 
nSH3  cSH3  27+- 10  50+- 7 
Smt3  GB1  9+- 3  65+- 7 
 
These studies revealed further, the effect of reducing conditions on the trans-splicing efficiency. 
Both the N- and C-intein contain cysteines which might form disulphide bonds if the proteins are 
not in reducing conditions. In case of SspDnaE intein 50mM dithiothreitol (DTT) blocks the Introduction 
  - 51 - 
trans-splicing and shifts the reactions completely to the side reactions, the trans-cleavages (Fig. 
25 b) and d))[143]. In fact, besides being a sulfhydryl reductant dithiothreitol (DTT) can act as a 
nucleophile and therefore induces N- and C-cleavage. Replacing dithiothreitol (DTT) with 
trialkylphospine(tris-(2-carboxyethyl)-phosphine,  TCEP), which is unreactive with cyteines, 
might improve the ligation in many cases for example for the ligation of Src homology 3 (nSH3) 
domain with cSH3 using the inteins NpuDnaE -IntN123/IntC15 [141]. 
4.4.4 Segmental labeling for nuclear magnetic resonance 
Segmental isotopic labeling is a method which was first established in vitro and allows 
incorporating isotopes selectively in regions or domains of the target protein to reduce the 
complexity of the spectra [119, 120, 144]. Iwai and his group established a convenient dual 
expression system which allows segmental isotopic labeling in Escherichia Coli and will be 
presented in the following part [128, 145]. In order to achieve the incorporation of NMR active 
isotopes only into one domain a dual vector system with two different tightly controlled inducible 
promoters for individual expression is indispensable. Additionally, the two vectors need two 
different antibiotic resistances and ORI’s to ensure a co-existence and similar distribution during 
cell division. The vectors used for this dual expression for the segmental labeling of the proteins 
GB1-CBD were pJJDuet30 (RSF ori, Kan
R, T7 Promotor, lacI) which can be induced by the 
addition of IPTG to the media and the vector pSFBAD09 (ColE1 ori, Amp
R, araBAD) which 
underlies the tight induction by L-arabinose.  
In the in vivo approach the preparation of an isotopically labeled sample takes place as 
following. For explanation, we take as example that the C-terminal extein, fused to the 
C-terminal intein, is under arabinose control and the N-terminal extein fused to the N-terminal 
intein is under T7 control. The exteins might be different domains, a tag and a domain or two 
different parts of a protein of interest. The E. coli cells containing both plasmids are grown in 
unlabeled media (Fig. 27 a)). At an appropriate OD the C-terminal extein fused to the 
C-terminal intein are induced by the addition of L-arabinose. The protein is then expressed for a 
certain amount of time, followed by media exchanged to 
15N-labeled medium by implementing a 
centrifugation step. An additional washing step allows incorporating 
15N afterwards to a level of 
97% [128](Fig. 27 b)). During the media exchange residual arabinose gets metabolized and the 
arabinose promoter turns off. After adaptation to the 
15N-labeled media the N-terminal protein 
fused to the N-terminal intein can be induced with IPTG. During the expression the protein 
trans-splicing takes place (Fig. 27 c)). After the 2nd expression the segmental labeled protein 
can be purified as usual [128] (Fig. 27 d)). The dual expression system gives high flexibility, 
tags can be added to the precursors in order to increase solubility or for purification purposes, 
the order of expression can be changed by switching the vectors. In fact, it is also possible to 
label the protein during the first expression step under arabinose control [128].  Introduction 
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Fig. 27: Preparation of a segmental isotopic labeled sample using in vivo trans–splicing. (a) The C-terminal 
protein (C-extein) fused with inteinC can be expressed by addition of L-arabinose. b) The medium will then be 
exchanged by centrifugation step into 
15N-labeled medium. During adaptation to the new media remaining arabinose 
will be metabolized and the arabinose promoter stops activity. The N-terminal protein fused to the N-intein is then 
induced by IPTG producing the 
15N isotopically labeled N-terminal precursor. C) The two N- and C-terminal precursor 
associate and protein trans-splicing occurs. In this way the 
15N-labeled N-terminal extein fuses with the unlabeled C-
terminal part. d) The fused protein can then be purified in the appropriate way (adapted from [128]). 
4.4.5 Three fragment ligation 
The two fragment ligation can be easily extended to three fragment ligation. In this way, if one 
uses an additional split intein that is able to catalyze spontaneous trans-splicing efficiently and 
specifically, even larger proteins can be accessed. For three fragment ligation it is important that 
the two Inteins are orthogonal with high splicing efficiency and without any cross-reactivity. This 
approach was elegantly solved using the two orthogonal split inteins, PI-PfuI and PI-PfuII [120]. 
However, the artificially split inteins of PI-PfuI and PI-PfuII required tedious refolding and 
optimization steps to restore the splicing activity due to insolubility of the precursors [120, 146]. 
Since refolding can also result in inactive proteins, avoiding any refolding steps would be highly 
beneficial. Hence, it is crucial to have split inteins with more robust and specific trans-splicing 
activity. The wild type Intein NpuDnaE-IntN102/IntC36 and the newly engineered splicing variant 
NpuDnaE-IntN123/IntC15, engineered by Iwai and collegues, are the key to this three fragment 
ligation without any tedious refolding steps [127, 129]) (4.4.3). The three fragment ligation using 
these intein pairs will be presented in detail in results and discussion (7.2). Materials 
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5 Materials 
5.1 Laboratory  equipment 
Name      Producer       
Agarose gel electrophoresis system  Peqlab Biotechnologie GmbH, Erlangen (Germany) 
ÄKTAprime plus          GE Healthcare Europe GmbH, München (Germany) 
ÄKTApurifier           GE Healthcare Europe GmbH, München (Germany) 
Amicon ultrafiltration membrane    Millipore Corporation, Billerica (USA) 
Amicon stirrer unit        Millipore Corporation, Billerica (USA) 
Amicon filter- centrifugation unit     Millipore Corporation, Billerica (USA) 
Analytical balance CPA124S-OCE   Sartorius AG, Göttingen (Germany) 
Autoclave  Tecnomara AG (Switzerland), Gettinge AB (Sweden) 
Avance 500 MHz NMR Spektrometer   Bruker BioSpin GmbH, Rheinstetten (Germany) 
Avance 900 MHz NMR Spektrometer   Bruker BioSpin GmbH, Rheinstetten (Germany) 
Cell disruptor Constant Systems    IUL Instruments GmbH, Königswinter (Germany) 
Centrifuge 5810 R         Eppendorf AG, Hamburg (Germany) 
Centrifuge Centricon H-401      Kontron-Hermle, Gosheim (Germany) 
Centrifuge Sorvall RC-5B       Sorvall Instruments, Bad-Homburg (Germany) 
Centrifuge Sorvall RC-5C       Sorvall Instruments, Bad-Homburg (Germany) 
Centrifuge rotor A 6.9        Kontron-Hermle, Gosheim (Germany) 
Centrifuge rotor F28-50       Sorvall Instruments, Bad-Homburg (Germany) 
Centrifuge rotor F34-6-38       Eppendorf AG, Hamburg (Germany) 
Centrifuge rotor GS-3        Sorvall Instruments, Bad-Homburg (Germany) 
Centrifuge rotor SS-34      Sorvall  Instruments,  Bad-Homburg  (Germany) 
Dialyse Cassette Slyde-A-Lyzer     Thermo Scientific, Rockford (USA) 
Dialysemembrane         Spectrum Laboratories, Ranco Dominguez 
(USA) 
Elektrophorese- system Mini-Protean  Bio-Rad Laboratories GmbH, München (Germany) 
Tetra, Cell 
Fermenter, 10-Litre        Sartorius AG, Göttingen (Germany) 
French press cell disruptor      Thermo Scientific, Rockford (USA) 
Heating unit           VWR International GmbH, Darmstadt (Germany) 
HPLC Pump PU-980         Jasco GmbH, Gross-Umstadt (Germany) 
HPLC Detector MD-910       Jasco GmbH, Gross-Umstadt (Germany) 
Incubation shaker         Infors AG, Bottmingen-Basel (Germany) 
Incubation  shaker    Innova 4330 New Brunswick Scientific GmbH, Nürtin 
(Germany) 
Magnetic stirrer RCT basic       IKA-Werke GmbH & Co. KG, Staufen (Germany) 
Membrane pump         VACUUBRAND GmbH & Co. KG, Wertheim  
(Germany) 
NanoDrop DN 1000         Peqlab Biotechnologie, Erlangen (Germany) 
Optilab rex (RI detector)  Wyatt Technology Europe GmbH, Dernbach 
(Germany) 
PCR-Maschine  TPersonal      Biometra biomedizinische Analytik, GmbH, Göttingen 
(Germany) 
pH-Metre PHM210       Radiometer-Analytical SAS, Villurbanne 
(France) 
Plate incubator           Memmert GmbH & Co. KG, Schwabach (Germany)  
Portable Precesion balance      Sartorius AG, Göttingen (Germany) 
Precesion balance PB3002      Mettler-Toledo GmbH, Gießen (Germany) 
Power supply EPS 300       Pharmacia Biotech/GE Healthcare Europe GmbH,  
München (Germany) 
Power supply Power PAC 3000     Bio-Rad Laboratories GmbH, München (Germany) Materials 
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Shaker Promax 2020         Heidolph Instruments GmbH & Co., KG, Schwabach 
       ( G e r m a n y )  
Sonificator  Labsonic U B. Braun Biotech International, Melsungen 
   (Germany) 
Spectrofluorometre FP- 6500     Jasco GmbH, Gross-Umstadt (Germany) 
Spectropolarimetre J- 810       Jasco GmbH, Gross-Umstadt (Germany) 
Table centrifuge Biofuge 13      Heraeus, Hanau (Germany) 
Table centrifuge Mikro 22R       Andreas Hettich GmbH & Co. KG, Tuttlingen  
(Germany) 
Waterbath shaker        New Brunswick Scientific Inc., Edison (USA) 
5.2 Chromatography 
Material/  Column      Producer      
IMAC Sepharose 6 fast flow        GE Healthcare Europe GmbH, München  
(Germany)  
Ni-NTA Superflow           Qiagen, Hilden (Germany) 
OmniFit 25/100 column         GE Healthcare 
HiLoad 1660 Superdex 200        GE Healthcare 
Superdex 75 10/300 column        GE Healthcare 
PerfectSil 250x 4,6 C18 column       MZ Analysetechnik GmbH, Mainz (Germany) 
Superose 6 10/300 column         GE Healthcare 
MonoQ  5/50GL       GE  Healthcare 
Amylose Resign     New England Biolabs GmbH, Frankfurt 
(Germany) 
5.3 Chemicals 
Name      Producer       
Acetyl phosphate lithium potassium salt  Sigma-Aldrich Chemie GmbH (Germany) 
Adenosine 5’-triphosphate (ATP)  Roche Diagnostics GmbH (Germany) 
Amino acids (unlabeled)  Sigma-Aldrich Chemie GmbH (Germany) 
Antifoam Y-30 emulsion  Sigma-Aldrich Chemie GmbH (Germany) 
L-(+)-Arabinose  Carl Roth GmbH+Co.KG (Germany) 
Bactotryptone  Carl Roth GmbH+Co.KG (Germany) 
Bovine serum albumin Fraction V  Sigma-Aldrich Chemie GmbH (Germany) 
Complete Protease Inhibitor Cocktail  Roche Diagnostics GmbH (Germany) 
Dimethylsulfoxide  Carl Roth GmbH+Co.KG (Germany) 
1,4-Dithiotreitol (DTT)  Carl Roth GmbH+Co.KG (Germany) 
Ethidiumbromide Carl  Roth GmbH+Co.KG (Germany) 
Folinic acid calcium salt  Sigma-Aldrich Chemie GmbH (Germany) 
Gene ruler 100bp, 1kb DNA ladder  Fermentas GmbH (Germany) 
Glucose monohydrate  Carl Roth GmbH+Co.KG (Germany) 
13C-Glucose monohydrate  Sigma-Aldrich Chemie GmbH (Germany) 
HEPES  Carl Roth GmbH+Co.KG (Germany) 
Imidazole  Carl Roth GmbH+Co.KG (Germany) 
IPTG  Carl Roth GmbH+Co.KG (Germany) 
KCl   Carl Roth GmbH+Co.KG (Germany) 
α-Ketoglutarate Sigma-Aldrich Chemie GmbH (Germany) 
KH2PO4  Carl Roth GmbH+Co.KG (Germany)   
K2HPO4  Carl Roth GmbH+Co.KG (Germany) 
Magnesium acetate tetrahydrate  Sigma-Aldrich Chemie GmbH (Germany) 
D-(+)- Maltose monohydrat  Sigma-Aldrich Chemie GmbH (Germany) 
2-Mercaptoethanol Carl  Roth GmbH+Co.KG (Germany) 
NaCl  Carl Roth GmbH+Co.KG (Germany) Materials 
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NaN3  Fluka, Sigma-Aldrich Chemie GmbH (Germany) 
NH4Cl Sigma-Aldrich  Chemie GmbH (Germany) 
15N-NH4Cl Sigma-Aldrich  Chemie GmbH (Germany) 
(NH4)2Fe(SO4)2* 6H2O   Carl Roth GmbH+Co.KG (Germany) 
Peptone, tryptic digest  Carl Roth GmbH+Co.KG (Germany) 
Phosphoenol pyruvic acid (PEP),  Sigma-Aldrich Chemie GmbH (Germany) 
monopotassium salt 
Potassium acetate  Sigma-Aldrich Chemie GmbH (Germany) 
Pyruvate kinase  Roche Diagnostics GmbH (Germany) 
Restriction enzymes  New England Biolabs GmbH (Germany) 
RiboLock RNase Inhibitor  Fermentas GmbH (Germany) 
Rotisphorese Gel 30  Carl Roth GmbH+Co.KG (Germany) 
Rotisphorese Gel 40  Carl Roth GmbH+Co.KG (Germany) 
SDS 
T4 DNA-ligase  New England Biolabs GmbH (Germany) 
TCEP  PIERCE, Thermo Fisher Scientific (Germany) 
tRNA E. coli MRE 600  Roche Diagnostics GmbH (Germany) 
Yeast extract  Carl Roth GmbH+Co.KG (Germany) 
5.4 Bacterial  strains 
Strain       Features      
NEB 5-alpha competent E. coli     F’ proA
+B
+ lacI
q ∆(lacZ)M15 zzf::Tn10 
(NEB GmbH)    (Tet
R)/fhuA2 ∆ (argF-lacZ)U169 phoA glnV44 f80 
∆ (lacZ)M15 gyrA96 recA1 endA1 thi-1 hsdR17 
 
T7 Express competent E. coli   fhuA2 lacZ::T7 gene1 [lon] ompT gal 
(NEB GmbH)    sulA11 R(mcr-73::miniTn10–Tet
S)2 [dcm] R(zgb-
210:: Tn10–Tets) endA1 ∆(mcrC-mmr)114::IS10 
 
M15 competent E. coli      NaI
S, Str
S, Rif
S, Thi
-, Lac
-, Ara
+, Gal
+,  
(Quiagen GmbH)    Mtl
-, F
-, RecA
+, Uvr
+, Lon
+, contains mutations in 
lac and mtl genes, contains pREP4  
 
Arctic Express (DE3)    E. coli B F– ompT hsdS(rB 
– mB 
–) dcm
+  
(Stratagene)   Tet
r gal λ (DE3) endA Hte [cpn10 cpn60 Gent
R] 
5.5 Enzymes 
Name      Producer       
Phusion DNA Polymerase       New England Biolabs GmbH, Frankfurt (Germany) 
Pfu Ultra II Polymerase        Stratagene, Agilent Technologies, Waldbronn  
(Germany)  
DpnI Endonuklease         New England Biolabs GmbH, Frankfurt (Germany) 
DNase  I       Sigma-Aldrich  Chemie GmbH, Taufkirchen (Germany) 
RNase  A       Sigma-Aldrich  Chemie GmbH, Taufkirchen (Germany) 
All restriction Enzymes       New England Biolabs GmbH, Frankfurt  (Germany) 
5.6 Kits 
Name      Producer       
NucleoSpin Plasmid         Macherey-Nagel GmbH & Co. KG, Düren (Germany) 
NucleoBond PC 100         Macherey-Nagel GmbH & Co. KG, Düren (Germany) 
QIAquick PCR Purification Kit     Qiagen GmbH, Hilden (Germany) 
QIAquick gel extraction kit    Qiagen GmbH, Hilden (Germany) Materials 
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5.7 Plasmids 
Plasmid     Feature       
pET-28a (+)  Kan
R; E. coli expression vector, T7 promotor and 
(Novagen)  T7 terminator with lac operon, option for N- or C-terminal 
hexahistidine affinity tag.  
 
pQE60   Amp
R; E. coli expression vector, T7 promotor and 
(Qiagen)  T7 terminator with lac operon, option for N- or C-terminal 
hexahistidine affinity tag.  
 
pBH4 Amp
R; modifed pet E. coli expression vector 
 
pRSF Kan
R; E. coli expression vector, contains T7 Promotor with  
(Merck)  lac operon and the T7 Terminator, N- terminal histidine tag 
with an enterokinase cleavage site possible as well as a C 
terminal S-tag possible, contains an RSF ori. 
 
pMAL-c2x    Amp
R; lacIq promoter and Ptac promotor; N- terminal MBP 
(New England Biolabs)    fusion protein; M13 Ori and pMB1 Ori 
  
pBAD/ His  Amp
R; araBAD promoter (PBAD); N-terminal polyhistidine  
(Invitrogen)  tag with Enterokinase cleavage site; pBR322 origin 
 
pCDF Strep
R; T7 promoptor and terminator with lac operon, a  
(Merck)  replication origin derived from CloDF13, N-terminal His Tag 
followed by an enterokinase (Ek) cleavage site and an 
optional C-terminal S- Tag sequence.  
 
pRARE Cam
R; pRARE derives from pACYC184 and codes for rare  
(Novagen)  t- RNAs for the codons AUA, AGG, AGA, CUA, CCC, and 
GGA 
 
5.8 Software 
Name      Function            
ASTRA 5.3.4.13          Processing and evaluation software for multi angle light  
scattering (MALS) data 
 
Ape   Processing software for DNA sequencing 
chromatogram files 
 
UNICORN 5.11    Software package for control, supervision of 
chromatograpy systems and processing of   
chromatograms 
 
PyMOL  Molecular graphics software for 3D presentation and 
analysis of molecules and proteins 
 
Molmol  Molecular graphics software for 3D presentation and 
analysis of molecules and proteins 
 
Sparky  Sparky is a graphical NMR assignment and integration 
program for proteins, nucleic acids, and other polymers Materials 
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Talos+    software for empirical prediction of phi and psi 
backbone torsion angles     
 
Cyana            software for automatically NOE spectra assignment  
and structure calculation 
 
5.9 Oligonucleotides 
All primers were ordered from Biospring (BioSpring GmbH, Frankfurt).  
5.10 Common buffers, media and reagents 
All solutions are prepared with MilliQ water and kept at –20°C if not stated otherwise. 
Sterilization by filtering is performed using 0.22 µm filters. 
Antibiotics: 
Ampicillin stock, 1000-fold:     100 mg/mL Na
+- ampicillin salt in H2O. 
Chloramphenicol, 1000-fold:    34 mg/mL salt in ETOH. 
Gentamycin, 1000-fold:    20mg/ml gentamycin sulfate 
Kanamycin stock, 1000-fold:     35 mg/mL kanamycin sulfate in H2O 
Inducers 
L- Arabinose stock:       20% in H2O. 
IPTG stock:         1 M in H2O. 
Media 
LB medium (1 liter):   10 g bactotryptone, 5 g yeast extract, 10 g NaCl. Adjust to pH to 
7.2- 7.4 (NaOH). Sterilize by autoclaving. 
2 x XYT medium:  16 g peptone, 10 g yeast extract, 5 g NaCl. Adjust to pH to 7.2- 7.4 
(NaOH). Sterilize by autoclaving. 
SOC medium (1 liter):   20 g bactotryptone, 5 g yeast extract, 0.5 g NaCl. Adjust to pH 7.0 
with NaOH and sterilize by autoclaving. Add final concentrations of 
25 mM KCl, 10 mM MgCl2 and 20 mM glucose solution (all 
filtersterilized). 
M9 medium (1 liter):  8.6 g Na2HPO4 * 2 H2O, 3 g KH2PO4, 5 g NaCl in 1 L H2O, Adjust to 
pH to 7.2-7.4 (NaOH). Sterilize by autoclaving. 
  After autoclaving add: 
  1.5 ml of autoclaved 1M MgSO4, 150 µl of autoclaved 1 M CaCl2, 3 
ml Vitamin solution (Sigma MEM Vitamin solution 100X cat no 
M6895), 2 ml solution Q. Dissolve in  H2O 1 g NH4Cl (
15N or 
unlabeled) and either 2 g of 
13C- Glucose or 4 g of 
12C- Glucose 
and add by filtersterilization. 
 
Solution Q (1L):   8 ml of 5 M HCl, 5 g FeCl2* 4 H2O, 184 mg CaCl2* 2 H2O, 64 mg 
H3BO3, 18 mg CoCl2* 6 H2O, 4 mg CuCl2* 2 H2O, 340 mg ZnCl2, 
605 mg Na2MoO4* 2 H2O, 40 mg MnCl2* 4 H2O  Materials 
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Reagents and buffers for cell-free expression 
Protease inhibitor cocktail:   1.197 mg/mL  AEBSF,  0.238 mg/mL  leupeptin,  0.154 mg/mL 
bestatin, 0.098 mg/mL aprotinin, 0.089 mg/mL E-64, 0.034 mg/mL 
pepstatin. 
Acetyl phosphate lithium potassium salt, AcP:  
1 M stock solution, pH 7,0, adjusted with 10 M KOH. 
Amino acid stock:   final concentration of 8 mM of each amino acid in H2O. Adjust pH 
to 8.0 with 10 M KOH. Suspensions are pipetted to the cell-free 
reaction set-up. 
Complete® protease inhibitors cocktail with EDTA:  
1 tablett with 1 ml H2O gives a 50- fold stock solution. 
DTT:         1M or 500 mM stock in H2O. 
Folinic acid calcium salt:  10 mg/mL  stock  in  H2O. Completely dissolve by incubation at 
37°C. 
HEPES:         2.4 M stock. Adjust to pH 8.0 with 10 M KOH. 
Lithium  chloride,  LiCl:    14 M stock solution in distilled RNase free water. Sterilize by 
filtering. Store at RT. 
Magnesium acetate tetrahydrate, Mg (OAc)2:  
1 M solution in H2O. 
NTP mix:  75-fold stock containing 90 mM ATP, 60 mM each GTP, CTP and 
UTP, pH 7.0 adjusted with NaOH. 
Phospho(enol)pyruvic acid monopotassium salt, PEP:  
1 M stock. Adjust to pH 7.0 with 10 M KOH. 
Polyethylenglycol 8000, PEG8000:   
40% (w/v) solution dissolved in H2O by heating in hand warm prior 
to use. 
Potassium acetate, KOAc:   4 M in H2O. 
 
Pyruvat kinase      Stock of 10 mg/mL. Commercial, no separate preparation  
(Roche Diagnostics):     necessary.        
 
RiboLock
TM RNase inhibitor: Stock of 40 U/µL. Commercial, no separate preparation necessary. 
(Fermentas) 
 
Sodium  acetate,  NaOAc:  3 M stock in distilled RNase free water, pH 5.5 adjusted with 
NaOH. Sterilize by filtering. Store at 4°C. 
Sodium azide, NaN3:     3% and 10% (w/v) stocks in H2O. 
 Materials 
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tRNA E. coli MRE 600:   40 mg/mL stock in H2O. 
 
Buffers for DNA-Agarose gels and SDS-PAGE 
Agarose:   e.g. 1% (w/v) agarose boiled in 1-fold TAE buffer. Store at 
RT. 
Ammoniumperoxid sulfate, APS:   10% stock solution by dissolving 100 mg/mL ammonium-
peroxid sulfate in H2O. Store at 4°C. 
Bradford  (1L):  100 mg Coomassie Brilliant Blue G250, 50 ml Ethanol 
(99%), 100 ml Phosphorsäure (85%) in H2O. 
Coomassie brilliant blue-staining solution for SDS gels:  
 
50% (v/v) ethanol (96%), 10% (v/v) acetic acid (100%) and 
0.1% (w/v) Coomassie Brilliant Blue G250. Dissolve in H2O 
and store at RT in a dark bottle to avoid exposure to light. 
DNA-loading dye, 6-fold:  40%  (w/v)  sucrose, 0.25% (w/v) bromphenol blue and 
0.25% xylene cyanol FF. Dissolve in H2O and store at 4°C. 
EtBr-stock solution:  10 mg/mL stock in H2O. 
SDS gel buffers: 
Running  buffer:  25 mM Tris-HCl, pH 8.0, 0.1% (w/v) SDS and 200 mM 
glycine. Store at RT. 
Stacking gel buffer:  0.4% (w/v) SDS, 0.5 M Tris-HCl, pH 6.8. Store at 4°C. 
Separating gel buffer:  0.4% (w/v) SDS, 1.5 M Tris-HCl, pH 8.9. Store at 4°C. 
SDS-PAGE  sample  buffer,  5-fold:  25% (w/v) glycerol, 25% (v/v) β-mercaptoethanol, 7.5% 
(w/v) SDS, 0.1% (w/v) coomassie G250, 300 mM Tris- HCl, 
pH 6.8. Store at RT. 
TAE buffer, 50-fold:   Dissolve 2 M Tris , 5.7% acetic acid (v/v) and 50 mM EDTA 
in H2O. Store at RT. 
Tricine gel buffers: 
Anode buffer, 10-fold:  1 M Tris-HCl, pH 8.9. Store at RT. 
Cathode buffer, 10-fold:  1 M Tris, 1 M Tricine, 1% SDS (w/v). The pH should self-
adjust to 8.25. Store at RT. 
Gel buffer, 3-fold:   3 M Tris-HCl, pH 8.45, 0.3% SDS (w/v). Store at RT. 
Protein purification and protein analysis 
Ni-NTA/IDA-Buffer A:   50 mM NaPP, 300 mM NaCl, 10 mM Imidazol, pH=8 
Ni-NTA/IDA-Buffer B:  50 mM NaPP, 300 mM NaCl, 600 mM Imidazol, pH=8 Materials 
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Ni-NTA/ IDA Stripping buffer:  500 mM NaCl, 100 mM EDTA, 20 mM TRIS, pH= 8; TRIS 
does not go into solution for pH<8   
Ni-NTA/ IDA Loading buffer:  100 mM NiSO4  
Amylose buffer A:   20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, pH=7.8 add 
fresh 10 mM β-Mercaptoethanol 
Amylose  buffer  B:  20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 10mM 
Maltose, pH=7.8 add fresh 10 mM β-Mercaptoethanol Methods 
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6 Methods 
6.1  Standard methods of molecular biology and microbiology 
6.1.1 Polymerase chain reaction (PCR) 
Conventional PCR [147, 148] reactions were performed in 100 μl volume using Phusion High 
Fidelity DNA Polymerase from NEB to according to manufacturer’s instructions. Primers were 
ordered from Biospring (Biospring, Frankfurt). 
6.1.2 PCR purification and gel extraction  
Restriction PCR purification and gel extraction were performed using the Qiagen QIAquick PCR 
Purification Kit and QIAquick Gel Extraction Kit according to manufacturer’s instructions.  
6.1.3 Restriction enzyme digest  
Restriction enzymes were purchased from New England Biolabs (NEB). Enzyme concentration 
and buffer conditions were used as suggested by the manufacturer. Circular plasmid DNA was 
digested for 1 hr at the recommended temperature. PCR products were usually digested 
overnight at the recommended temperature. 
6.1.4 Ligation of DNA fragment 
For ligation of DNA fragment, T4-DNA-ligase was purchased from NEB. Ligation reactions were 
performed in a 10 μl volume containing 1 μl 10x T4-Ligase buffer, 1 μl digested backbone 
(40 ng), 7 μl digested insert (depending on the size and concentration of the insert, usually a 
molar ratio of 1:3 [vector to insert] was used), and 1 μl T4-DNA-ligase. The reaction was 
incubated overnight at 16°C and transformed the next day into bacteria. 
6.1.5 Cloning 
After PCR amplification of the gene of interest with gene- specific primers containing 
overhanging ends with restriction enzyme recognition sequences, the PCR product was purified 
and digested with the appropriate restriction enzymes. The vector backbone was as well 
digested with restriction enzymes and dephosphorylated using Antarctic Phosphatase from NEB 
according to the manufacturer’s Instruction. Backbone and PCR products were separated by 
agarose gel electrophoresis and extracted from the gel. PCR product and backbone were 
ligated; the ligation mix was transformed into bacteria, and plated onto LB agarose plates. After 
overnight incubation at 37°C, colonies were picked, and grown in 5 ml liquid LB culture 
overnight. The next day, plasmid DNA was purified and analyzed by restriction digestion for 
insertion of the PCR product into the vector backbone. Sequences were verified by Sequencing.  Methods 
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6.1.6 Transformation of bacteria  
For transformation competent bacteria (DH5α or BL21) [149] were incubated with circular 
plasmid DNA or ligation mixtures for 20 min on ice, heat-shocked for 1 min at 42°C, recovered 
on ice for 2 min, incubated with 400 µl SOC media at 37°C, centrifuged at 6000 rpm for 1 min 
and plated onto LB- Agar plates with appropriate antibiotics in 100-200 µl liquid. The LB- Agar 
plates were incubated overnight at 37°C. 
6.1.7 Plasmid DNA preparation from bacteria  
Plasmid DNA was prepared from bacteria using either the Nucleo Spin Plasmid Kit for mini 
preps or Nuclo Bond PC 100 for midi preps both from Macherey Nagel according to 
manufacturer’s instructions. 
6.1.8 Determining DNA Concentration 
DNA concentrations were determined spectrometrically using the NanoDrop 1000 
Spectrophotometer (Peqlab Biotechnologie GmbH). 
6.1.9 Mutagenesis 
Mutagenesis PCR was carried out using the either Pfu Turbo Polymerase or PfuUltra II 
Fusion HS DNA Polymerase from Stratagene according to manufacturer’s instructions. 
Primers were ordered from Biospring (Biospring, Frankfurt). Mutations were verified by DNA 
sequencing. 
6.1.10 DNA sequencing 
DNA sequencing was performed by Sequence Laboratories Göttingen (Seqlab, Göttingen). 
Plasmid DNA and primers were submitted at the suggested concentration and volume. 
6.1.11 SDS-PAGE 
Proteins were analyzed by Tris-Glycine-SDS gels [150] using the Bio-Rad Mini Gel System. For 
the Bio-Rad Mini Gel system, gels were poured with 4% stacking (Table 4) and the percentage 
of the resolving gel was chosen according to the size of the protein of interest (Table 4). Protein 
samples were mixed 1: 5 with 5 x SDS sample buffer, incubated for 5 min at 95°C, and 
spun down for 1 min at 13000 rpm. Bio-Rad Mini Gels were run in home-made 1 x SDS-PAGE 
buffer. Proteins were separated at 100 V for 15 min followed by 200 V for 45 min with constant 
current (time varied with % of the gel). 
 
 
  Methods 
  - 63 - 
 
Table 4: Pipetting scheme for two 12 or 16% SDS separating gels and two 4% stacking gels. 
Compound 
Seperating gel
(12%) 
Seperating gel
(16%) 
Compound 
Stacking gel
(4%) 
H
2
O  3.4ml 2.1ml  H
2
O  6.1ml 
1.5M Tris/HCl pH 8.8  2.5ml  2.5ml  0.5 M Tris/HCl pH 6.8  2.5ml 
30% Acrylamide  4ml  5,3ml  30% Acrylamide  1.3ml 
10% SDS  0.1ml  0.1ml  10% SDS  0.1ml 
10% APS  0.05ml  0.05ml  10% APS  0.025ml 
TEMED  0.005ml  0.05ml  TEMED  0.005ml 
Summe  ~10ml  ~10ml    ~10ml 
 
As Tris-Tricine-PAGE gives a higher resolution proteins with a molecular weight less than 
30 kDa ACPs and PCPs were analysed by 11% Tris-Tricine-SDS gels [151, 152] (Table 5). 
11% Tris-Tricine-SDS gels were run in home-made 1 x cathode (inside the chamber) and anode 
buffer. Proteins were separated at 80 V for 15 min followed by 130 V for 50 min with constant 
current (time varied with % of the gel). 
Table 5: Pipetting scheme for two 11% Tris- Tricine- SDS separating gels and two 4% stacking gels. 
Compound  Seperating gel (11%) Stacking gel (4%) 
30% (w/v) Polyacrylamid (37,5:1)  4,4 ml  0,84 ml 
Gelbuffer, 3-fold  4 ml  1,5 ml 
Glycerol (98%)  1 ml  - 
H2O  2,6 ml  3,61 ml 
APS (10%)  0,1 ml  0,045 ml 
TEMED  0,001 ml  0,0045 ml 
Summe  12 ml  6 ml 
6.1.12 Coomassie brilliant blue staining  
After SDS-PAGE gel electrophoresis, the gel was placed in Coomassie brilliant blue solution 
and incubated for 1hr at room temperature, with shaking. The staining solution was then 
exchanged against water and cooked in the microwave for 1min. After cooling the water was 
supplemented with 10% acetic acid and destained under shaking for 30min up to ON until the 
background was completely clear. 
6.1.13 Cross linking 
300 µl of mixture of HMG-ACPI and Hal with 2, 8, 20, 40 µM of each protein were mixed with 
Glutaraldehyd leading to an end concentration of 0.125% and 0.25%. The samples were 
incubated at RT without any shaking. After 0, 3, 20 and 60 min 40 µl of sample were taken and  Methods 
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supplemeted with 10 µl reducing buffer (5X). Samples were directly frozen in N2 to slow down 
the reaction. Samples were not boiled prior to gel running.  
6.2 Proteinbiochemical  methods 
6.2.1 Determination of protein concentration 
The protein concentrations of purified proteins were determined as a routine 
spectrophotometrically using a NanoDrop 1000 Spectrophotometer (Peqlab Biotechnologie 
GmbH, Erlangen, Germany) and then calculated using the extinction coefficients at 280 nm. 
The coefficients were determined using Protparam software and are given for the different 
target proteins which were used most frequently in Table 6. 
Table 6: Calculated extinction coefficients at 280 nm for the most frequently used target proteins. 
Protein  Vector  Tag  Number of amino acids 
Molecular weight 
[g/mol] 
ε280 [mg/ml]
oxidized state 
TycB1- PCP  pBH4  N- terminal H6,TEV 105  11776.2  0.973 
ECH1  pet24b  C-terminal H6  262  29412.8  1.169 
ECH2 pet28a  C-terminal  H6  250 27894.9  0.534 
Hal  Pet28b  N-terminal H6  351  40456.8  1.144 
CurB Pet28b  N-terminal  H6 99  10973.7 0.136 
ACPI,II,III  Pet28a  N-terminal H6  324  36054.6  1.078 
ACPI Pet28a  C-terminal  H6 110  12274.7 12274.7 
 
Several proteins such as CurB suffered from a low extinction coefficient. In that case or to verify 
exact concentrations Bradford was used as an additional method to determine the 
concentration. Therefore 990 µl of Bradford solution were mixed with 10 µl of protein of interest 
in solution. After 3 min the sample was measured at 595 nm. The concentration was determined 
using the Bradford standard curve. 
6.2.2 Concentrating the proteins 
Concentrating the proteins took place with either an Amicon stirring unit or an amicon 
centrifugation unit according to the manufacturer’s instructions. The pore size of the filter was 
chosen according to the size of the protein of interest. For ACPs and PCPs with a size ~10 kDa 
filter units with a cut of of 3 kDa were chosen for bigger proteins a cutoff of 10 kDa was used. 
6.2.3 Protein expression 
Expression of pet and pMal, pBH4 vectors 
In general for protein expression fresh transformation was performed into competent cells of the 
bacterial strain of interest. Next day 100 mL LB medium supplemented with the appropriate 
antibiotic(s) ((pMal, pBH4) ampicillin 100 µg/L, (pet28a/b, pet24b) kanamycin 35 µg/L, pRARE  Methods 
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Chloramphenicol 20 µg/L) were inoculated with the transformants. After growth of 2-3 hrs at 
37°C and 180 rpm 1 L of media in a 2 L flask, supplemented with the appropriate antibiotic(s), 
was inoculated with 10-20 ml of the fresh preculture. Cells were then grown at 37°C or 30°C to 
an OD of 0.5-1 and the temperature was reduced to the required temperature (15°C). Cells had 
to adapt to the new temperature for 20-30 min and were then induced with 0.4 mM IPTG. After 
expression the cells were harvested in the Kontron A6.9 for 10 min at 4°C at 6000 rpm. Cell 
pellets were resuspended in buffer A for Ni-purification and supplemented with protease 
inhibitor. In case of MBP-tagged proteins the cells were resuspended in amylose buffer A 
(20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 10 mM β-Mercaptoethanol, pH 7.8). The different 
proteins differ in the optimal OD for induction, the temperature used for cell growth and 
induction and in the optimal time span for expression. Some proteins needed additional 
supplements in their media e.g the ACPs got modified for expressions longer than 10 hrs at 
15°C. All these specialities follow in Table 7.  
Table 7: Requirements for the expressions of the most frequently used pet constructs 
Protein 
Bacterial strain/ 
Supplementation 
Media 
Cell growth 
at T 
(°C) 
OD 
Expression at T 
(°C) 
Expression 
(hrs) 
 
ACPI,II,III 
constructs 
BL21 
0.05 mM Fe(II) 
1L LB  37 
0.5-
1 
15 7-10 
Hal 
 
BL21 
 
1.2L 
XYT 
30  1.0  15  13-15 
 
ECH2 
BL21 1L  LB  30  0.6  15  13-15 
 
ECH1 
 
BL21  1L LB  30  0.6  15  13-15 
CurB 
 
BL21/pRARE 
0.05 mM Fe(II) 
1L LB  37  0.7  15  7-10 
 
Labeling For 
15N and 
13C labeling the LB precultures were spun down at 6000 rpm for 5 min 
and solubilized in M9 before inoculation. For experiments which needed more than 98% 
incorporation of the isotopes precultures were done ON in labeled M9 media. 
6.2.4 Cell free expression 
Continous exchange cell free expression (CECF) expression reactions in P-CF mode were 
basically performed as previously described in detail [153, 154]. Analytical scale reactions were 
carried out in 24-well microplates in Mini-CECF reactors. Appropriate dialysis membranes, type  Methods 
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27/32, having a MWCO of 12-14  kDa (Roth, Karlsruhe, Germany) were used to separate 
reaction mix (RM) from feeding mix (FM). The RM volume was 55 µL and the FM volume 800 µl 
giving a ratio of 1:15. Optimal concentrations of Mg
2+ ions for the S30 extract batch were 
analysed in analytical scale reactions in the P-CF mode. CF expressions were separated into 
precipitate (P-CF) and supernatant (SNT) by centrifugation at 18.000 x g for 10 min at 4°C. The 
soluble proteins Hal, ECH2 and CurA ACPI,II,III were expected in the soluble fraction. Each 
reaction was performed in doublets. 2 µL of SNT and precipitate of P-CF over expressed protein 
were analysed by SDS polyacrylamide gel electrophoresis (SDS-PAGE). In Table 8 is the 
pipetting sheme for the cell-free reaction of ECH2 given as an example. 
Table 8: Pipetting sheme for the analytical scale P-CF mode cell-free expression of ECH2.  The pipetting 
scheme is for two analytical scale reactions for reaction mix (RM) volumes of 55 µL and 800 µL of feeding mix (FM). 
Compound 
Concentration unit
unit  MM (µl)  FM (µl)  RM (µl) 
stock  final 
NaN3 10  0,05  %  8,6     
PEG8000  40  2  %  85,5    
KOAc 4000  150,8  mM  64,5     
Mg(OAc)2  1000  11,1  mM  19    
HEPES buffer  2500  100  mM  62,7     
Complete  50  1  X  34,2    
Folinic acid  10  0,1  mg/ml  17,1     
DTT  500  2  mM  6,8    
NTP mix  75  1  X  22,8     
PEP  1000  20  mM  34,2    
AcP 1000  20  mM  34,2    
AA-mix  4  0,5  mM  213,8    
RCWMDE-mix 16,7  1  mM 102,6     
Sum       706   
MM         660,5  45,40 
S30 buffer  100  35  %    560   
AA-mix 4  0,55  mM    220   
Pyruvate kinase  10  0,04  mg/ml      0,44 
tRNA E. coli  40  0,5  mg/ml      1,38 
T7- RNAP  420  6  U/µl      1,57 
RiboLockTM 40  0,3  U/µl     1,20 
Template DNA  200  0,015  µg/ml      8,30 
S30 extract  100  35  %      38,5 
H2O          160  13,3 
Sum  1600,5 110,10 
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6.2.5 Protein purification 
General protocol for His-tagged proteins 
For purification of histagged proteins, ACPI,II,III and truncations as well as mutants, CurB and 
TycB1, cell suspensions were thawed, a small amount of Lysozym added and disrupted either 
by french press (SLM Aminco Instruments Inc. (USA)) or a sonificator (Labsonic U B. Braun 
Biotech International, Melsungen). After centrifugation (17.000-19.000 rpm, 4°C, 30 min) the 
supernatant was carefully removed and in case of the recombinant proteins ACPI,II,III  and 
truncations as well as mutants, CurB and TycB1 the recombinant protein was purified by Ni-
NTA (Qiagen) affinity chromatography using a FPLC system (Amersham Pharmacia Biotech). 
Therefore the 5 ml Ni-column was equilibrated in Ni-NTA/IDA-buffer A (50 mM NaPP, 300 mM 
NaCl, 10 mM Imidazol pH 8.0), the supernatant was loaded using an external pump with a flow 
rate of 1 ml/min. After washing an increasing gradient of imidazole was employed (10 mM to 
240 mM in 20 min, flow rate 3 ml/min). Fractions containing the recombinant protein were 
identified by SDS-PAGE analysis, combined, and dialysed against the modification buffer 
(20 mM Hepes, 50 mM NaCl, 20 mM MgCl2, pH 7,5). The proteins were aliquoted, flash frozen 
in liquid nitrogen and stored at -80°C until usage.  
Hal, ECH2 
The lysis of Cur Hal and ECH2 was performed as described above for histagged proteins. After 
centrifugation, the recombinant protein present in the SNT was purified by Ni-IDA (GE 
Healthcare) affinity chromatography using a FPLC system (Amersham Pharmacia Biotech). The 
10 ml Ni-IDA column was equilibrated in Ni-NTA/IDA-buffer A (50 mM NaPP, 300 mM NaCl, 
10 mM Imidazol pH 8.0), the supernatant was loaded using an external pump with a flow rate of 
1 ml/min. After loading the proteins were extensively washed with Ni-NTA/IDA-buffer A. For the 
purification of Hal the first wash was followed by a 50 mM and a 80 mM Imidazol washing step. 
Hal was then eluted using 400 mM Imidazol and dialyzed ON against the reconstitution buffer 
(50 mM PP and 200 mM NaCl, pH 7.5) or gelfiltrated on Superdex 200 with the same buffer. 
The Halogenase was then reconstituted anaerob following the reconstitution protocol as 
described under the corresponding section. Freezing of Cur Hal before reconstitution leads to 
precipitation of protein. ECH2 was washed with 10 mM followed by 70 mM Imidazol wash and 
then eluted with 400 mM Imidazol and either dialyzed ON against 20 mM Tris, 100 mM NaCl, 
pH 7.5 or gelfiltrated on Superdex 200 with the same buffer.  
MBP tagged Proteins 
For purification of MBP tagged proteins, cell suspensions were thawed, a small amount of 
lysozym added and disrupted either by french press (SLM Aminco Instruments Inc. (USA)) or a 
sonificator (Labsonic U B. Braun Biotech International, Melsungen). After centrifugation (17.000-
19.000 rpm, 4°C, 30 min) the supernatant was carefully removed and the recombinant protein  Methods 
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was purified via amylose resin. Therefore the column was equilibrated with amylose buffer A 
(20  mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 10 mM β-Mercaptoethanol, pH 7.8) after 
supernatant loading (1 ml/min) using an external pump the protein was extensively washed and 
then eluted using amylose buffer B (20 mM Tris-HCl, 200 mM NaCl, 10 mM Maltose, 1 mM 
EDTA, 10 mM β-Mercaptoethanol, pH 7.8) 
Anaerob reconstitution of Hal 
For the reconstitution glass and buffers were exposed to nitrogen atmosphere in a tent for a 
minimum of three days, plastic had to be exposed to nitrogen atmosphere for a minimum of five 
days. After Ni-purification Cur Hal was either gelfiltrated or dialysed against 50 mM PP, 200 mM 
NaCl, pH=7.5. Then the protein was concentrated in a stirring amicon to concentrations of 
12 mg or higher. The protein was transferred to a glass vial and oxygen removed by three 
alternating cycles of nitrogen aeration and vacuum application (More exact one cycle was 
composed of nitrogen aeration for 30 s followed by vacuuming for 1 min, this three times 
repeated and then 5 min vacuum were applied to the protein. Then the next cycle followed). In 
the tent the protein was then supplemented with 0.5 mM α-KG and 0.75 mM Fe(NH4)2(SO4)2 
and stirred for 30 min at 25°C. The protein was then centrifuged to remove precipitated protein 
(10 min, 4°C at 10 krpm) and dialyzed against nitrogen treated buffer which was chilled in 
nitrogen environment for five days (buffer 20 mM Hepes, 50 mM NaCl, α-KG 0.5 mM (freshly 
added) pH=7). After that the protein was centrifuged again for 10 min at 10 000 rpm. Finally 
protein was at concentrations of approximately 100 µM and frozen in closed glas vials. Shock 
freezing of aliquots in eppendorf tubes in liquid nitrogen if proper closing was assured and 
stored at -80°C. Contact with air had to be prevented prior freezing because it led to 
precipitation and unfunctionality.  
6.2.6 Size exclusion chromatography 
SEC with prepacked columns (GE Healthcare Europe, München, Germany) was used in order 
to assess the homogeneity and the stability in diverse buffer systems of different proteins on a 
superose 6 column (10_300) at 16°C. Usually 100 µl with concentrations ranging from 50 µM-
1 mM were loaded and run at 0.5 ml/min. Protein preparations were centrifuged at 13 000 x rpm 
for 10 min or filtered (0.2 µm) prior to loading. For preparative scale 5 ml of protein were loaded 
on a preparative superdex 200 (GE Healthcare Europe, München, Germany) and run at 
1.5  ml/min at 4°C on an Äktapurifier station (GE Healthcare Europe, München, Germany). 
Absorption was monitored at 280 as well as at 260 nm during the run. 
6.2.7 Modification of ACP constructs 
The recombinant ACPs and PCP (200 μM) were artificially loaded with either coenzyme A 
(CoA) or analogs (Acetyl-, Malonyl-, HMG-CoA) by using the promiscuous B. subtilis  Methods 
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phosphopantetheinyl (Ppan) transferase Sfp (3 μM). The loading reaction was incubated at RT 
for 1 hr in buffered aqueous solution (pH 7.5, 20 mM HEPES, 50 mM NaCl, 20 mM MgCl2). To 
ensure that complete loading was achieved the reaction mixture was analyzed directly by 
MALDI-MS. 
6.2.8 Analysis of the iron content 
The content of the iron cofactor for the halogenase was determined using the chromogen 
Ferene S assay as previously published [155]. To the corresponding halogenase (10 nmol in 
800  μL dd. H20) concentrated hydrochloric acid (100 μL) was added and incubated in an 
Eppendorf Thermomixer (10 min, 400 rpm, 25°C). Proteins were precipitated by addition of 80% 
trichloroacetic acid followed by centrifugation (13.000 rpm, 10 min, RT). The supernatant was 
transferred into an acid washed clean glass tube and 200 μL of a 45% (w/v) sodium acetate 
solution was added. 1.8 mL of the Ferene S solution (0.75 mM Ferene S, 10 mM L- ascorbic 
acid, 45% (w/v) sodium acetate) was admixed and 1 ml of the mixture was measured 
photometrically at α=593 nm. The obtained absorbance values were compared with the 
recorded calibration curve (App. 1), which was recorded analogously with distinct iron 
concentration. FeCl3  was used as iron source and the amount was varied between 0 and 
20 nmol. 
6.3  Spectroscopical and spectrometrical methods 
6.3.1 Nuclear magnetic resonance (NMR) 
Structural studies and interactions studies 
0.6 -1 mM solutions of ACPI were prepared in 50 mM arginine/50 mM glutamate buffer at pH 6.8 
containing 5% D2O and 0.15 mM DSS (4, 4-dimethyl-4-silapentane-1-sulfonate). NMR spectra 
were collected at a temperature of 291 K on 950, 900, 800 and 600 MHz on Bruker Avance 
spectrometers equipped with cryogenic 5 mm z-axis gradient triple resonance probes and a 
500 MHz Bruker Avance spectrometer equipped with 5 mm x,y,z-axis gradient triple resonance 
room temperature probe. For backbone and aliphatic side chain assignments [
15N,
1H]-TROSY 
[156] version of HSQC, HNCACO, HNCO, HNCACB, (H)C(CCO)NH-TOCSY, and 
H(CCCO)NH-TOCSY were recorded. Aromatic ring resonances were assigned with 
(H)CB(CGCC-TOCSY)H
ar experiments [157]. 
15N and 
13C separated 3D NOESY experiments 
were recorded with 70 ms mixing time. All spectra were processed with TopSpin (Bruker 
Biospin) and analysed with Sparky [158]. For the acyl chain binding studies, standard 
sensitivity-enhanced [
15N,
1H]-TROSY spectra were acquired. Steady state {
1H}
15N hetero NOE 
measurements were performed on a 600 MHz instrument using a TROSY-type pulse sequence 
[159].  Methods 
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To observe NOEs between the 4’-Ppant arm and HMG loaded 4’-Ppant arm and the ACP 
domain highly 
13C, 
15N enriched ACPI was loaded with unlabeled 
12C-CoA or HMG-CoA. The 
protein was concentrated to 1 mM in 50 mM arginine/ 50 mM glutamate buffer at a pH of 6.8 
and a 3D F1-
13C/
15N-filtered, F3-
13C-separated NOESY-HSQC was acquired at 800 MHz using 
a mixing time of 80 ms and filter delays of 93 Hz for 
1JNH and to 125 Hz and 147 Hz for 
1JCH. For 
the assignment of the unlabeled cofactor a 2D F1/F2-
13C/
15N double-filtered NOESY experiment 
[160] with 150 ms mixing time was acquired at 950 MHz. Fully 
13C/
15N-labeled ACPI was loaded 
with unlabeled 
12C-HMG-CoA and the protein was concentrated to 1 mM in 25 mM NaPi and 
50 mM NaCl at a pH of 6.8 and measured at 291K.  
6.3.2 Titration experiments 
Interaction between the different ACPI forms and their interaction partners (ECH2, Hal) were 
investigated by NMR titration experiments. [
1H,
15N]-TROSY were recorded of 
15N-labeled 
protein alone (either HMG-ACPI, apo ACPI or apo TycB1) and then the unlabeled interaction 
partner (ECH2, Hal) was added in several steps (([
15N]ACP)1:1(Interaction partner); 1:2, 1:4, 1:8 
molar ratio) (Lower ratios were not necessary due to the weak and transient nature of the 
interaction). The amount of labeled protein ranged between 100-300 µM depending on the 
solubility of the interaction partner. Chemical shift changes were monitored by [
1H,
15N]-TROSY 
experiments, measured with spectral widths of 400 points and 1536 points in the 
15N and 
1H 
dimensions, respectively 
6.3.3 Spectra analysis 
NMR spectra were processed with Top Spin 2.1 (Bruker Biospin) and analysed using Sparky 
Version 3.114 (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, San 
Francisco).  
Structural calculation 
Backbone torsion angle restraints were obtained from chemical shift data using the TALOS+ 
algorithm [161]. NOE-based distance restraints from 3D 
15N-NOESY-HSQC and 
13C-NOESY 
HSQC spectra were assigned automatically by CYANA [162, 163], which was also used for the 
structure calculations by torsion angle dynamics [164]. The final structure calculations included 
2852 distance restraints and 162 backbone torsion angle restraints (App. 10). 100 conformers 
were computed using 10000 torsion angle dynamics steps. The 20 conformers with the lowest 
target function values were subjected to restrained energy refinement with the program OPALP 
[165] using the AMBER force field [166]. The quality of the structures was checked by 
PROCHECK [167] and WHATCHECK [168]. 
For the structure calculations with HMG a model of HMG was created using the online 
version of the program CORINA for 3D structure generation (http://www.molecular- Methods 
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networks.com/online_demos/corina_demo). HMG was attached covalently to the Ser1989 
residue. For the structure calculation with CYANA [169], a residue consisting of a serine 
backbone connected to the HMG cofactor was added to the standard residue library and the 
dataset was complemented with additional NOE information for the cofactor. The resulting 
structures were subjected to restrained energy minimization using OPALp [165]. The necessary 
partial charges for HMG-serine were calculated using the PRODRG server [170]. 
Molecular imaging 
Molecular graphic images were produced using pyMOL Molecular Graphic system (2007, 
Delano DeLano Scientific LLC) 
Hetero NOE experiment 
Steady state {
1H}
15N hetero NOE measurements were performed on a 600 MHz instrument 
using a TROSY-type pulse sequence [159]. The sample was 0.4 mM 
15N-labeled holo CurA 
ACPI-ACPII-ACP-III in 50 mM arginine and 50 mM glutamate buffer at pH 6.8 and 291 K. For the 
measurements two standard {
1H}
15N-hetNOE-TROSY experiments were performed, one with 
presaturation of the protons and one control experiment without presaturation (reference 
spectra without hetNOE), both spectra were recorded in an interleaved manner. The spectra 
were recorded with spectral widths of 288 points and 1536 points in the 
15N and 
1H dimensions, 
respectively. For analysis peak heights were used instead of peak volumes due to the high 
overlay of the peaks. For hetNOE calculations the peak intensitities (Ihet, Iref) of both spectra 
were multiplied by 2
NCproc (where the NC proc is an internal scaling factor of bruker). Then the 
hetNOE value could be calculated by deviding the modified Ihet/Iref. The relaxation data obtained 
by the hetNOE measurements give evidence about the motional properties of the amide groups 
of the protein. Hetero NOE values of around 0.8 represent highly structured regions whereas 
hetero NOE <0.4 indicate unstructured, highly flexible regions. 
Tract measurement 
The rotational correlation time also called tumbling rate is a fundamental parameter to draw 
conclusions about the multimeric state; in addition it helps to draw conclusions about the 
relaxation behaviour. The TROSY for rotational correlation times (TRACT) is one fast method to 
determine  τ c value [171]. The tract method is based on the TROSY principle and allows 
determining  τ c without interference from dipole-dipole relaxation and chemical exchange 
induced relaxation. Therefore a series of one-dimensional experiments are recorded. This 
allows extracting the R2 relaxation rate upon integration over the amide region. The obtained τ c 
is an averaging of fast and slow relaxing components occurs during integration. The more 
precise τ c can be achieved with a two-dimensional version of the TRACT experiment. This 
leads to the possibility to distinguish between highly flexible loop regions and highly structured 
regions which mostly display faster relaxation.   Methods 
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6.3.4 Circular dicroisme (CD) spectroscopy 
Proteins were purified as described before. Concentrated proteins were dialysed at 4°C against 
high salt buffers and then diluted prior to CD measurements to 10 µM giving the buffer 
conditions below. CD spectrometry and melting curves were measured with a Jasco J-180 
spectropolarimeter (Jasco Labortechnik, Gross-Umstadt, Germany) in the CD-buffer giving 
below. Experiments were carried out at standard sensitivity with a band width of 1 nm and a 
response of 1 s. The data pitch was set to 0.1 nm and a scanning speed of 100 nm/min was 
used. CD spectra were recorded from 190 to 250 nm at 20°C in a cuvette of 1 mm cell length. 
The data represent an average of three to five accumulations and were baseline corrected by 
subtraction of a buffer spectrum recorded under identical conditions. Melting curves were 
measured with a band width of 1 nm, a response of 1 s and a data pitch set to 0.1 °C at a 
wavelength of 208 nm with a slope of 2°C/min from 4°C to 95°C. For CD measurements the 
following conditions were used: ECH1 (20 mM Na2HPO4, 50 mM NaCl at pH 6.5); ECH2 (20 mM 
Na2HPO4, 50 mM NaCl at pH 7.4); ACPs (2 mM Hepes, 5 mM NaCl, pH= 7.5); Hal (10 mM 
Hepes, 25 mM NaCl, pH= 7.2) 
6.3.5 Matrix-assisted laser desorption/ionization mass spectrometry (MALDI- MS)  
Mass spectrometry was performed by Dr. Bahr in the group of Prof. Karas. Mass spectra were 
recorded on a MALDI-TOF mass analyzer (Voyager STR, Applied Biosystems, Framingham 
MA, USA) in linear positive ion mode. Samples were diluted with water to a concentration of 5-
10 µM and 1 µL was mixed with 1 µL MALDI matrix (sDHB, Bruker, Germany) directly on the 
sample target.  Spectra were accumulated over 50-100 laser shots.  
6.3.6 Fluorescence anisotropy 
Fluorescence anisotropy measurements with Hal, ECH2 and fluorophore labeled ACPI were 
performed using a Jasco spectrofluorometer FP-6500 (Jasco Labortechnik, Gross-Umstadt, 
Germany). ECH2, Hal and ACPIG89C as well as TycB1 PCP as a control were expressed and 
purified as described before. For the fluorescin labeling the cysteine mutants were Ni-purified as 
usual. After dialyzing them against the fluorescin labeling buffer (20 mM MES, 100 mM NaCl, 
pH= 6) the proteins were incubated with 0.5 mM TCEP at least two hours on ice. Then 
10  molar- excess of fluorescin-malemide (AAT Bioquest, Sunnyvale (USA)) (dissolved in 
DMSO) were added and the protein incubated for 1 hr at RT. Afterwards the buffer was 
exchanged on a PD10 column against the anisotropy assay buffer (for Hal: 20 mM Hepes, 
50 mM NaCl, pH= 7.5, 0.5 mM α-KG; for ECH2: 20 mM Tris, 100 mM NaCl, pH= 7.5). Fractions 
were checked for labeled protein using Bradford. MALDI-MS was performed to check for the 
amount of labeled protein. Longer incubation times as well as higher pH turned out to lead to 
the attachment of 1-3 fluorophores and are therefore crucial. For the measurement excitation  Methods 
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and emission maxima of the f-ACPI have been determined for 485 nm for 518 nm, respectively. 
The G-factor of the ligand was measured in assay buffer (Hal: 20 mM Hepes, 50 mM NaCl, pH= 
7.5, 0.5 mM α-KG; for ECH2: 20 mM Tris, 100 mM NaCl, pH= 7.5) with a value of 1.50. For 
saturation binding, 60  nM of f-apo-ACPI or f-HMG-ACPI was incubated with increasing 
concentrations of ECH2 or Hal (0.5- 400  µM) for 1  hr at RT in a final volume of 500  µL. 
Anisotropy was determined as mean value of ten repetitions per data point. The Anisotropy of f-
ACPI without the interaction partner was subtracted from each point for normalization. Data 
were processed by non-linear regression curve fitting using Origin 8.5 (OriginLab Corporation, 
Northampton, MA 01060 USA). 
6.3.7 Multi angle light scattering measurement (MALS) 
Size exclusion chromatography (SEC) is well suited as basic means to analyse protein 
homogeneity as well as its stability over time. Nevertheless for proteins which have not a global 
fold the MW determination via SEC can be strongly influenced and gives therefore higher 
molecular masses. Multi angle light scattering (MALS) determines the absolute molecular mass 
as well as the oligomerization state by correlating molecular mass and concentration of the 
protein to the amount of scattered light. This technique does not take into account the shape of 
proteins [172]. Combined SEC-light scattering analysis was performed on a Superdex 75 5/150 
column (GE Healthcare Europe, München, Germany) at a flow rate of 0.3 ml/min on a Jasco 
HPLC unit (Jasco Labor- und Datentechnik GmbH, Gross-Umstadt, Germany) connected to a 
light scattering detector measuring at three angles (mini Dawn Treos, Wyatt Technology Europe 
GmbH, Dernbach, Germany) and a refractive index detector (Optilab rex, Wyatt Technology 
Europe GmbH, Dernbach, Germany)). The column was equilibrated for at least 16 h with SEC 
buffer (20 mM HEPES pH 7.5, 50 mM NaCl, filtered through 0.1 µm pore size VVLP filters 
(Millipore, Eschborn, Germany). The Proteins were Ni-purified followed by gelfiltration. 20 µL of 
protein samples (4 mg/mL) were separated on the column. Data analysis was accomplished 
using the ASTRA software package 5.3.4.13 (Wyatt Technology Europe GmbH, Dernbach, 
Germany). 
6.4  Analysis of functionality 
6.4.1 ECH1 and ECH2 activity test 
For the Activity test 5 μM ECH1 and or 5 μM ECH2 were mixed with 100 μM HMG-ACPI or 
500 μM HMG-CoA. In case of HMG-ACPI as a substrate the reaction was incubated for 3.5 hrs 
at 25°C. Using HMG-CoA the reaction was incubated for 12 hrs at 37°C. The reactions were 
analysed using MALDI-MS. In case of HMG-CoA high performance liquid chromatography 
(HPLC) was used to characterize substrates and products by retention time on a 
chromatography column followed by mass spectrometric analysis. Reversed-phase (RP)  Methods 
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chromatography is based on hydrophobic interactions with the non-polar stationary phase 
(carbon, C18 or C4 coated silica gel). Elution is mediated by non-polar acetonitrile, which 
competes with the adsorbed analytical compounds for non-covalent binding positions. For 
HPLC analysis a PerfectSil 250x 4.6 C18 column was used in a Jasco HPLC System. The 
running buffers were H2O with 0.1% TFA and acetonitril with 0.1% TFA. Prior to running the 
500 µl samples were filtered with a 0.2 μm cellulosemembrane. The elution was done following 
the gradient described in Table 9 with a flowrate of 1 ml/min at 25°C. Fractions of 500 μl were 
collected and subjected to electron spray ionization mass spectrometry (ESI- MS). 
Table 9: Elution profile for the seperation of the products of the ECH1 and ECH2 activity test.  
Time (min) H2O( % ) Acetonitril (%)
0 98  2 
2  98  2 
20 80  20 
25  50  50 
26 2  98 
29  2  98 
30 98  2 
37  98  2 
 
6.4.2 Cur Hal activity test 
For the Halogenase activity test Cur hal was purified and reconstituted as described before. 
100  µl of 100 µM HMG-ACPI in 20 mM Hepes, 50 mM NaCl, 20 mM MgCl2 pH 7.2 were 
supplemented with 0.5 mM α-KG and 75 µM Fe-II- SO4 and 5 µM Hal. (MgCl2 was not essential 
for the reaction but derived from the previous modification). The reaction was incubated at 25°C 
open and under shaking (800 rpm) for 10 min and 1 hr. The reaction products were analysed 
using MALDI-MS.      
6.5 Segmental  labeling 
6.5.1 Construction of vectors 
Plasmids for the expression of ACPI, II, III from CurA 
The three consecutive ACP domains (ACPI, II, III) located at the C-terminus of the polypeptide 
CurA were amplified from genomic DNA of Lyngbya majuscula strain 19L (a gift from Dr. C. 
Walsh, Harvard University, USA) using the oligonucleotides: #CurAT1T2T3-NdeI-F (5’-
GGGCATATGG GCAGCAGCCA TCATCATCA), #CurAT1T2T3-XhoI-R (5’-GGCTCGAGTC 
ACAGCTTAGA ACCACCAGTA). The PCR product was digested with NdeI and XhoI and 
cloned into pET-28b(+) vector (Novagen), resulting in the new expression vector pet28-01.  Methods 
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Plasmid for three-fragment ligation of CurA 
The first domain (ACPI) of the three consecutive ACP domains of the CurA protein was 
amplified using the primers: #I1CurAT1-NcoI-F (5’-GGCCATGGCC ACTCCTCAGG 
TAAATCAAGT) and #I1CurAT1-BamHI-R (5’-CCGGATCCCG GTTTGGTACC CTGAGAGCTC 
A). For the construction of the N-terminal precursor protein (H6-Smt3-ACPI-NpuIntN∆C15), the 
PCR product was digested with NcoI and BamHI and cloned into pHYRSF66-36, resulting in the 
new expression vector pABRSF-1. pHYRSF66-36 was derived from pHYRSF49-36 by 
eliminating  NcoI site using the two oligonucleotides #HK181 (5’-CTTTAATAAG 
GAGATATAACA TGGGCAGCAG) and #HK182 (5’-CTGCTGCCCA TGTTATATCT 
CCTTATTAAAG) and by replacing the NdeI site with NcoI site using the two oligonucleotides 
#HK183 (5’-CAGATTGGTG GTTCCATGGA GTACAAACTT ATCC) and #HK184 (5’-
GGATAAGTTT GTACTCCATG GAACCACCAA TCTG). This plasmid expresses H6-Smt3- ACPI 
-NpuIntN∆C15 fusion protein upon induction with isopropyl-D-thiogalactoside (IPTG). The 
second domain (ACPII) of the CurA protein was amplified using the primers: #I2CurAT2-KpnI-F 
(5’-CCGGTACCCA GCAATCTCTG AAAA) and #I2CurAT2-HindIII-R (5’-CCAAGCTTTT 
ATTTAGTGCC CTGAGAGGCC A). The PCR product was digested with KpnI and HindIII and 
cloned into the vector pSABAD120. The pSABAD120 was constructed by transferring the 
inserted gene in pSARSF120 into pSKBAD2 by using the restriction sites of NdeI and HindIII. 
The new expression vector pABBAD-02 expressed the fusion protein of the C-terminal 15 
residues of NpuDnaE-IntC with ACPII (H6-NpuIntC15-ACPII) for the ligation with ACPI. In order 
to construct the central precursor protein for the three-fragment ligation, the plasmid pABRSF03 
was constructed by transferring the gene of NpuIntC15 and ACPII into pHYRSF49- 36 by using 
NdeI and BamHI sites. The resulting plasmid pABRSF-3 expresses H6- Smt3-NpuIntC15-ACPII-
NpuIntN∆C36 fusion upon induction with IPTG. For the C-terminal precursor, the gene of the 
third ACP domain (ACPIII) of the CurA protein was amplified using the two primers #IBCurAT3-
KpnI-F (5’-CCGGTACCAAAACCCTGCAG CCGCTGCC) and #IBCurAT3-HindIII-R (5’-
GGAAGCTTTC ACAGCTTAGA ACCACCAGTA GCAGC). The PCR product was digested with 
KpnI and HindIII and cloned into the vector pHYRSF1-02. The new expression vector pABRSF-
2 expressed the fusion protein of H6-NpuIntC36-ACPIII under the control of T7 promoter. The 
plasmid pABBAD-15 was constructed by transferring the gene encoding NpuIntC36-ACPIII into 
pBAD vector using NdeI and HindIII sites. The resulting plasmid pABBAD-15 expresses the 
fusion protein of NpuIntC36-ACPIII upon induction with L-arabinose 
6.5.2 Segmental isotopic labeling of a central domain of CurA (ACPI,II,III) 
Protein expression and purification of CurA (ACPI,II,III) and H6-Smt3-ACPI-NpuIntN∆C15 apo- 
CurA (ACPI,II,III) was expressed in E. coli ER2566 using the plasmid pET28-01. 40 ml of 
overnight culture were spinned down at 1000×g and inoculated into 2 L 
15N labeled M9 medium 
supplemented with 25 mg/ml kanamycin and grown at 37°C. The M9 media contains 0.05 mM  Methods 
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FeCl2 which inhibits the apo to holo conversion of the protein. The cells bearing the expression 
vector were grown to an OD of 0.6 at 37°C and then transferred to 20°C and induced with 
0.4 mM IPTG at an OD of 0.7- 0.9. After 6 hours induction with IPTG, the cells were harvested. 
The protein was purified by affinity- chromatography using Ni-NTA superflow (QIAGEN). Total 
amount of purified protein was estimated to be 32 mg. Unlabeled H6-Smt3-ACPI-NpuIntN∆C15, 
which is a precursor protein for the three-fragment ligation, was expressed using the plasmid 
pABRSF-1 in 1.4 L of LB medium supplemented with 25 g/ml kanamycin and 0.05 mM FeSO4. 
The E. coli ER2566 cells bearing pABRSF-1 were grown to an OD of 0.6 at 37°C and then 
transferred to 30°C, followed by the induction with a final concentration of 0.4 mM IPTG at an 
OD of 0.7-0.8. The cells were grown for another 6 hours and harvested by centrifugation at 
9,000 ×g for 15 min. The pellet was frozen and stored at –80°C for further purification. 
The first step in vivo protein ligation for central fragment labeling of CurA (ACPI,II,III) 
 E. coli ER2566 bearing the two plasmids pABRSF-03 (H6-Smt3-NpuIntC15-ACPII- 
NpuIntN∆C36) and pABBAD-15 (NpuIntC36-ACPIII) were grown at 37°C in 2 L of LB medium 
supplemented with two antibiotics 100 μg/ml ampicillin and 25 μg/ml kanamycin and 0,05 mM 
FeSO4. The C-terminal precursor protein (NpuIntC36-ACPIII) was first induced with 0.1% (w/v) 
L-arabinose at an OD of 0.4-0.5 for 4 hrs and transferred to another shaker adjusted to 30°C. 
The culture medium was replaced with 2 L of 
15N-labeled M9 medium supplemented with 
25 μg/ml kanamycin, 0.05 mM FeCl2 and a final concentration of 0.4 mM IPTG. The 
replacement of the medium was done by spinning down the cells at 900×g with a rotor SLA-
3000. The cell pellets were gently resuspended with 100 ml of the labeled M9 medium and then 
span down once more at 900×g for 10 min. The cell pellets were then resuspended with 2 L of 
the 
15N-labeled M9 medium. After further 5 hours of the second induction, the cells were 
harvested at 9,000 ×g for 10 min and frozen at –80°C. 20 mg of the segmentally isotope-labeled 
ligated product of H6-Smt3-NpuIntC15-ACPII-ACPIII was obtained after IMAC purification. 
The second step in vitro protein ligation for central fragment labeling of CurA (ACPI,II,III) 
The purified two precursor proteins, H6-Smt3-NpuIntC15-ACPII-ACPIII and H6-Smt3-ACPI-
NpuIntN∆C15 were dialyzed against PBS, pH 7.4. About 20 mg of H6-Smt3-NpuIntC15-ACPII-
ACPIII were mixed with a total amount of 5 mg H6-Smt3-ACPI-NpuIntN∆C15. The final 
concentration of H6-Smt3-NpuIntC15-ACPII-ACPIII was 50 μM in the reaction mixture. H6-Smt3-
ACPI-NpuIntN∆C15 had a final concentration of 11 μM in the reaction mixture. The reaction 
mixture was incubated at room temperature in the presence of 0.5 mM TCEP for 10 hrs. In the 
reaction mixture yeast ubiquitin-like protein-specific protease 1 (Ulp1) was added for removal of 
the H6-Smt3 fusion tag. After 10 hours the buffer was exchanged with 10 mM Tris, 500 mM 
NaCl, 0.5 mM EDTA, 0.5 mM TCEP using a centrifugal filter unit (MWCO 5000) (Amicon). In 
this ligation buffer (10 mM Tris, 500 mM NaCl, 0.5 mM EDTA, 0.5 mM TCEP), the reaction was 
continued for further 7 hrs at 25°C with agitation at 200 rpm. After the reaction, the H6-Smt3  Methods 
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fusion tag was removed by IMAC. The flow through from IMAC was collected and concentrated 
by a centrifugal filter unit (MWCO 5000) (Amicon). The buffer was exchanged to 10 mM Na 
phosphate, pH 7.2 for further purification with ion exchange chromatography. The ligated 
product was purified by anion exchange chromatography using MonoQ 5/50GL. Fractions were 
collected and dialysed for over night against 5 L of 50 mM Na phosphate, 100 mM NaCl, pH 
7.2. The protein concentrated to 500 µl with a centrifugal filter unit for NMR measurements. The 
total amount of segmentally 
15N-labeled ACPI-[
15N]-ACPII-ACPIII was 1.7 mg. 
6.5.3 Segmental isotopic labeling of ACPI domain in CurA (ACPI,II,III) 
Protein expression and purification of labeled H6-Smt3-ACPI-NpuIntN∆C15 
The N-terminal precursor protein was expressed in E. coli ER2566 using the plasmid pABRSF-
1. 40 ml of the 100 ml pre-culture were spun down at 1,000×g and inoculated into 2 L 
15N-labeled M9 medium supplemented with 25 µg/ml kanamycin and grown at 37°C. The M9 
media contains 0.05 mM FeCl2 which inhibits the apo to holo conversion of the protein. The 
cells bearing the expression vector were grown to an OD of 0.5 at 37°C and then transferred to 
20°C and induced with 0.4 mM IPTG at an OD of 0.6-0.7. After 6 hrs induction with IPTG, the 
cells were harvested. The protein was purified by Immobilized Metal ion Affinity 
Chromatography (IMAC) using Ni-NTA superflow (QIAGEN). Total amount of purified protein 
was estimated to be 40 mg. 
Co-expression and purification of unlabeled C-terminal precursor H6-Smt3-NpuIntC15- 
ACPII- ACPIII  
E. coli ER2566 bearing the two plasmids pABRSF-3 (H6-Smt3-NpuIntC15-ACPII-NpuIntN∆C36) 
and pABBAD-15 (NpuIntC36-ACPIII) were grown at 37°C in 2 L of LB medium supplemented 
with two antibiotics 100 μg/ml ampicillin and 25 μg/ml kanamycin and 0.05 mM FeSO4. At an 
OD of 0.4 cells were transferred to another shaker adjusted to 30°C. The C-terminal precursor 
protein (NpuIntC36-ACPIII) was first induced with 0.1% (w/v) L-arabinose at an OD of 0.5- 0.6 
for 1 hr. Then the N-terminal precursor protein was induced with 0.4 mM IPTG. The two proteins 
were co-expressed for further 7 hrs. The cells were harvested at 9,000×g for 10 min and frozen 
at –80°C. 160 mg of the unlabeled, ligated product of H6-Smt3-NpuIntC15-ACPII-ACPIII were 
obtained after IMAC purification. 
The in vitro protein ligation for N-terminal ACPI domain labeling of CurA (ACPI,II,III) 
The purified two precursor proteins, H6-Smt3-NpuIntC15-ACPII-ACPIII and 
15N-labeled H6-Smt3-
ACPI-NpuIntN∆C15 were dialyzed against ligation buffer (10 mM Tris, 500 mM NaCl, 0.5 mM 
EDTA) for the second step in vitro ligation. About 42 mg of H6-Smt3-NpuIntC15-ACPII-ACPIII 
were mixed with a total amount of 40 mg H6-Smt3-ACPI-NpuIntN∆C15. The final concentration 
of H6-Smt3-NpuIntC15-ACPII-ACPIII and H6-Smt3-ACPI-NpuIntN∆C15 was 50 μM in the 
presence of 0.5 mM Tris (2-carboxyethyl)phosphine (TCEP). The reaction mixture was  Methods 
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incubated at room temperature for 13 hrs with agitation at 200 rpm. Then the yeast ubiquitin-like 
protein specific protease 1 (Ulp1) was added for removal of the H6-Smt3 fusion tag and 
incubated for further 12 hrs. After the reaction, the H6-Smt3 fusion tag was removed by IMAC. 
The flow through fraction from IMAC was collected and concentrated by a centrifugal filter unit 
(MWCO 10000) (Amicon). 30 mg of the ligated protein were obtained and the buffer was 
exchanged to 10 mM Na phosphate, pH 7.2 for further purification with ion exchange 
chromatography. The ligated product was purified by anion exchange chromatography using 
MonoQ 5/50GL. The fractions containing the ligated protein were collected and dialysed for over 
night against 5 L of 50 mM Na phosphate, 100 mM NaCl, pH 7.2. For the NMR measurements, 
the protein was concentrated to 0.4 mM using a centrifugal filter unit for NMR measurements. 
The total amount of segmentally [
15N, 
15C]-labeled [
15N/
13C]-ACPI-ACPII-ACPIII was 13 mg. 
6.5.4 Nuclear magnetic resonance spectroscopy 
All the NMR measurements were performed on either a Bruker Avance Spectrometer or Varian 
INOVA spectrometer at 
1H frequency of 600 MHz, which are equipped with cryogenic probe 
heads. The spectra were recorded with 80 mM sample for the segmentally isotope- labeled 
ACPI-[
15N]ACPII- ACPIII and with a 0.4 mM sample for uniformly 
15N-labeled CurA (ACPI-ACPII- 
ACPIII) at 18°C. The sample conditions were 50 mM Naphosphate, pH 7.2, 100 mM NaCl with 
1 mM 
2H12- DTT.  Results 
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7 Results   
7.1  Expression and purification of CurA ACPI,II,III interaction partners 
It is known that eight to ten different domains interact during biosynthesis with the triplet ACP 
(compare  Fig. 15). For structural investigations we started to work on all enzymes of the 
assembly line and excluded during target evaluation the ones with too low solubility. The 
3-hydroxy-3-methyl-gluconate (HMG) cassette (HCS (CurD), KS (CurC), ACP (CurB)) is 
responsible for producing the β-methylated hydroxymethyl-glutaryl (HMG). Attempts to increase 
the solubility of the HMG-ACP synthase (HCS) and the lone standing ketosynthase (KS) to turn 
them into target proteins for structural investigations are described briefly in 7.1.1, the CurB 
ACP is described in 7.1.7. Similarly, we tried to obtain the ketosynthase-acyltransferase (AT-
KS) didomain soluble for interaction studies. These efforts are described in 7.1.2. We optimized 
as well the expressions and purifications of the chlorinating enzyme Cur Hal (7.1.6) the 
dehydratase ECH1 (7.1.4) and the decarboxylase ECH2 (7.1.5), these three enzymes were used 
for further investigation covering NMR titration experiments, fluorescence anisotropy and activity 
assays all described starting from 7.4. 
7.1.1  The hydroxymethyl-gluconate cassette (HCS and KS) 
The genes CurC (GenBank accession number: AAT70098.1) and CurD (GenBank accession 
number: AAT70099.1) encode homologs of the 3-hydroxyl-3-methyl-glutaryl-CoA synthase, the 
KS (CurC) and the HMG-CoA synthase (HCS, CurD), respectively. The HMG-CoA synthase 
acts in trans on the β-ketoacyl-S-ACP intermediate to add the C2-carbanion of acetyl-S-ACP 
into the ketone, the acetyl group is delivered by the single ACP CurB (7.1.7). The expression 
constructs of HCS and KS were obtained as a gift from the Sherman lab. The full length gene 
CurD coding for HCS was cloned into pet24b (using NdeI and XhoI) giving raise to a C-terminal 
His6-tag. The full length gene CurC coding for the KS was cloned into pet28b (using NdeI and 
XhoI) giving raise to an N-terminal His6-tag. The constructs were expressed at 15°C, 25°C and 
37°C in standard BL21 E. coli cells and Arctic Express E. coli cells, coexpressing cold adapted 
chaperons. In all cases no soluble protein was be obtained. To improve solubility HCS and KS 
were cloned into a petM-60 vector (EMBL) (App. 2) in which the NusA leader was substituted 
with a modified ubiquitin between the NcoI  and  BamHI  sites (App. 3). The final constructs 
contain ubiquitin as an N-terminal fusion protein with a linker containing His6-tag and TEV 
cleavage site. We cloned both proteins into a modified pMAL-c2x vector giving an N-terminal 
fusion with the maltose binding protein (MBP) via a poly N-linker containing an additional His6-
tag and TEV cleavage site (App. 4). In both cases the protein was still expressed in inclusion 
bodies. In a next step we aimed for inclusion body expression (expressed for 4 hrs at 37° in 
BL21 E. coli cells) and Ni-purified them in denaturating conditions, followed by refolding (1:200  Results 
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dilution into 50 mM NaPP, 400 mM Arg, 200 mM NaCl, 0.5 mM EDTA, 5 mM Gluthathion (red) 
and 0.5 mM Gluthathion (ox)). Protein quality was verified by 16% SDS-PAGE (Fig. 28). From 
1L XYT 18 mg Ub-HCS and 36 mg Ub-KS were obtained with 20-30% impurities.  
     
Fig. 28: SDS analysis of Ub- fusion proteins. Proteins were expressed in inclusion bodies and Ni-purified in a one 
step protocol in denaturating conditions.   
7.1.2 The ketosynthase and acyltransferase didomain 
The ketosynthase and acyltransferase (KS-AT) didomain of CurA and the KS and AT of DEBS 
modul 3 (PDB: 2QO3, Fig. 29) share 38% identity and 65% similarity (Emboss Needle 
alignment surfer). This alignment was used to exactly define the linker regions and the start and 
end of the domains. To further define the start and end point of a domain a multiple alignment 
was performed with DEBS3, DEBS5 (PDB: 2HG4) and huFAS (UniProtKB/Swiss-Prot-entry: 
P49327) (App. 5). 
 
Fig. 29: Shematic presentation of one monomer of the DEBS3 KS-AT didomain (PDB: 2QO3) (adapted from 
[21]) 
To improve solubility, regions of low hydrophobicity were chosen for the N- and C-termini of the 
constructs. The hydrophobicty of the sequence was determined using protscale 
(http://www.expasy.ch/cgi-bin/protscale.pl). Interestingly, linker regions in the DEBS3 structure 
have shown to play an important structural role in activity and solubility [21]. Especially the post- Results 
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AT linker is required for KS catalyzed β-ketoacyl-ACP synthase activity and ACP recognition. 
Tang and colleagues obtained soluble constructs by keeping the KS-to-AT linker. The linkers 
mainly have hydrophobic interactions with catalytic domains and with each other. Therefore we 
decided to clone constructs containing the linkers despite the fact that they have quite high 
hydrophobicity and are less structured [21]. Taken together, all these aspects result in different 
core expression constructs summarized in Table 10. These core constructs were cloned in the 
pet28a (+) (Novagen) without any solubility tag but a C-terminal His6-fusion, into a modified 
pMAL-c2x with MBP as an N-terminal solubility tag and in some cases into petM-60 (EMBL) 
with Ub as an N-terminal solubility tag. Some proteins did not express very well neither in 
pet28a (+) nor with MBP. Proteins were purified and analysed via analytical gelfiltration (on a 
Superose 6 column). Even in case of MBP fusion, most constructs showed mainly soluble 
aggregation. Gelfiltrations were performed with and without reducing agents (DTT up to 10 mM) 
and in different buffers containing compounds to prevent the protein from aggregation (e.g.: 
arginine, glutamate, sucrose). Nevertheless no constructs were useful to go on with structural 
studies due to aggregation appearing already at low concentration (50 µM). 
Table 10: Table summerizing the different fusion constructs for AT and KS from CurA. PMAL stands for an N-
terminal MBP fusion based on a modified pMAl-c2x vector, pet28a(+) for no solubility tag but a C-terminal His6-fusion 
and petM-60 (EMBL) for an Ub His6-fusion at the N-terminus. 
1indicates that the gelfiltratin profiles are attached (App. 
6). The amino acids are indicated based on the pubmed entry of CurA (Accession: AAT70096) 
Construct 
Amino 
Acid 
pMal (MBP-Fusion)  Pet28a (+) 
Pet60 (Ub 
Fusion) 
AT-L  1086- 1484  Gelfiltration: soluble aggregates 
Gelfiltration: different 
multimers
1 
Expressed 
 
L-AT-L  974- 1484  Weak expression  No expression   
L-AT  974- 1408  Gelfiltration: just MBP 
1 No  expression   
AT  1086- 1408  Gelfiltration: just MBP  Expressed   
KS-L-AT-L  540-1484  Gelfiltration: soluble aggregates  Expressed   
KS  540- 980 
Gelfiltration: soluble 
aggregates
1 
-   
7.1.3 A peptidyl carrier protein (PCP) 
The TycB1 PCP is a peptidyl carrier protein (PCP) from the tyrocidin synthase II (Tyc) from 
Brevibacillus brevis. PCPs and ACPs share many common features– both shuttle the substrate 
via a thiolinkage- and share the general carrier fold, however differ in their overall charge: ACPs 
are acidic whereas PCPs are neutral [32, 46]. We were interested in the question whether this 
overall charge might interfere in the interaction once we replace CurA ACPI with this PCP. In 
case it disturbs the interaction the PCP would present an ideal negative control. For expression 
purposes the TycB1 PCP was cloned into a pBH4 vector leading to a construct with a 
N-terminal His6-tag followed by a TEV cleavage site and corresponding to the native aminoacids 
968-1049 of TycB1 (Gene bank accession code: YP_002772269) (App. 7). The PCP was  Results 
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expressed and Ni-purified according to the protocol for the ACPs with a yield of 20 mg purified 
protein per 1L LB (Fig. 30a). The quality of the protein was reviewed via Tricine gels. A double 
band was present for TycB1. The slightly bigger protein eluted earlier (Fraction 18-21), then the 
smaller one (33-36). To understand the reason for two different PCP populations both were 
subjected to mass spectrometry analysis. The protein sample from the fraction 18-21 for a 
15N-labeled sample gave a molecular mass of 11.777 kDa determined via matrix-assisted laser 
desorption/ionization (MALDI) measurements. The molecular weight for the full length protein is 
11.776 kDa containing 141 nitrogens. In case of a 
15N-labeled sample this would give for the full 
length protein and 98% labeling 11.915 kDa. It is known that in E. coli methionine 
aminopeptidase might remove the initiator methionine depending on the nature of the adjacent 
residue– the smaller the 2nd aminoacid the better the substrate [173]. Taking this into account 
11.777 kDa represents presumably N-terminal processed TycB1 with 99% incorporated 
15N 
(11.645kDa without N-terminal methionine and with 140 Nitrogens) (App. 8 a). 
 
Fig. 30: Quality assessment of TycB1 PCP a) 11% Tricine gel of the Ni-NTA purified TycB1 with Line 1: marker; 2: 
before induction; 3:  ppt; 4: snt; 5: frct. 11; 6: frct. 18; 7: fract.19; 8: frct. 20; 9: frct. 21; 10: frct. 26; 11: frct. 35; 12: frct. 
38. b) Superose 6 run of  TycB1 c) [
1H,
15N] TROSY of 
15N-labeled TycB1 PCP at 500 MHz in 20 mM Tris, 100 mM 
NaCl at pH 7.5.  Results 
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A molecular mass of 10.782 kDa was obtained for the later fractions of the 
15N-labeled sample. 
This is a difference of 995 Da (App. 8 b)). Despite the difference in the molecular weight, the 
different fractions give nearly the same spectrum. Two peaks are not present which might be 
presumably glycines, an assumption based on their particular chemical shifts (App. 8 b)). The 
fact that the shortened protein and the longer protein, both stick to the Ni-column and the fact 
that glycines might be missing which are present at the C-terminus; all this taken together might 
indicate a C-terminal degradation or incomplete translation for a portion of TycB1. Nevertheless 
due to the small differences in the spectra and the irrelevance of the last C-terminal amino acids 
for function we combined the fractions for NMR titration experiments (7.4.2). The maximal 
concentration in our NMR buffer was 200 µM higher concentration gave raise to soluble 
aggregates. For quality assessment a gelfiltration on the semi analytical superose 6 was 
performed at 18°C. The fraction 18-21 of TycB1 PCP elute at 17.35 ml which corresponds to a 
molecular weight of 41 kDa (Fig. 30b)). The PCP is known not to dimerize, therefore the early 
elution is presumably due to a non globular behaviour of the protein. 
15N-TROSY experiments 
measured at 500 MHz of the combined fractions display a spectrum with 76 dispersed peaks 
with homogenous intensities. 94 amino acids are present in the TycB1 construct, of which the 
first 20 amino acids belong to the His6-tag and the TEV cleavage site. These first 20 aminoacids 
are presumably unstructured and flexible and therefore do not appear in the [
1H,
15N]-TROSY 
spectrum. 
7.1.4 The dehydratase (CurE- ECH1) 
ECH1 (CurE) is a dehydratase domain from the curacin cluster described in 4.2.3. The construct 
of ECH1 was received as a gift from the Sherman lab. The construct in pet24b is composed of 
the native sequence spanning from amino acid 1 to amino acid 253 (GenBank accession code: 
AAT70100.1), C-terminally tagged with a His6-tag. The protein was successfully expressed in 
BL21 at 15°C. High amounts of protein aggregates and stays in the pellet after sonification. The 
soluble part was successfully purified via Ni-NTA and was concentrated to 10 µM in the activity 
test buffer (30 mM Tris, 50 mM NaCl, pH=6.5) and CD buffer (20 mM Na2HPO4, 50 mM NaCl at 
pH 6.5) (Fig. 31). The protein precipitated at higher concentrations. This is also the case when 
ECH1 was kept at 10 µM at 4°C for several days. Storage at -20°C turned out to be impossible, 
even at low concentrations. For quality assessment circular dichroism (CD) spectroscopy (Fig. 
31a)), CD-melting curves (Fig. 31b)) and SDS-PAGE analysis (Fig. 31c)) were performed. The 
CD curve displays a folded protein with no unfolded content. The melting curve shows that 
ECH1 has a melting temperature of 38.66± 0,12°C.  Results 
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Fig. 31: Quality assessment of ECH1. a) CD spectroscopy of ECH1 b) CD melting curve of ECH1 c) SDS-PAGE 
analysis of ECH1 
To overcome the low solubility of the protein and to make it available for structural studies we 
cloned it into a modified petM-60 (EMBL) to fuse it at the N-terminus with ubiquitin and cloned it 
into a modified pMal-c2x to obtain an N-terminal MBP fusion. Expressions were performed in 
BL21 and Arctic Express cells at 15°C. High amounts of the protein were mainly expressed in 
the insoluble fractions. Solubilty was not increased by the fusions. Therefore, we decided to use 
the pet24b construct described above and perform activity assays with ECH1 (7.4.1). 
7.1.5 The decarboxylase (CurF- ECH2) 
ECH2 is located at the N-terminus of CurF and has decarboxylative activity [68] (as described in 
4.2.3). We received the CurF didomain ECH2 with ER in cis as a gift from David Sherman. ECH2 
was then cloned into pet28a (+) containing a C-terminal His6-tag. The protein is expressed with 
an N-terminal truncation and ranges from amino acid 17-257 of the CurF protein (Gene bank 
accession code: AAT70101.1). Geders and colleagues used this construct for crystalisation 
[70]. We expressed the protein in the BL21 E. coli strain at 15°C and purified it by Ni-NTA 
affinity chromatography as described in the method section. The purified protein was 
concentrated and the quality analysed using CD-spectroscopy (Fig. 32 a) b)) SDS-PAGE with 
comassie staining (Fig. 32c), and gelchromatography (Fig. 32d)). CD spectroscopy showed the 
spectra of a well folded protein with a dominant α-helical content. From the CD melting curve of 
ECH2 the derived melting temperature was 45± 0.1°C. The protein was purified by Ni-NTA 
purification to a high purity with minor impurities (< 5%). Per 1L LB we obtained 20 mg purified 
ECH2. In some cases we performed additional gelfiltration on a superdex 200 but no soluble 
aggregates were observed at any point. ECH2 has a calculated molecular weight of 27 kDa, 
however, elutes on a superose 6 column at 17.1 ml corresponding to a molecular weight of 
55 kDa indicating a dimeric state. 
  Results 
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Fig. 32: Quality controls of the ECH2-contruct (17-257) a) Circular dichroism (CD) spectroscopy from 190 nm to 
250 nm of ECH2 b) Denaturation curve using CD spectroscopy at 208 nm c) SDS-PAGE of the ECH2 Ni-NTA 
purification: 1) ppt after lysis 2) snt after lysis 3) marker 4) flow through 5) 10 mM imidazol wash 6) 60 mM imidazol 
wash 7) 400 mM elution 8) after gelfiltration run d) gelfiltration run of ECH2 on a superose 6 10_300 column. The 
protein elutes at 17.1 ml which corresponds to 55 kDa. 
Different buffers were screened and in high salt buffer (50 mM PP, 200 mM NaCl, 1 mM DTT, 
pH 7.4) it is possible to concentrate ECH2 to 900 µM. In this buffer, ECH2 can be frozen when 
the protein is not concentrated higher than 50 µM and supplemented with 10% glycerol. For our 
experiments we prepared fresh ECH2. In low salt buffers, which are necessary for NMR and CD, 
ECH2 was concentrated to 500 µM and 560 µM (in 20 mM Tris or NaPP, 100 mM NaCl, 1 mM 
DTT, pH 7.5) but started then to precipitate over time (2 hrs at 4°C; 10 min RT). Therefore we 
tried Ub (petM-60) and MBP (modified pMAL-c2x) fusions to increase solubility. Additionally we 
elongated the C-terminus and removed the N-terminal truncation. All these constructs did not 
improve the stability. Therefore, we worked in this thesis with the pet24b ECH2-construct (17-
257) characterized above and used before in other studies [65, 68-70, 76]. Gelfiltrations were 
performed in different buffers with and without DTT (10 mM) all profiles show no soluble 
aggregation and a peak at 17.1 ml corresponding to a molecular weight of 55 kDa 
corresponding to a dimeric state. Geders and his colleagues obtained in their crystalls trimeric 
ECH2, but they suppose a dimeric state for the protein in solution [70]. In our research this 
dimeric state was not influenced neither by high concentrations of ECH2 (400 µM) nor by DTT 
(10 mM). One initial objective of this work was to map the interaction site between the ACPI and 
the interaction partner ECH2. For fast mapping approaches labelled amino acids that are at the 
end of biosynthetic pathways (Lys, Arg, His) can be added directly to the minimal medium 
without scrambling, when the protein of desire is expressed in E. coli BL21 cells. For other 
amino acids (such as Ala, Asp, Tyr, Phe, Leu, Ile and Val) the auxotrophic strains (DL39) that 
suppresses any cross-labeling can be used [100]. Another way to label specific amino acids is 
possible by using the cell free system. This approach allows more flexibility [174]. Therefore we 
tried cell free expression of ECH2. An initial Mg
2+ screen was performed at 25°C and 30°C 
ranging from 15-21 mM Mg to find the optimal Mg
2+ concentration for ECH2 expression (18 mM 
Mg
2+ was
 the optimum for GFP expression in the cell free extract used). A very faint band is 
visible in the soluble part of 15 mM Mg
2+ for 25°C and a little bit more at 30°C (Fig. 33 a) and 
b)).  Results 
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Fig. 33: ECH2 cell free expression and [
1H,
15N]-TROSY measurements a) Magnesium screen at 25°C with Lane 
1: marker; Lane 2: 15 mM reaction mix (RM); 3: 15 mM pellet (ppt); 4: 15 mM supernatant (snt); lane 5: 17 mM RM; 
6: 17 mM ppt; 7: 17mM snt; lane 8: 19 mM RM; 9: 19 mM ppt; 10: 19 mM snt; Lane 11: 21 mM RM; 12: 21 mM ppt; 
13: 21 mM snt; Lane 14: RM without an overexpression. b) Magnesium screen at 30°C with Lane 1: 15 mM RM; 2: 15 
mM ppt; 3: 15 mM snt; 4: marker; 5: 17 mM RM; 6: 17 mM ppt; 7: 17 mM snt; 8: 19 mM RM; 9: 19 mM ppt; 10: 19 mM 
snt; Lane 11: 21 mM RM; 12: 21 mM ppt; 13: 21 mM snt; Lane 14: from E. coli purified ECH2. c) [
1H,
15N]- TROSY of 
15N-labeled ECH2 at 291K at 900 MHz in 20 mM Tris, 100 mM NaCl, 1 mM DTT at pH = 7.5. 
The amounts of soluble protein obtained by cell free expression were too small and far away 
from 1-2 mg/ml, turning this method in case of ECH2 to a non-reasonable approach. In a next 
step we expressed ECH2 
15N-labeled and recorded a [
1H,
15N]-TROSY to see how the protein 
behaves under NMR conditions (20 mM Tris, 100 mM NaCl, pH=7.5) (Fig. 33 c)). The peaks 
are not homogenously distributed and are of low intensity. The apparent molecular weight of 
55 kDa leads to fast relaxion and a fast decline of signal intensity (Fig. 33 c)). In conclusion the 
fast mapping approach for ECH2 is not feasable. 
7.1.6 The halogenase (Cur Hal) 
The halogenase Cur Hal is a dimeric protein which was crystalized in 2010 [67]. We received 
the construct as a gift from D. Sherman. Cur Hal was cloned into the vector pET28b with an N-
terminal His6-tag. The native protein seuence covers the amino acids 1599 to 1930 of CurA 
according to the sequence accessible at NCBI (GenBank accession code: AAT70096.1). The 
CD spectrum shows a folded protein with α-helical contents, which dominate the CD spectra 
(Fig. 34 a)). The protein has a melting temperature (TM) of 42.7± 0.027°C (Fig. 34 b)). Cur Hal 
shows high affinity to the Ni-IDA column and was purified in a convenient three step protocol (1
st 
wash 50 mM imidazol, 2
nd wash 80 mM imidazol, elution with 400 mM imidazol). The protein  Results 
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purity was monitored using SDS-PAGE and coomassie staining (Fig. 34 c)). For high purity of 
Cur Hal no further purification step was required. However gelfiltration was performed to assure 
a homogenous sample but skipped later on due to 50% protein loss. Therefore gelfiltration was 
only applied for quality assessment (Fig. 34 d)). Hal elutes on a superose 6 column at 16.6 ml. 
This corresponds to a molecular weight of 76 kDa, hal has a calculated molecular weight of 
40.5  kDa therefore the apparent molecular weight obtained by gelfiltration corresponds to a 
dimeric state. This is in accordance with results obtained by Khare and colleagues [67]. Addition 
of 10 mM DTT did not affect the dimeric state. 
   
Fig. 34: Quality assessment of Cur Hal. a) CD curve b) CD melting curve c) SDS-PAGE d) Gelfiltration profile 
The iron content of the non-heme iron (II) and α-KG dependent halogenase was determined by 
using the Ferene S [3-(2-pyridyl)-5,6-bis(2-(5-furyl-sulfonicacid))-1,2,4-triazine] dye (6.2.8) [155]. 
The Ferene S dye chelates iron and the complex has an absorption maximum at 593 nm which 
allows determination of the amount of the complex present in solution. A standard curve for 
calibration of the Ferene S-iron complex was obtained by using stock iron solutions and 
measuring the absorption at 593 nm versus a blank run (App. 1). For Hal the A593nm value 
was 0.199± 0,007. From this value the iron content was calculated using the equation of the 
linear regression of the calibration curve. This led to a calculated iron content of 5.81 nmol. As 
13.83 nmol of the enzyme was used, this value corresponds to 42% iron content. The crystal 
structure reveals that each active monomer within the dimer contains one iron center for 
catalytic activity. The fact that 42% of the protein contains iron means that a maximum of 42% 
might be active not considering that parts of the iron might be oxidized and therefore inactive. 
Nevertheless keeping in mind that iron can be presumably replaced by other divalent cations 
during purification the presence of iron in 42% of the protein represents a quite good protein 
quality. We assessed the iron content as well from Cur Hal expressed in media supplemented 
with iron and the iron content was 40%. Therefore supplementing the media with extra iron is 
not accompanied by higher incorporation.  
Cur Hal is a well behaving protein; it can be concentrated to 900 µM without aggregation and 
survives freezing and thawing as long as it is kept anaerob. Once it was in contact with oxygen 
it started to precipitate and lost activity. We obtained 3 mg of purified, not reconstituted Cur Hal 
from 1L LB. To improve expression yields we tried N-terminal MBP (modified pMAL-c2x) and  Results 
  - 88 - 
Ub-fusions (petM-60). In fact the expression was improved but the requirement of tag cleavage 
and further purification reduced the yield and turned the fusions inefficient (Table 11). Looman 
and colleagues showed that the 2
nd codon following the AUG initiation codon has a strong effect 
on the expression yield of a modified lacZ gene in E. coli expression. In their study the codon 
AAA as a 2
nd codon gave by far the best yield for the expression in E. coli [175]. We applied the 
same idea to our protein. Actually, by changing the 2nd codon from GGC to AAA at least 
doubled our protein yields (Table 11). In all experiments displayed in this thesis we finally 
worked then with the resulting mutant HalG2K. 
Table 11: Comparison of different phy constructs in term of necessary purification and yield per 1L LB. 
Construct   1
st   2
nd  3
rd 
Hal  Ni-NTA: 6mg/1L LB  Gefi: 3mg  / 
Ub-Hal  Ni-NTA: 10 mg/1L LB  Tev and Rev. Ni-NTA: 2mg/1L LB  Gefi : 1mg/1L LB 
MBP-Hal  Amylose: 8 mg/1L LB  Rev. Ni-Nta: 2 mg/1L LB  / 
Hal G2K  Ni-NTA: 12 mg/1L LB  Gefi: 6 mg  / 
 
The halogenase turned out to be an interesting target for the fast mapping approach and we 
were interested in evaluating the feasibility of this approach for Hal. In the Cell- free expression 
we obtained the best expression for Hal at 16 mM Mg
2+ at 30°C for the extract used. 
Nevertheless, at this optimum 50% of the soluble expressed protein was precipitated and 
present in the insoluble fraction, the pellet (Fig. 35a)). Additionally we expressed Hal in E. coli 
DL39 cells. DL39 cells are auxotroph for the amino acids Ala, Asp, Tyr, Phe, Leu, Ile and Val. 
They have to be added to the minimal media and can be labeled without cross-labeling [100]. 
Unfortunately proteins that have a tendancy to aggregate during expression are even more 
difficult to express in DL39 cells. Nevertheless, we expressed Hal in DL39 cells and labeled Lys 
15N. The protein was purified and reconstituted and we recorded a [
1H,
15N]-TROSY spectra (Fig. 
35 b)). A Cur Hal monomer contains 31 Lysines. In case of a symmetric dimer we would expect 
31 signals in case of dissymetrie 62 in a [
1H,
15N]-TROSY. The recorded spectrum suffers from 
high peak overlap and inhomogenous intensities even when recorded at 900 MHz.  Due to the 
dimeric state in solution the protein relaxes very fast allowing only 60 increments to be recorded 
and therefore restricts the resolution. To summerize Cur Hal turned out to be a well behaving 
protein for NMR and therefore not a feasible target for fast mapping approaches.   Results 
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Fig. 35: Cell free expression of Cur Hal and [
1H,
15N]- TROSY a) Magnesium screen of cell free expression of Cur 
Hal. Magnesium screen at 30°C with lane 1: marker; lane 2: 15 mM supernatant (snt); lane 3: 15 mM pellet (ppt); lane 
4: 16 mM snt; lane 5: 16 mM ppt; lane 6: empty; lane 7: 17 mM ppt; lane 8: 17 mM snt; 9: 18 mM ppt; 10: 18 mM snt; 
Lane 11: 19 mM ppt; lane 12: 19 mM snt; lane 13: 20 mM ppt; Lane 14: 20 mM snt. b) [
1H,
15N]- TROSY of 
15N- 
Lysine labeled Hal. Sample was 0.1 mM Hal in 20 mM Hepes, 71 mM Arg, 50 mM Glu, 0.5 mM α-KG at a pH of 7.5 
and 291 K at 900 MHz. The sample was in anaerob conditions. The spectrum was recorded with TD1 60 and 512 
numbers of scans. Hal contains 31 lysines; due to dimerization 31- 62 signals are expected. The peak intensities are 
not homogenous and clustered in the middle area.  
In NMR titration experiments presented in detail later on, no interaction was observed between 
Hal and ACPI in different chemical states (7.4.3). Marius Clore and his group showed that 
transient interaction can be detected by paramagnetic NMR [176, 177]. For these experiments 
paramagnetic probes must be attached to cysteines located near to the active site (maximal 
distance of 15 Ǻ). To try this approach for interaction studies via NMR, we created several 
cysteine mutants with a cysteine in a range of 15 Ǻ around the active site (Cys19Ala, Cys19Ser, 
Ile61Cys, His109Cys, Gly111Cys, Tyr274Cys, His168Cys and Ser178Cys). Unfortunately all 
mutants turned out to be insoluble. 
Linker regions can enforce the interaction of two domains, especially in case of low KDs. We 
expressed the constructs Hal-ACPI,II,III-CD and Hal-ACPI. Both constructs turned out to be 
insoluble. Due to the fact that the single constructs are soluble we tried to express the single 
domains fused to inteins for carrying out segmental labeling (compare with 4.4 and 7.2). The 
idea behind was, that even if inteins are known to decrease solubility additional solubility tags 
might help the domain precursors to stay in solution. The Cur Hal protein which was expressed 
soluble containing the N-terminal sequence SISS (indicated in pink) therefore the same site was 
chosen as cleavage site for the intein fusions (C/N-Intein). After a fusion this linker region would 
keep some mutations which are presented in   Results 
  - 90 - 
Fig. 36. There the wild type sequence (WT) of the linker region and the sequence which would 
result from segmental labeling (SL) are compared.   
 
WT              PHVQQTLAARMAAGAISFEETPSISSAPQTQQPLKTLQPL 40 
SL              PHVQQTLAARMAAGAISFEETPSGSCFNGTQQPLKTLQPL 40 
                *********************** *.   *********** 
 
Fig. 36: Sequence of the Hal-ACPI linker site which was chosen for the segmental labeling approach. In pink is 
indicated the sequence of the Hal construct which was expressed soluble.  
The individual domain precursors were not soluble despite the fact that they contained SMT3 as 
a solubility tag (Data not shown).  
7.1.7 The single acyl carrier protein (CurB- ACP) 
CurB is a lone standing ACP. It belongs to the HMG cassette together with HCS and KS (4.2.1) 
and is the substrate deliverer for the acetyl group (Fig. 15) necessary for introducing the β-
branched methyl group. Therefore it is supposed to interact with the proteins KS (CurC) and 
HCS (CurD). We obtained the construct for CurB from D. Sherman. The full length gene of CurB 
(Gene bank accession code: AAT70097.1) was cloned in pet28b with an N-terminal His6-tag 
giving raise to 99 amino acids whereof 20 are artificial due to the N-terminal tag [68]. We were 
not able to express CurB in BL21 cells as described before [68]. Therefore we first tagged the 
CurB construct N-terminally with Ub (petM-60) which also did not express in BL21 or Arctic 
Express cells. Further investigations showed that CurB is encoded with a high amount of rare 
codons (35 rare codons out of 99). Therefore we co-expressed the CurB construct with the 
vetor pRARE which codes for rare t-RNAs (NEB). As a result, both the Ub-tagged and non-
tagged version of CurB was expressed and purified via Ni-NTA affinity chromatography in high 
amounts (Fig. 37a)) (Ub-CurB data not shown). For CurB we obtained 42 mg Ni-NTA purified 
protein per 1L LB for Ub-tagged CurB 41 mg. Due to no significant increase in expression for 
the Ub-tagged protein we worked with the N-terminally His6-tagged version. At high 
concentrations such as 0.6 mM in 20 mM Hepes and 50 mM NaCl, pH 7.5, CurB is pretty 
unstable. It precipitates after 10 min. Acetyl-CurB is more stable than CurB.  At pH 5 acetyl 
CurB is much more stable and can be kept at least for several hours. We performed buffer 
screens with acetyl CurB (pH 5:  20 mM NaAc, 50 mM Arg/Glu; pH 6:  20 mM MES, 50 mM 
Arg/Glu; pH 7:  20 mM Hepes 50 mM Arg/Glu; pH 8:  20 mM Hepes, 50 mM Arg/Glu) on a 
gelfiltration column (superose 6) and recorded [
1H,
15N]-TROSYs (Fig. 37 b) and c)).   Results 
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Fig. 37: PH dependant quality assessment of acetyl-CurB a) Tricine-PAGE b) [
1H, 
15N]-TROSY at different pH at 
500 MHz. The different red circles indicate regions of interest, e.g. number 1 indicates peaks which are unaffected in 
terms of intensity by increasing the pH. In comparison region 2 and 3 present peaks which disappear with increasing 
pH c) Gelfiltration profile of acetyl CurB on a superpose 6 column at different pH.  
At a pH of 5 we obtained the best spectra. With increasing pH signals start to disappear. It is 
known that at pH>7 amide proton signals have the tendancy to disappear due to the increased 
NH exchange of the backbone; but in case of acetyl-CurB this effect is already visible at pH 6. 
The gelfiltrations display that CurB exists in a pH dependant multimeric state. At pH 5 (blue) 
CurB is manly in its monomeric and dimeric state. With pH 6 (red) monomer, dimers and trimers 
are present. The higher the pH the more dimers and trimers are populated (Fig. 37 b) and c)). 
In order to confirm the mulitmeric state of acetyl-CurB, we performed size exclusion 
chromatography (SEC) multi angle light scattering (MALS) measurements at pH= 5. The protein 
eluted with one peak which we separated into a front and a back part for analysis. The front part 
appeared to be a monodispers, dimeric state and the back part confirmed the monomeric state. 
It is important to mention that 100 µM CurB was modified with 3 µM SFP. This SFP is an 
impurity, nevertheless the front part of the peak is not polydisper it is a homogenous dimer peak 
(Fig. 38, Table 12).  Results 
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Fig. 38: SEC-MALS measurements of acetyl CurB at pH 5. For the measurement a Superdex 75 5/150 column 
was used with a Optilab rEX Refractive Index Detector and a Dawn Heleos II with a wavelength of 658 nm (Wyatt 
Technology). In the Picture are displayed the UV curves at 280 nm (red) and the determination of the molecular 
weight (black). On the y-axis is marked the determined molecular weight of the protein in g/mol.  
Table 12: Results of the SEC-MALS measurement of acetyl CurB. For analysis the UV curve of the elution with 
the weight determination was divided into two parts (Fig. 38). For each sample the averaged molecular weight of the 
eluted molecules is indicated. 
Protein 
Molecular weight 
front part [kDa] 
error [kDa] 
Molecular weight 
back part [kDa] 
error [kDa] 
acetyl CurB  27.46 (3%)  0,823 11.71  (6%)  0,35 
7.1.8 ACPI,II,III  and the isolated domains 
The triplet ACP domains ACPI,II,III are located at the C-terminus of the CurA protein from 
Lyngbya majuscula. The initial structural studies of the triplet ACP (CurA-ACPI,II,III) were done 
with a truncated version missing the C-terminal Cd-domain (Cd, CurA 2261–2311) [76]. During 
this study single domain constructs as well as double domain constructs were prepared in the 
pet28a (+) vector. The constructs contained either a C-terminal or an N-terminal His6-tag. In 
Table 13 the different ACP constructs used in this study are listed with the accoding yields after 
expression in labeled minimal media and after Ni-purification. 
Table 13: ACP constructs and there yields after Ni-purification. 
Construct  Amino Acid  His-tag 
Yield in mg 
M9- Medium 
ACPI,II,III  1946- 2248  N-terminal 9,2 
ACPI,II,III-Cd  1946– 2311  N-terminal  11,5 
ACPI 1946-  2034 N-terminal  33.3 
ACPII  2055- 2143  N-terminal  24,48 
ACPIII 2145-  2248  N-terminal  26,67 
ACPI,II  1946- 2151  C-terminal  8.13 
ACPII,III  2035- 2248  C-terminal  7.2 
 
All constructs were expressed in BL21 in LB or M9 media at 15°C for 7-10 hrs, media was 
supplemented with 0.04 mM Fe-II-solution in order to prevent modifications by an endogenous 
PPTase [22]. Longer expressions in fact produced small amounts of holo-ACP proteins. All  Results 
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proteins were purified by affinity chromatography using Ni-NTA. Due to the weak binding the 
proteins were purified via a gradient protocol and eluted around 70 mM imidazol. The purity of 
the proteins was monitored via SDS-PAGE analysis (for ACPI,II,III) or Tricine gels (for single 
domains). The proteins were expressed as apo proteins and then modified according to the 
protocol in the material and method section (6.2.7). The modification was monitored using 
MALDI-MS analysis to assure 100% conversion and exclude impurities of holo Protein (e.g.: 
presented on apo to HMG conversion of ACPI (Fig. 39).  
 
Fig. 39: MALDI-MS analysis of apo ACPI and HMG-ACPI after conversion. a) MALDI-MS spectra of apo ACPI. No 
peak is observable corresponding to the mass of holo ACPI or HMG-ACPI b) MALDI-MS analysis of HMG-ACPI. No 
mass is detected corresponding with the MW of apo ACPI. The conversion took place ~100%. 
For apo ACPI,II,III  and apo ACPI,II,III-Cd 
15N-labeled NMR samples were prepared in 50 mM 
arginine and 50 mM glutamate buffer with a pH of 6.8 and a [
1H,
15N]-TROSYs were recorded at 
950 MHz and the same samples were run on a superose 6 column (Fig. 40). Apo ACPI,II,III which 
has a calculated molecular weight of 36 kDa elutes at 16.5 ml, which corresponds to a 
molecular weight of 81 kDa-2.25 bigger than expected. Apo ACPI,II,III-Cd has a molecular weight 
of 44 kDa and elutes as 16.13 ml which corresponds to a molecular weight of 104 kDa- hence 
the protein runs 2.36 times bigger than expected. Despite the fact that ACPI,II,III-Cd is 60 AA 
longer than ACPI,II,III no big differences are visible in the overlay of the [
1H,
15N]-TROSY spectrum 
for these proteins. In the region ~8.5 ppm many peaks are present with high overlay (Fig. 40). 
This is the region mainly occupied by less structured regions of the protein. Due to the high 
peak overlay it can not be excluded that some new peaks appear in this region.  
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Fig. 40: Comparison of ACPI,II,III and ACPI,II,III-Cd. a) Gelfiltration chromatography of apo ACPI,II,III (red) and ACPI,II,III–
Cd (black). b) Overlay of [
1H,
15N]-TROSY of apo ACPI,II,III (red) and ACPI,II,III-Cd (black). With the C-terminal elongation 
some peaks become less intensive. No new peaks occur in the structured region. 
In the following is the quality assessment of one isolated ACPI presented. The CD spectra of 
ACPI shows a high α-helical content (Fig. 41 a)). The melting temperature (TM) of the protein is 
62.8°C (Fig. 41b)). The quality of the purification was monitored usind Tricine gels from 
Schaegger [151] and does not show any impurities (Fig. 41c)). ACPI elutes on a superpose 6  
column at 18.51 ml corresponding to a molecular weight of 21 kDa-1.75 times more than the 
expected MW of 12 kDa and presumably a dimeric state. 10 mM DTT as reducing agent did not 
effect the gelfiltration profile.   
 
Fig. 41: : Quality assessment of ACPI a) CD curve b) CD melting curve c) Tricine gel d) Gelfiltration profile on 
superose 6 10_300 column 
Beside Crawford and Wong nobody reported any dimerization of ACP domains without a 
dimerization domain [36, 178].  The rotational correlation time (τ c) also called tumbling rate is a 
fundamental parameter to draw conclusions about the multimeric state in addition it helps to get 
insights into the relaxation behaviour of the protein of interest. The TROSY for rotational  Results 
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correlation times (TRACT) is one fast method to determine τ c value [171]. We performed the 
two-dimensional version of the TRACT experiment for a more precise determination of τ c. 
TROSY and anti-TROSY components were recorded in an interleaved manner, and the mixing 
time ∆ was incremented from 3ms to 141ms in 6ms steps. For data analysis, or each amino 
acid peak heights in each of these spectra were plotted versus the delay time and fitted 
exponentially. From this first order exponential fit, τ c was derived for each single amino acid. 
The derived τ c values were then plotted against the sequence (Fig. 42). The ACPI is 110 aa 
long of which the first 21 are unstructured and should be removed from the tumbling rate 
calculation (Fig. 42). For a dimeric state we can calculate and expect a tumbling rate of 15.9 ns 
[171, 179].  
 
Fig. 42: TRACT measurements of apo ACPI.  The rotational correlation time τ c of ACPI  was determined by 
TRACT. Experiments were conducted as 2D versions at 291 K using fully 
15N-labeled ACPI. Peak heights were 
analysed by Sparky yielding individual τ c values for each amino acid. The obtained values vary with the secondary 
structure. Unstructured linker regions at the C- and N-terminus have lower τ c values than residues in α-helical 
regions. 
The experimental results for τ c are in an average 11.1 ns which is between a monomer and a 
dimer. In order to obtain a non ambigous result about the multimeric state of ACPI we performed 
light scattering experiments. Light scattering experiments allow determining the averaged 
molecular weight of the molecules present in the detector. By coupling a gelfiltration column to 
the light scattering set up, the proteins can be separated by their size and then be directly 
analyzed by light scattering. In this way a molecular weight can be assigned to each peak. The 
technic allows as well to determine how disperse and homogenous a sample is. The 
combination of size exclusion chromatography and multiple angle light scattering is called SEC- 
MALS. Apo ACPI and the different loading states (holo, acetyl, HMG) were applied to a 
Superdex 75 5/150 column and then measured via Optilab rEX Refractive Index Detector and a 
Dawn Heleos II Laser with a wavelength of 658 nm (Wyatt Technology). The obtained curves 
are displayed in Fig. 43. The peak elutes at ~6 min.   Results 
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Fig. 43: SEC-MALS measurements of ACPI in different chemical states. For the measurement a Superdex 75 
5/150 column was used with a Optilab rEX Refractive Index Detector and a Dawn Heleos II with a wavelength of 658 
nm (Wyatt Technology). In the Picture are displayed the UV curves of apo ACPI (blue), holo ACPI (pink), acetyl ACPI 
(red) and HMG ACPI (green) at 280 nm and their determination of the molecular weight. On the y-axis is marked the 
determined molecular weight of the protein in g/mol.  
The SEC-MALS measurements of the different loading states such as holo ACPI, acetyl-ACPI 
and HMG-ACPI reveal that there is a mixture of at least two populations. Due to this fact the 
peak was distinguished into a front and a back part for separated analysis. For the unmodified 
apo ACPI no separation was necessary because only one population was present. In all cases a 
second peak was observed after 7 min, but the RI excluded this to be a protein. No further 
analyses were performed to observe what was responsible for the 7 min peak. The results for 
the analysis of the SEC-MALS measurements are summarized in Table 14. For the modified 
proteins we have a polydisperse solution which elutes with an average mass of 21 kDa. This 
might be a mixture of aggregation and a contamination of SFP due to the modification. In the 
back part proteins elute with a MW of 15 kDa which fits the monomeric state of ACPI. Apo-ACPI 
only elutes with 15 kDa indicating that the ACP is monomeric and SFP modification might lead 
to some aggregation for holo, acetyl- and HMG-ACPI. 
Table 14: Result of the SEC-MALS measurement. For analysis the UV curve of the elution with the weight 
determination (Fig. 43) was divided into two parts. For each sample is indicated the averaged molecular weight of the 
eluted molecules. 
Protein 
Molecular weight 
Front part [kDa] 
Error 
Molecular weight 
Back part [kDa] 
Error 
Apo ACPI      15,57  0,47 
Holo ACPI   21,64  0,22  15,58  0,62 
Acetyl ACPI  23,31  0,7  15  0,3 
HMG ACPI   20,34  0,3  14,74  0,29 
7.2 Segmental  labeling 
NMR is the ideal tool to characterize the structure and dynamics of biological interesting 
proteins, improving the comprehension of complex biological problems. However, NMR 
spectroscopic analysis of multiple domain proteins, often suffer from high signal overlap. This  Results 
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problem becomes even more profound when proteins contain recurring modular domains or 
highly disordered regions, like in the case of the of three consecutive ACP (ACPI,II,III) which 
appear in the curacin A assembly line. High sequence identity (100-93%) among all three 
modules of this investigated protein leads to a severe peak overlap in NMR spectra, which 
would make NMR structure investigation impossible (Fig. 44).  
 
T1              -TPQVNQVNLSEIKQVLKQQLAEALYTEESEIAEDQKFVDLGLDSIVGVEWTTTINQTYN 59 
T2              -TPQVNQVNLSEIKQVLKQQLAEALYTEESEIAEDQKFVDLGLDSIVGVEWTTTINQTYN 59 
T3              PLPQP-QVNLSEIKQVLKQQLAEALYTEESEIAEDQKFVDLGLDSIVGVEWTTTINQTYN 59 
                  **  ****************************************************** 
 
T1              LNLKATKLYDYPTLLELSGYIAQILSSQGTKPISSSSQTQQSLKTLQPLP 109 
T2              LNLKATKLYDYPTLLELAAYIAQTLASQGTKPQVS----QQPLKTLQ--- 102 
T3              LNLKATKLYDYPTLLELAPYIAQEIAATGGSKL----------------- 92 
                *****************: **** ::: * .     
 
Fig. 44: Clustal W multiple alignment of the triplet ACPs ACPI,II,III of CurA with each other. 
Using segmental isotopic labeling to incorporate stable isotopes only into one desired domain of 
the three-domain protein solves the problem and allows distinguishing the different domains. 
We applied segmental isotopic labeling to individual domains of curacin A by a combination of in 
vivo and in vitro approaches of protein ligation. Segmental isotopic labeling turned out to be an 
essential tool for investigating the structure and interaction of the three consecutive ACP 
domains. 
The central idea of our approach is to apply segmental isotopic labeling to the ACPII middle 
domain in order to reduce the complexity of the spectrum but to keep the domain in its native 
context. One promising approach therefore is to ligate three polypeptide fragments using protein 
trans- splicing (PTS) with two split inteins (denoted in Fig. 45 as Int1 and Int2). PTS does not 
require any cumbersome steps to create an N-terminal cysteine needed for expressed protein 
ligation (EPL) (Fig. 45a)) [120, 144, 180] (4.4.3). One of the main aspects to consider for this 
approach is that the two split inteins used, must be orthogonal without any cross-reactivity and 
should have a high splicing efficiency. Therefore DnaE inteins cannot be directly used because 
the domain or fragment inserted in the middle of the precursor protein containing both N- and 
C-intein (IN/IC) resulted in cyclization or polymerization (Fig. 45 b)) [122, 127, 128, 181, 182]. To 
solve this problem Hideo Iwai and his group exploited engineered NpuDnaE inteins with the 
same sequence but different split sites [141]. Shortening for example the C-intein prevented the 
formation of a functional intein with the unmodified N-intein (IN1). The splicing activity, however, 
can be restored in reactions with a modified N-intein (IN2) bearing the missing sequence (Fig. 45 
c) (4.4.5)). We used these engineered inteins in order to set up an easy system and protocol for 
the segmental isotopic labeling of a middle domain. The results of this approach will be 
presented in detail on the next pages. 
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Fig. 45: Sheme for three fragment ligation a) Segmental isotopic labeling of a central region of protein of interest 
(POI) by three-fragment ligation using two orthogonal split inteins (Int1 and Int2). b) The direct use of inteins for the 
design of a central precursor protein can lead to cyclization reaction in cis. c) The solution for cyclization reaction. 
Elimination of protein splicing activity can be achieved by shortening the C-intein. The restoration of protein splicing 
activity can be realized by complementation with an elongated N-intein. Note, however, that a combination of IN2 and 
IC1 shows cross-reactivity and should therefore be avoided [129]. 
7.2.1 The ligation site 
As mentioned in the introduction, the extein sequence has a high impact on the fact if the 
ligation reaction can take place. Several aspects play therefore a role: 
a)  Accessibility of the ligation site [111, 127] 
b)  Size of the amino acid prior to the active site [111, 183] 
c)  Compatibility of extein and intein amino acid composition [141]. 
In a first approach we decided to simplify the three fragment ligation to a two fragment ligation 
between ACPI  and ACPII,III. The ligation site was chosen at the end of helix IV which was 
defined based on structure modeling. This first ligation version (V1) is presented in a sequence 
alignment (Fig. 46 V1 in red). This first approach failed and will not be treated in more detail in 
this work. The ligation sites which were chosen in a second approach are indicated in green 
(Fig. 46 V2 in green). The ligation sites where chosen to preserve as much as possible the 
native amino acid sequence. However for the ligation between ACPI and ACPII the sequence 
ISSSSQGT will be changed to GSCFNGT due to ligation and between ACPII and ACPIII 
QVSQQPL will be changed to GSCFNGT after ligation. Nevertheless determining a suitable 
ligation site is the first important step which is then followed by several further optimization 
steps presented and explained in detail on the following pages.  Results 
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Fig. 46: Ligation sites used for segmental labeling. V1 is the ligation site used for the first, unsuccessful approach. 
V2 shows the sequence which originates if the two ligations between ACPI and ACPII and ACPII and ACPIII are 
realized within the 2
nd approach. 
During the optimization process several constructs were created and are listed in Table 15. 
Cloning procedures are not described in detail for each of the plasmid but for some of them 
(pABRSF-1, pABRSF-3 and pABBAD-15 (6.5.1)), which were used for the labeling of the middle 
domain in the three fragment ligation (7.2.6) (Shematic presentation of these vectors in Fig. 47).  
Table 15: Constructs which were cloned and used for three fragment ligation optimization. 
Vector  Protein Size (kDa) Extinction  PI 
pABRSF-1 H6SMT3  ACPI ∆15 37,410 0,815  4,98 
pABBAD-1  C15 ACPII  13,496  0,960  4,67 
pABBAD-2 H6C15  ACPII 15,659  0,827  6,02 
pABRSF-2 
pABCDF-1 
pABBAD-17  H6C36 ACPIII  17,502  0,91  6,43 
pABBAD-11 H6  ACPII ∆36 24,452  1,064  4,83 
pABBAD-12  ACPII ∆36  22,289  1,16  4,36 
pABBAD-13 C15  ACPII ∆36 25,575  1,02  4,49 
pABBAD-14  H6C15 ACPII ∆36  27,739  0,943  4,98 
pABBAD-15 C36  ACPIII 15,339    5,15 
pABBAD-16  C15 ACPIII  12,892    4,58 
pABBAD-18 H6C15  ACPIII 15,055   5,84 
pABRSF-3  H6SMT3c15 ACPII ∆36  38,501  0,72  4,96 
pABRSF-49-36 H6SMT3GB1∆15 33,594 0,86  5,11 
pABBAD-19  H6SMT3 C16 ACPII ∆36  38,501  0,72  4,96 
ACPI 
ACPII 
ACPIII  Results 
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Fig. 47: Maps of the plasmids pABRSF-1, pABRSF-3 and pABBAD-15 used for segmental isotopic labeling of 
CurA ACPI,II,III by three fragment ligation. T1= ACPI, T2= ACPII, T3= ACPIII 
7.2.2 Ligation between ACPII and ACPIII 
The ligation of two fragments can be evaluated in a fast approach by using the dual expression 
system that is explained in chapter 4.4.4. In order to evaluate if the ligation between ACPII and 
ACPIII occurs, we modified the protocol slightly from the protocol used for segmental labeling. In 
a first approach the fusion between ACPII and ACPIII was the main focus. Therefore BL21 cells 
were co-transfected with the vector pABBAD-12 (ACPII-∆C36, Ara) and pABRSF-2 (H6-c36-
ACPIII). Cells were grown in 4 ml LB to an OD of 0.4 and then transferred to 30°C and 20°C 
after 20 min adaption the cells were induced using 0.04% Arabinose. After 1.5 hrs they were 
further induced by 0.4 mM IPTG.  
 
Fig. 48: 18% SDS gel showing the ligation between the proteins ACPII-∆C36 and H6-C36-ACPIII. At 20°C and 
30°C co-expression leads to ligation. The MW of the precursors and product as well as the intein is indicated on the 
left side with an arrow.   Results 
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Samples were taken in a time course manner: before arabinose induction, after arabinose 
induction and after IPTG induction and analyzed using SDS-PAGE (Fig. 48). For the 
expressions at 30°C we observed after 1.5 hrs a band which occurs at the size corresponding to 
the size of ACPII-∆C36 (22, 29 kDa). After 3 hrs total expression (containing 1.5 hrs IPTG 
induction) nothing changed. After 5.5 hrs a band appeared corresponding to the size of the 2
nd 
precursor (H6-C36-ACPIII, 17.5 kDa). In addition a fainte band, smaller than 14 kDa appeared 
corresponding to the intein (∆C36, 11.8 kDa) and indicates therefore, that a splicing reaction 
took place. After 5.5 hrs a 4th band which is slightly smaller then the precursor ACPII-∆C36 
appeared corresponding to the product of the ligtion reaction. At 20°C the intein and the product 
gave a light band after 6.5 hrs. We can conclude that 1
st the ligation between ACPII and ACPIII 
took place and 2
ndly that the temperature has a high impact on the reaction. 30°C seemed to be 
advantageous for the yield and therefore better suited for the ligation reaction. 
7.2.3 Engineering the middle fragment 
Cyclization  
In order to perform a ligation of the middle fragment, ACPII needs to be fused to inteins on its C- 
and N-terminus. We showed that ACPII fused on its C-terminus to ∆C36 reacts with c36-ACPIII 
(7.2.2). Fusing ACPII at its N-terminus to a intein which cross-reacts with ∆C36 might lead to 
cyclization (4.4.5) [131, 184]. In order to prove this hypothesis our cooperation partners created 
H6-C36-ACPII-∆C36 and expressed it for 3 hrs, taking samples at the beginning, after one and 
three hrs (Fig. 49). After three hours a band appeared smaller than 14 kDa representing the 
intein, indicating that a splicing reaction took place. A second band appeared at a much smaller 
molecular weight representing the cyclized ACPII which runs at a much smaller molecular 
weight then the uncyclized version (compare with Fig. 48). Even when co-expressed with H6-
C36-ACPIII no trans-ligation was observed (C36-ACPII-ACPIII, ~24 kDa) which would be 
expected at slightly smaller size than H6-C36-ACPII-∆C36 (~26 kDa) (Fig. 49b)). Our 
experiment shows that the intra-molecular reaction is entropically favoured, protein splicing in 
cis  of ACPII takes place immediately after protein synthesis. Therefore, cyclization by cis-
splicing dominates the ligation (or polymerization) reaction by protein trans-splicing.  
In our case using the same split inteins for the central fragment  leads clearly to a circular form 
of the central target protein and trans-splicing is not detectable (<5%). This is an observation 
which has been made previously and could be strategically used to produce cyclized proteins to 
stabilize them [122, 130, 131]. For three fragment ligation, however, cyclization must be 
avoided.  Results 
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Fig. 49: Cyclization of ACPII a) Cis-splicing by C36-ACPII-Int∆C36 resulting in the spontaneous protein splicing in 
cis after induction. b) Co-expression with ACPIII using the same intein with the original site indicates little or no trans-
splicing. Due to space limitations ACPII and ACPIII are indicated by T2 and T3, respectively. 
Solubility 
In order to prevent our middle domain from this intra molecular reaction we used an N-terminal 
intein fusion which can not react with C-terminal intein fusion. The intein pair ∆C15 and C15 
matches our requirements. ∆C15 is highly reactive with c15, but c15 can not react with ∆C36 
because of the missing 20 aa which would be required for restoring the activity. First we were 
interested in evaluating the ligation efficiency of our new reaction partners. pABBAD-13 
contains the ACPII construct (C15-ACPII-∆C36) and pABRSF-2 as before the ACPIII construct 
(H6-C36-ACPIII).The reactivity of the new constructs were monitored as described before (7.2.2). 
The first induction at an OD of 0.4 at 30°C (best temperature from 7.2.2) was perfomed with 
0.04% arabinose and 0.1% arabinose, followed by 0.4 mM IPTG after 1 hr. Time course 
analysis by SDS-PAGE reveal that we obtained in both cases a product band appearing below 
the precursor (C15-ACPII-∆C36, 25.5 kDa) (Fig. 50 a)). Therefore the N-terminal fusion of c15 
does not prevent the reaction observed before between ACPII and ACPIII in 7.2.2. It is clearly 
shown that we obtain a stronger product band for the induction with a lower arabinose 
concentration. 
 
Fig. 50: Time course of c15-ACPII-∆C36 coexpression with H6-c36-ACPIII. The ligation of the two precursors was 
performed. a) The expression was started with arabinose induction for the precursor c15-ACPII-∆C36 followed by 
IPTG induction for H6-c36-ACPIII. b) The expression was started with IPTG induction for the precursor H6-c36-ACPIII 
followed by arabinose induction for c15-ACPII-∆C36.  
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However after 7 hrs we obtained beside the product, residual unreacted precursors. On one 
hand some amounts of the precursors might not have reacted due to the equilibrium of the 
reaction, on the other hand it is possible that the reaction was inhibited due to low solubility of 
one of the precursors or both. We repeated the experiment with inverse induction. In case the 
IPTG induced protein has a higher solubility we should obtain higher ligation efficiency. First we 
induced the cells with 0.4 mM IPTG followed by arabinose induction after 1 hr (Fig. 50 b)). In 
this case we obtained much more H6-C36-ACPIII in the cells but no excess of C15-ACPII-∆C36, 
instead, only the band corresponding to the ligation product occured. We conclude that C15-
ACPII-∆C36 protein suffers from low solubility. If expressed first, it is stored in inclusion bodies 
and only low amounts can react with the 2
nd precursor. This might become a problem for the 
labeling procedure which requires longer expression times and a M9 medium which usually 
means more stress for the cells effcting even more the solubility of proteins in a negative way. 
Therefore we decided to use Smt3 as a solubility tag to overcome solubility problems. 
7.2.4 Ligation of ACPI and ACPII 
The amino acid composition in the linker region between ACPI and ACPII differs from ACPII and 
ACPIII (Fig. 46). Before going for three fragment ligation we wanted to assure that the ligation 
between ACPI and ACPII takes place as well to elimate eventual problems which might occur 
later on. Therefore, we co-transformed the vector pABBAD-1 (c15-ACPII) and pABRSF-1 (H6-
Smt3-ACPI-∆C15, 37.4 kDa) and induced the proteins first by arabinose 0.04% for 2 hrs 
followed by 0.4 mM IPTG. The ligated product H6-Smt3-ACPI-ACPII (34.9 kDa) is very similar in 
size to the ACPI-precursor and is therefore difficult to distinguish on a SDS gel. Nevertheless 
the fact that a reaction occurred, can be seen firs by the inteins which appear, secondly by the 
product band which appears slightly smaller then the ACPI–precursor. No big difference is 
observable for the reaction performed at 20°C in comparison with the reaction performed at 
30°C (Fig. 51). 
   
Fig. 51: Time course of c15-ACPII co-expressed with H6-SMT3-ACPI-∆C15. The ligation of the two precursors was 
performed at two different temperatures. The molecular weight of precursors and product is indicated by arrows on 
the left side.  Results 
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7.2.5 One pot reaction 
We showed that H6-Smt3-ACPI-∆C15 reacts with C15-ACPII (7.2.4) and furthermore that C15-
ACPII-∆C36 reacts with H6-C36-ACPIII. Furtermore it was of interest to perform a one pot 
reaction by co-expressing of H6-Smt3-ACPI-∆C15, C15-ACPII-∆C36, and H6- C36-ACPIII. 
Therefore, the proteins must be all coded on different vectors with different ORIs and different 
antibiotic resistences (pABBAD-13 [Amp
R, arabinose], pABRSF-1 [IPTG, Kan
R], pABCDF-1 
[IPTG, Strep
R] (see Table 15)). In this case pABRSF-1 (H6-Smt3-ACPI-∆15) and pABCDF-3 
(H6-C36-ACPIII) are both under IPTG control but can not cross-react due to the missing 20 
amino acids. We performed the expression protocol as usual by varying the order of expression 
and the arabinose concentration (Fig. 52:). In all cases a band appeared at 30 kDa which was 
never observed before and is presumably a stress protein expressed as stress response to tzhe 
different antibiotics. In general the SDS gels (Fig. 52: a) and b)) looked comparable to the SDS 
gels from the ACPII and ACPIII ligation (Fig. 48). An explanation herefore is that the biggest 
precursor H6-Smt3-ACPI-∆C15 was not at all expressed. The ACPII and ACPIII precursors are 
expressed and ligated as shown before (7.2.2). 
 
Fig. 52: Three fragment ligation by one pot reaction. The three plasmids expressing pABBAD-13 (c15-ACPII-
∆C36), pABRSF-1 (H6-Smt3-ACPI-∆C15), pABCDF-1 (H6-c36-ACPIII) were co-transformed in BL21 a) Time course of 
the co-expression inducing first H6-Smt3-ACPI-∆C15, H6-c36-ACPIII by IPTG followed by c15-ACPII-∆C36 expression 
b) Time course of the co-expression inducing first c15-ACPII-∆C36 by arabinose induction followed by IPTG induced 
H6-Smt3-ACPI- ∆C15, H6-c36-ACPIII expression.   
7.2.6 The final three fragment ligation protocol 
Based on the results shown in the previous chapters (7.2.1- 7.2.5) we developed the following 
strategy for the three fragment ligation for labeling the middle domain. The first ligation step 
between ACPII and ACPIII was performed in vivo using the precursor H6-Smt3-c15-ACPII-
NpuN∆C36 (pABRSF-3 (Fig. 47)) and NpuC36-ACPIII (pABBAD-15 (Fig. 47) on the basis of 
time delayed dual expression (4.4.4) followed by Ni-purification of the NpuC15-[
15N]ACPII-ACPIII 
precursor. In a 2
nd step, the in vitro ligation step the precursor from step one was mixed with H6-
Smt3-ACPI-NpuN∆C15 which was expressed and purified before individually (Fig. 47). The in  Results 
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vitro ligation was then followed by a ULP digestion and reverse Ni-purification leading to ACPI-
[
15N]ACPII- ACPIII (Fig. 53).  
 
Fig. 53: Strategy for segmental isotopic labeling of a central domain in CurA. 
In vivo reaction 
For the in vivo reaction BL21 cells were co-transfected with the plasmids pABRSF-3 (H6-Smt3- 
NpuC15-ACPII-NpuN∆C36) and pABBAD-15 (NpuC36-ACPIII) and grown at 37°C in 2 L of LB 
medium supplemented with two antibiotics 100 μg/ml ampicillin and 25 μg/ml kanamycin and 
0.04 mM Fe-II-SO4. The C-terminal precursor protein (NpuC36-ACPIII) was first induced with 
0.1% (w/v) L-arabinose at an OD of 0.4-0.5 after 20 min adjustment to to 30°C. After 4 hrs the 
culture medium was replaced with 2 L of 
15N-labeled M9 medium supplemented with 35 μg/ml 
kanamycin, 0.05 mM FeCl2 and a final concentration of 0.4 mM IPTG. After further 5 hrs of the 
second induction, the cells were harvested and Ni-NTA purified later on. In case of the in vivo 
ligated product, it has accidentally the very same apparent size (37,87 kDa) as the 
precursor protein (H6-Smt3-NpuC15-ACPII-NpuN∆C36, 38,5 kDa) and therefore the proteins 
cannot be distinguished in SDS gel (18%), thus the gel of the in vivo ligation shown in Fig. 54 
for the segmental isotopic labeling provides little information for demonstrating the in vivo 
ligation. However, we know the ligation was successful due to a) the intein band which 
appeared and b) the decreased c36-ACPIII band and c) because it was tested without the Smt3 
fusion as well (refer to Fig. 50).   Results 
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Fig. 54: The first step of the segmental labeling protocol. SDS gel analysis of the in vivo ligation between H6-
Smt3-c15-ACPII-∆C36 and c36-ACPIII. Ligation product (H6-Smt3-c15-ACPII-ACPIII) and precursor (H6-Smt3-c15-
ACPII-∆C36) are impossible to differentiate on the SDS gel due to the similar molecular weight. Less precursor of 
c36-ACPIII after 7 hrs expression and appearing intein bands indicate that a reaction takes place. The different 
proteins are indicated with arrows on the right side. 
In vitro reaction 
H6-Smt3-ACPI-NpuN∆C15 was expressed and purified individually. About 20 mg of H6-Smt3-
NpuC15-ACPII-ACPIII was mixed with a total amount of 5 mg H6-Smt3-ACPI-NpuN∆C15. The 
final concentration of H6-Smt3-ACPII-ACPIII was 50 μM in the reaction mixture.  H6-Smt3-ACPI-
NpuN∆C15 had a final concentration of 11 μM in the reaction mixture. The reaction mixture was 
incubated at room temperature in PBS in the presence of 0.5 mM TCEP for 10 hrs. In the 
reaction mixture yeast ubiquitin-like protein-specific protease 1 (Ulp1) was added for removal of 
the H6-Smt3 fusion tag. After 10 hrs the buffer was exchanged into the ligation buffer 10 mM 
Tris, 500 mM NaCl, 0.5 mM EDTA, 0.5 mM TCEP was continued for further 7 hours at 25°C 
with agitation at 200 rpm. Samples were taken for SDS analysis of the in vitro ligation (Fig. 55). 
After the reaction, the H6-Smt3 fusion tag was removed by reverse Ni-purification. The ligation 
product was further purified with ion exchange chromatography (MonoQ). The total amount of 
segmentally 
15N-labeled ACPI-[
15N]-ACPII-ACPIII was 1.7 mg (more detilas about the protocol in 
6.5.2). 
 
Fig. 55: Time course of the second in vitro step of the protein splicing reaction. 18% SDS Page shows the 
ligation between H6-Smt3-ACPI-∆C15 and H6-Smt3-ACPII-ACPIII. A small band corresponding with the molecular 
weight of the product appears over time. The different proteins are idicated with arrows on the right side.  Results 
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7.2.7 Evaluation of CurA ACPI,II,III containing the middle domain 
15N labeled 
The different steps of the segmentally labeled protein have been observed via SDS-PAGE and 
the product was further verified via MALDI-MS. For 100% 
15N-labeled ACPII domain in ACPI,II,III 
we would expect a molecular weight of 34.054 kDa. The measured molecular weight was 
34.087 kDa. With respect to the high molecular weight for this technic and the peak broadening 
due to isotopic labeling the result matches the expected value (Fig. 56). 
 
 
Fig. 56: Maldi-MS of the segmental lsotope-labeled ACPI-[
15N]ACPII-ACPIII protein. 
We prepared different segmentally labeled samples in which the 1
st (protocol 6.5.3), then the 2
nd 
and then the 3
rd domain have been labeled 
15N. The overlay of the spectra shows that the peaks 
of the segmentally labeled domains perfectly match the peaks of the full length wt spectra. 
Slight differences are due to the modifications in the linker regions. 
 
Fig. 57: Result of segmental labeling a) 
Primary structure of CurA containing three 
ACP domains. b) An overlay of [
1H,
15N]- 
TROSY spectra from uniformly 
15N-labeled 
CurA (ACPI-ACPII-ACPIII) (black) and 
centrally 
15N-labeled CurA (ACPI-
[
15N]ACPII-ACPIII) (red), and N-terminally 
15N-labeled [
15N]ACPI-ACPII-ACPIII (green). 
Insets (A)–(D) are the magnifications of 
regions in the spectra. The assignments of 
a few residues are indicated. 
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Yields of the splicing reaction 
Performing quantitative analysis of the yields of the splicing experiments with the ACP domains 
is difficult, due to the fact that the ligation product (37.876 kDa) of the first ligation steps has 
accidentally the same size as one of the precursors (38.501 kDa) such a quantitative analysis is 
in this case not possible. The yield for the 2
nd in vitro ligation step, however, was determined to 
be 40%. 
Isotope cross labeling 
Isotope cross labeling might pose a major challenge for the three way ligation method using in 
vivo ligation as it is described. The protocol presented here is based on the effect that arabinose 
is used as an inducer for the first expression gets then metabolized and therefore can be 
effectively removed from the media upon media exchange [128, 142, 145]. A washing step 
further reduces the isotopic cross labeling. It was shown, that when applying the in vivo protocol 
described by us, the isotopic cross labeling is less than 5% [128, 142, 145]. To prove that in our 
particular triple ACP labeling experiment, however, cross labeling does not occur to any 
significant amount we have analyzed the corresponding NMR spectra. While many resonances 
of the individual domains severely overlap in the uniformly labeled sample, some resonances 
show chemical shift differences. For these amino acids the cross labeling percentage can be 
determined from the spectra of the uniformly and the segmentally labeled samples. These data 
are provided below and reveal a cross labeling of less than 5% (Fig. 58 this page and next 
page). 
 
Fig. 58: Evaluation of cross labeling (a) shows an overlay of the HSQC spectra of the uniformly 
15N-labeled CurA 
(ACPI-ACPII-ACPIII) (black), of the central segmentally 
15N-labeled CurA (ACPI-[
15N]ACPII-ACPIII) (red), of the N- 
terminal segmentally 
15N-labeled [
15N]ACPI-ACPII-ACPIII  CurA (green) and of the C-terminal segmentally 
15N-labeled 
ACPI-ACPII-[
15N]ACPIII CurA (blue). (b) Displays the central segmentally 
15N-labeled CurA (ACPI-[
15N]ACPII-ACPIII)  Results 
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(red) HSQC plotted at a lower level to show the background noise. Additionally the [
1H,
15N] TROSY spectra of the C- 
terminal, segmentally 
15N-labeled ACPI-ACPII-[
15N]ACPIII (blue) is shown. In case of cross labeling red peaks would 
occur at the positions of the blue peaks. Insets (A-E) are magnifications of those regions indicated in (a) and (b). In 
addition, we show 1D slices for the C-terminal, segmentally 
15N-labeled ACPI-ACPII-[
15N]ACPIII (blue) and the central, 
segmentally 
15N labeled CurA (ACPI-[
15N]ACPII-ACPIII) (red) taken at those positions that are highlighted with a 
dashed line. In the central segmentally 
15N-labeled CurA ACPI-[
15N]ACPII-ACPIII (red) no peaks are detectable at the 
positions of the ACPIII resonances. Therefore we can conclude that cross-labeling should be below the detection level 
of approximately 10%. These results confirm earlier investigations reported in [128, 145]. 
 
7.3  Characterization of the ACP domain 
7.3.1 The triplet ACPI-ACPII-ACPIII 
The triplet ACP domains are located at the C-terminus of the CurA protein from Lyngbya 
majuscula. ACPI,II,III (residues 1946-2248) further dimerizes through a C-terminal domain (Cd-
domain, residues 2261–2311) [76]. Our initial objective was to evaluate whether the presence of 
the triplet ACPI,II,III domains or their dimer leads to domain-domain interactions that adopt a 
prefered conformation. [
15N,
1H]-TROSY spectra of the two proteins CurA-ACPI,II,III with (in black) 
and without Cd (in red) were recorded and compared in Fig. 40. The absence of chemical shift 
differences indicates, that no conformational changes occur. Some peaks decrease in intensity 
upon adding the 60 aa Cd domain. However, surprisingly we do not observe new peaks 
representing the Cd domain. Due to dimerization the overall size increases from 36 kDa to 89 
kDa [76], which affects the rotational correlation time of the protein and most likely broadens the 
resonances of the Cd domain beyond the detection limit. Parts which tumble independently, 
such as the individual ACP domains are affected less by this increase in size (Fig. 40). The 
[
1H,
15N]-TROSY of the ACPI,II,III domain showed severe peak overlap due to the high sequence 
identity (93-100%) (Fig. 44). Therefore a distinction of the individual domains in a three domain 
construct was impossible using usual techniques such as combinatorial labeling techniques. 
The use of segmental labeling allowed us to distinguish the three domains from each other and 
assign the backbone of the full length construct [129] (Fig. 57). Isolating ACPI, ACPII or ACPIII 
from the three domain construct CurA-ACPI,II,III showed us in [
1H,
15N]-TROSY experiments 
strong chemical shift perturbations (CSP). The assignment of the full length construct enabled  Results 
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us to identify, that these strong CSP only occur at the N- and C-terminus. Both parts are 
disconnected from their natural environment upon isolation, explaining the CSP (Fig. 59 next 
page). 
 
Fig. 59: A plot of chemical shift perturbations due to ACPI isolation from CurA-ACPI,II,III. Both proteins were in 
their holo forms. Due to presentational purposes the CSP for Q2032 and T2034- indicated with a star (*)- are not 
completely displayed. Their CSP is 1.95 ppm (Q2032) and 1.26 ppm (T2034) 
These data support the aspect that there are no interactions between the individual domains. 
We performed additionally titration experiments of ACPI (1946- 2043) with the didomain 
construct ACPII,III (2044-2248). No shifts were observed for ACPI (Data not shown). In addition, 
no inter-domain NOEs were detected in 3D 
13C–edited/
15N-separated NOESY-HSQC 
experiments with a [
15N]ACPI–[
13C]ACPII-ACPIII, labeled version (data not shown). Taken 
together these data show that the ACP triple and didomains lack domain-domain interactions. 
To investigate the dynamics of the ACP linker regions which were found to be structured in 
other systems [21, 29, 185] we performed {
1H}
15N-heteronuclear NOE measurements. Nearly all 
amino acids of the structured domains ACPI, ACPII and ACPIII was identified, the additional 
signals can therefore be associated with the linker region. Heteronuclear NOE values of around 
0.8 represent highly structured regions (Fig. 60 a) b) c)) which is the case for the assigned 
amino acids within the ACP domains, whereas values around 0.2 were measured for the 
unassigned peaks, indicating that the linkers are unstructured and highly flexible (Fig. 60 d)).  Results 
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Fig. 60: Hetero-NOE measurements. Backbone {
1H}
15N hetero-NOE values of ACPI (a), ACPII (b) and ACPIII (c) 
domains within the full length protein. Most values are around 0.8 reflecting a well defined structure. Towards the N- 
and C-terminus hetNOE values decrease continuously. The unassigned Peaks (d) are mostly located in the linker 
region between the domains. Those values are on average around 0.2 reflecting that these regions are most likely 
very flexible and unstructured. 
7.3.2 Characterization of ACPI 
Taken together we showed in the previous chapter that the linker region between the ACP 
domains is unstructured and that the ACP domains behave independently from each other in 
ACPI,II,III as well as in the dimerized form of ACPI,II,III-Cd. This leads to the conclusion that the 
interaction between Cur Hal and ACP domains can be studied using one representing ACP 
domain of the triplet, for example ACPI  (residues 1946-2043). The ACPI domain was cloned into 
the pet28 vector with an N-terminal His6-tag as recently described [69]. The histag showed to be 
structurally disordered and does not interact with the protein. Thus in the final sample the first 
21 aa are non natural amino acids of which the first 11 amino acids including the histag are so 
flexible that they do not give raise to any signals in a [
1H,
15N]-TROSY. The following 10 aa give 
backbone NH signals but no NOEs, making them structurally undefined. The residues 22-110 
are identical to the CurA ACPI residues 1946-2043 (CurA, GenBank accession code 
AAT70096.1). Protein sample purity and quality assessment is described in 7.1.8 and Fig. 41. 
The protein was expressed during inhibition of the endogenous phosphopantetheinee 
transferase [22] and was in vitro modified using CoA and SFP. Expression and modification was 
verified via MALDI-MS and confirmed, that minimal 98% of the protein was in the apo form and 
minimal 98% were converted into the modified form (holo form) (Fig. 39). It has been shown 
that the 4’-Ppant arm is in presence of small substrates (acetyl, malonyl, buturyl) or without 
substrates solvent exposed and flexible and only interacts transiently with the ACP [34-36, 39]. 
In this work, we proceeded to determine the solution structure of holo ACPI, HMG-ACPI and the 
interaction site between HMG-ACPI and Cur Hal.  Results 
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7.3.3 Resonance assignment 
The [
1H,
15N]-TROSY spectrum of ACPI is shown in Fig. 62. The spectrum is well resolved, with 
sufficient chemical-shift dispersion in both the 
1H and the 
15N dimension. Only in a few instances 
for the side chains the spectra suffered from peak overlap. Over 95% of the sequence-specific 
backbone and side chain assignments were achieved using the data from a series of triple- 
resonance NMR experiments described in materials and methods (6.3.1). 
7.3.4 Quality of the calculated structure 
Backbone torsion angle restraints were obtained from chemical shift data using the TALOS+ 
algorithm [161]. NOE-based distance restraints from 3D 
15N-NOESY-HSQC and 
13C-NOESY 
HSQC spectra were assigned automatically by CYANA [162, 163], which was also used for the 
structure calculations by torsion angle dynamics [164]. The final structure calculations included 
2852 distance restraints and 162 backbone torsion angle restraints (App. 10). 100 conformers 
were computed using 10000 torsion angle dynamics steps. The 20 conformers with the lowest 
target function values were subjected to restrained energy refinement with the program OPALP 
[165] using the AMBER force field [166]. The quality of the structures was checked by 
PROCHECK [167] and WHATCHECK [168]. 
The structural statistics demonstrate good agreement of the structures with the experimental 
data, giving rise to no upper limit violations greater than 0.12 Ǻ (App. 9). A measure of precision 
for this family of 20 structures is given by the superposition of residues Val1950–Gly2033 of the 
ensemble on the mean structure, with a backbone RMSD value of 0.24 Ǻ and non- hydrogen 
atoms RMSD value of 0.54 Ǻ. Ramachandran statistics (evaluated with PROCHECKNMR 
software v.3.5.4 fo residues Val1949–Thr2034  of the ensemble of 20 structures) [167] show 
88.6% of the backbone torsion angle pairs occupying the most favored regions, 11.4% in the 
additionally allowed regions (App. 9). 
7.3.5 Tertiary structure 
The overall structure of holo-ACPI consists of a right-hand twisted bundle formed by four major 
α-helices (I,II,III,VI) connected by three loops. Helix II and VI are orientated parallel to each 
other. Helix I is turned around 45° to the orientation of helix II and IV.  The third helix (III) is 
much shorter in size and lies nearly perpendicular to the helices II and IV. Figure 61 shows the 
ribbon diagram of the minimized mean structure. The observed right-twisted helical bundle 
topology matches the conserved fold for the ACP and PCP family [7, 10, 34-36, 41-43, 52, 186, 
187], with helix I (residues 1954–1968) running anti-parallel to helices II (residues 1989–2002), 
the perpendicular orientated helix III (residues 2009–2014) and the C-terminal helix IV (2018-
2030). Helix I, II, IV are quite similar in size ranging from 14 (helix I) to 13 (helix II) and 12 (helix 
IV) amino acids in length. Helix III is comparably short ranging only over five amino acids.   Results 
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Fig. 61: Structure of holo ACPI. Ribbon diagram of the averaged and minimized NMR structure of holo ACPI from 
Lyngbya majuscula. Helixes I–VI are colored light blue, yellow, orange-brown and red, respectively. The active 
ser1989 is indicated in red at the N-terminus of helix II 
The long loop between helices I and II contains two structurally well defined areas (1973-1975; 
1982-1985) the rest of the loop is less defined. Hydrophobic interactions stabilize the helical 
bundle, as evidenced by the NOE signals between core leucine, valine, alanine and tryptophan 
residues. For example, helix I and helix II are aligned by the NOEs between Leu1961 and 
Trp1985, Ala1968 and Trp1985. Furthermore we have a hydrogen bond between Phe1982 and 
Pro2016, which might stabilize the position of helix III. 
7.3.6 Comparison of different chemical states 
During the biosynthesis ACPI is loaded with different substrates. The unloaded state without any 
cofactor is called apo form. The apo form undergoes interaction with the phosphophanteinyl 
transferase and gets activated by being loaded with the 4’-Ppant arm, called holo state [188] 
(Compare chapter 4.1.2). In the following step ACPI interacts with the upstream located 
acyltransferase domain which loads ACPI with malonyl. In the proceeding step the upstream 
located KS decarboxylates the malonyl to acetyl and couples the previous activated acetyl with 
the acetyl giving 3-oxo-butanoyl. Being loaded with this diketone the ACP interacts with the 
HMG-cassette (CurC, CurD, CurB) resulting in a modification of 3-oxo-butanoyl to 3-hydroxy-3-
methylglutaryl (compare Fig. 15). We investigated some of these different situations measuring 
[
1H,
15N]-TROSY spectra of apo, holo, acetyl, 3-hydroxy-3-methylglutaryl (HMG) and 4-chloro-3- 
hydroxy-3-methylglutaryl (Cl-HMG) (Fig. 62). 4-chloro-3-hydroxy-3-methylglutaryl was obtained 
by a reaction of (R,S)3-hydroxy-3-methylglutaryl-ACPI with Cur Hal. Due to the stereo-specificity 
for (S)-HMG we obtained a 50% mixture of (R)-3-hydroxy-3-methylglutaryl-ACPI and (S)4-
chloro-3-hydroxy-3-methylglutaryl-ACPI. The loading state of all samples was checked by 
MALDI-MS (Fig. 39).  Results 
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Fig. 62: Comparison of apo and holo ACPI a) An overlay of [
1H,
15N]-TROSY spectra from uniformly 
15N-labeled 
apo ACPI (black) and 
15N-labeled holo ACPI (red). The assignments of the amino acids undergoing the strongest 
chemical shift perturbations are indicated. b) A plot of chemical shift perturbations of ACPI holo compared to ACPI 
apo. The secondary structure elements are indicated.  
The analysis of the NMR spectra show, that the apo to holo conversion is accompanied by 
strong chemical shift perturbations (CSP). The amino acids around the active site S1989 show 
two different peaks for the apo and holo version such as D1988, S1989, V1991, G1992, V1993 
which are located near to the active site S1989 and helix II and L2012, Y2013, Y2015 which are 
located on helix III (all >0.05ppm CSP). I1990 shows a peak in the holo form which is not 
present in the apo form (Fig. 62). In order to prove if the chemical shift perturbations are due to 
a conformational exchange we recorded 
15N-NOESY-HSQC for apo and holo ACPI. The 
comparison of the strip blots show that the NOEs for the apo and the holo forms are 
indistinguishable (Fig. 63). Therefore we can conclude that the chemical shift perturbations are 
due to transient interactions with the 4’-Ppant arm and we can exclude major conformational 
changes upon loading. Similar observations have been made in other systems as well [34-36, 
189, 190]) (Compare 4.1.4).  
  Results 
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Fig. 63: Comparison of NOEs for apo and holo ACPI. Observed NOE-pattern in a 
15N-separated NOESY-HSQC 
for the amino acids which undergo chemical shift perturbations (> 0.035ppm) for the apo and holo form of ACPI. 
The fact that we can exclude structural rearrangements, allows us to map the amino acids 
undergoing CSPs for the apo to holo conversion on the surface of the holo structure (Fig. 65). 
The amino acids which are involved in the transient interaction are located on the first loop 
towards the N-terminus of helix II (V1983), around the active site S1989 and helix II and helix III. 
The data show that the 4’-Ppant arm is transiently located in a hydrophobic pocket located 
between helix II and III (Fig. 64 a) b) c)). We were interested in the fact if different substrates 
have different impacts on the chemical shift perturbations (CSP). Therefore we calculated the 
chemical shift perturbations for acetyl, HMG, and Cl-HMG versus the holo form. In case of a 
strong interaction between the protein ACPI and the substrate, CSP should be significant for the 
substrate and not the 4’-Ppant arm (Fig. 64). In all three cases we observe small CSPs, all 
affecting the same amino acids. V1983, D1988, I1990, A2009 are involved in all three cases. 
Interestingly these amino acids have smaller CSP for acetyl, higher CSP for HMG and the 
strongest CSP for Cl-HMG. The differences in CSP might be linked to the longer chain length 
and in case of Cl-HMG to the chlorid-Ion (Fig. 64). This data are in accordance with Evans and 
his colleagues who observed for acetyl, malonyl, 3-oxobutyl and 3,5-dioxohexyl ACP (PKS II, 
act ACP from Streptomyces coelicolor) only minimal or no interactions with the ACP giving small 
CSP [39]. But for a growing acyl chains such as butyryl-, hexanoyl-, and octanoyl-ACP they 
observed that in each case the acyl chain is clearly bound in a cleft which is also located 
between helices II and III of the PKS ACP which was also apparent due to stronger CSP [39].  Results 
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Fig. 64: Comparison of the different chemical states of ACPI. a) An overlay of [
15N, 
1H] TROSY spectra of holo- ACPI 
(red) and acetyl-ACPI (yellow), HMG-ACPI (light blue), Cl-HMG-ACPI (magenta). Assignments of the amino acids 
undergoing the strongest chemical shift perturbations are indicated and their magnifications are presented on the top 
panel. The right hand panel presents plots of chemical shift differences between holo-ACPI and acetyl-ACPI (b), 
HMG-ACPI (c), Cl-HMG-ACPI (d). The secondary structure elements are indicated below. 
When we map the CSP for apo to holo on the structure we can see that the cleft to which the 
4’-Ppant arm is bound is framed by helix II and III (Fig. 65). The amino acids building this 
pocket are highly hydrophobic. Interestingly when we change the substrate, there are no further 
amino acids involved in substrate interactions. This means, the 4’-Ppant arm and its substrate 
under investigation will not occupy more space in the hydrophobic pocket than a smaller 
substrate. Nevertheless for the longer substrate, such as HMG and Cl-HMG the same amino 
acids show slightly stronger CSP assuming that with growing chain length and chloride 
modification the 4’- Ppant arm with substrate presumably has longer contact times with the 
surface. Interestingly Asp2014 is the only amino acid which is involved in addition to the binding 
of acetyl as well as Cl-HMG but not with HMG.  
  Results 
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Fig. 65: Graphical presentation of ACPI and the amino acids involved in substrate interaction a) and b) ribbon 
diagram and surface diagram of holo ACPI with its hydrophobic amino acids (cyan); c) and d) The CSP for apo to 
holo conversion of ACPI are mapped in dark blue (CSP > 0.05ppm), the active serine is colored in red. e) and f) The 
amino acids of of ACPI which are involved in the transient interaction with acetyl, HMG and Cl-HMG are indicated in 
magenta (CSP >0.02ppm).  
7.3.7 Localization of the cofactor with the substrate 
For a detailed characterization of the interaction of ACPI with Cur Hal the localization of the 
substrate on the surface has to be defined. We expressed 
13C/
15N-labeled ACPI and modified it 
in vitro with unlabeled CoA and (R,S)-HMG-CoA. NOEs between 
12CH groups of the attached 
cofactor and the 
13CH groups of the protein were detected in a 3D F1-
13C/
15N filtered, F3-
13C-
separated NOESY (Fig. 66 a)). Surprisingly, we obtained NOEs for both the holo and HMG 
state. In a next step we recorded F1/F2-
13C/
15N double-filtered 2D-NOESY spectra to selectively 
detect the 
12CH-
12CH NOEs present within the 4’-Ppant arm loaded with HMG (Fig. 66 c)). 
Using the assignment of the 4’-Ppant arm loaded on TycC3 PCP [7] and combining it with the 
assignment of the 4’-Ppant chain loaded with hexanoyl in an ACP bound state from a 
mammalian FAS ACP [190]. This combination enabled us to finally assign the 4’-Ppant chain. 
The 1D spectra of CoA and HMG-CoA then gave rise to the unambiguous assignment of the 
protons of the HMG methyl group (66,67,68), which was used to assign these methyl groups in 
the ACP-bound form.   Results 
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Fig. 66: Isotope filtered NOESY experiments for the structure determination of HMG-ACPI a) F1-F3 strips from 
a 3D F1-
13C/
15N filtered, F3-
13C-separated NOESY-HSQC of holo and HMG-ACPI filtering the 
13CH-
15NH NOEs. The 
protein was loaded in vitro and the substrate is therefore unlabeled giving strong NOEs from 
12CH- to the 
13CH 
groups of the protein surface. b) the cofactor S-HMG and its numeration; c) Expansion of the two-dimensional F2-
filtered NOESY spectrum of 
13C,
15N-labeled HMG-ACPI. The 4’-Ppant chain and the HMG group are unlabeled and 
give rise to strong NOE connectivities within the 4’-Ppant arm. 
. 
  
Fig. 67: Comparison of 1D spectra of HMG-CoA (red) and CoA (blue). The protons of the HMG-CoA methyl group 
(HMG:CH3) was unambiguously assigned with a chemical shift of 1,35 ppm in the free form.  Results 
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To calculate the structure of HMG-ACPI we combined the restraints obtained for holo-ACPI with 
the NOE-based distance restraints obtained for HMG, assuming that no major conformational 
changes occur between the different states. Structural statistics are given in Table App. 9 . 
X-ray studies of the E. coli FAS II ACP demonstrated that starting from C4 chain length the 
substrate and the 4’-Ppant arm is sequestered into a hydrophobic pocket [37, 38]. These results 
were similar to the NMR findings for the PKS actinorhodin system of Streptomyces Coelicor 
[39]. For ACPI from Lyngbya majuscula HMG which has a chain length of C5 is clearly not 
bound to a hydrophobic cleft. Instead it seems to switch between solvent exposure and surface 
attachment (Fig. 68).  
  
Fig. 68: Presentation of HMG- ACPI a) Presentation of the ensemble of structures of (S)-HMG-ACPI in a ribbon 
diagram. The 4’-Ppant arm with hydroxy-methyl-glutaryl (HMG) from all 20 structures is shown as well. b) 
Presentation of the complete mean structure of HMG-ACPI. The amino acids which undergo chemical shift 
perturbations once the 4’-Ppant arm is added are labeled in blue, amino acids which undergo slight chemical shift 
perturbations when HMG is added to the 4’-Ppant arm are indicated in magenta (CSP >0.04ppm). The shifts are 
located around the attachment site of the substrate on helix II and helix III. 
7.4 Interactions  with  ACPI 
7.4.1 Activity assay of ECH1  
It has been shown that ECH1 accepts CurB and ACPII as a substrate deliverer [68-70]. 
Furthermore it has been shown that ECH1 accepts HMG-CoA as substrate but has a 10* fold 
higher affinity towards the ACP bound substrate [68] [69]. The activity test was performed using 
HMG-ACPI (12.627 kDa) and HMG-CoA (911 Da). ECH1 catalyzes dehydration which leads in 
both cases to a loss of 18 kDa (Fig. 69 a) -d)). Interestingly we observed product formation for 
HMG-ACPI after 3.5 hrs at 25°C but for HMG-CoA we had to incubate it with more ECH1 (8 µM 
instead of 5 µm) for a longer time (24 hrs). Nevertheless a direct comparison is not possible 
because higher amounts of HMG-CoA were used (500 µM) than for HMG-ACPI. For the HMG-
TycB1 no reaction product was observed. 
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Fig. 69: Result of activity test of ECH1. a,b) MALDI-MS of 100 µM HMG-ACPI incubated with 5 µM ECH1 for 3.5 hrs 
at 25°C. The product is indicated with a red arrow in b). c) and d) ESI-MS of 500 µM HMG-CoA incubated with 8 µM 
ECH1 at 25°C for 24 hrs the product is indicated with a red arrow.e) and f) MALDI-MS of the same reaction as in a),b) 
with HMG-TycB1 but no product was built.  
Reaction conditions for ECH1 were optimized (buffer, time and temperature), either 24 hrs at 
25°C or 37°C about 12 hrs (compare Fig. 69) turned out to be the best with about 10% product. 
Furthermore we wanted to see if we can separate the product methylglutaconyl-CoA of the 
ECH1 catalyzd dehydration of the educt (R,S)-HMG-CoA. Therefore 500 µM HMG-CoA were 
incubated with ECH1 (5 μM) at 37°C for 12hrs and then subjected to a HPLC (PerfectSil 250x4,6 
C18) (more details in 6.4.1). The elution profile is presented in Fig. 70. Fractions of the different  Results 
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peaks were analyzed via ESI-MS. ESI-MS analysis proved, that the molecular weight (MW) of 
the fraction corespending with peak 1 is identical with CoA, which builts up over the time due to 
hydrolosis. Peak 3 correspends with the MW of HMG-CoA and Peak 4 contains the product 
methylglutaconyl-CoA. Peak 2 was identified via ESI-MS but due to control runs it is either 
ECH1 itself or a compound associated with the enzyme used. 
 
Fig. 70: Elution profile of the HPLC purification of methylglutaconyl-CoA. 500 µM HMG-CoA were incubated 
with ECH1 (5 μM) at 37°C for 12 hrs and then subjected to a HPLC (PerfectSil 250x4,6 C18). ESI-MS analysis of the 
fractions revealed that peak 1 correspends with the molecular weight of CoA, 3= HMG-CoA, 4= methylglutaconyl-
CoA 
The experiment shows that the product of the ECH1 reaction can be purified from the educts. 
The HPLC runs were repeated with different incubation times amd temperatures to further 
improve the conditions (data not shown), but the best conditions are the ones presented here 
(Fig. 70). In a next step the sample was further incubated (either in parallel or iteratively) with 
ECH2. Unfortunately no further peak was obtained for the decarboxlated product methylcrotonyl 
(data not shown).   
7.4.2 NMR Titration of ACPI with ECH2 
For the NMR titration HMG-ACPI, apo ACPI and apo TycB1-PCP were titrated with ECH2 in the 
ratios 1:0, 8:1, 1:1, 1:2, 1:4 und 1:8. The ACP/PCP concentration was not kept constant and 
chosen as high as possible in order to obtain best spectra quality. The titration experiments 
were performed at 20 mM Tris, 100 mM NaCl, pH= 7.5 at 500 MHz and 291 K. During the 
measurent protein precipitated and the ratios were therefore analyzed on SDS-PAGE after 
measurement (data not shown). Due to co-precipitation, the ratios up to 1:4 (ACPI: ECH2) did 
not change and was therefore analyzed (Fig. 71). For apo ACPI the amino acids Asp1988, Ser 
1989, Ile1990 and Gly1992 show slightly higher CSP then 0.02 ppm. For HMG-ACPI titrated 
with ECH2 we obtain slightly higher CSP than 0.02 ppm for Leu1954, Leu1969, Asp1988, 
Ser1989 and Gly1992 (App. 12). Ser1989 is the active center to which the cofactor is attached 
and the amino acids undergoing CSP a grouped around this active site in both cases for apo  Results 
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ACPI as well as HMG-ACPI ( Fig. 71a)). The PCP TycB1-PCP was not assigned at the 
compilation of this thesis. Hence all peaks are just numerated aribitrary from 1-84 independant 
of the position in the amino acids. For the apo PCP titration with ECH2 we obtain two amino 
acids with CSP higher than 0.02 ppm (Fig. 71b)). 
.  
Fig. 71: A plot of chemical shift perturbations for ACPI titration with ECH2 a) of HMG-ACPI with ECH2 (in black) 
and apo ACPI with ECH2 (in red). Titrations were performed at 500 MHz. The CSP calculation is based the 
comparison of 1:0 spectra with 1:4 molar excess spectra. In the graphic below are indicated the secondary elements. 
b) plot of CSP of the apo TycB1 Titration with ECH2. The CSP calculation is based the comparison of 1:0 spectra with 
1:4 molar excess spectra recorded at a 500 machine.  
7.4.3 Interaction of ACPI and Hal 
Hal activity and NMR Titrations 
The curacin biosynthesis differentiates from other β-branching pathways in the introduction of a 
c-chlorination step on (S)-3-hydroxy-3-methylglutaryl (HMG) mediated by Cur Hal, a non-heme 
Fe(II), α-ketoglutarate-dependent enzyme [69]. Recent studies convinced that the chlorination 
step takes place before the dehydration catalyzed by ECH1 and decarboxylation followed by 
ECH2 leading to 4-chloro-3-methylcrotonyl-ACP. ECH1 and ECH2 are known to be promiscuous 
enzymes. ECH1 for example uses either S-HMG- or Cl-(S)-HMG either bound to one of the 
triplet ACPs [69] or CurB [70] or even in a CoA form. To investigate the activity of hal we used 
an activity assay similar to the one described before [67, 69]. In this activity assay we loaded  Results 
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ACPI with (R,S)-HMG and detected substrate chlorination by MALD-MS. We showed that the 
halogenase which we expressed and purified was active and that it specifically interacts with 
ACPI but not with CurB and not TycB1 PCP (Fig. 72). This specificity has been shown already 
previously; furthermore distinguishes hal between R- and S-HMG [67, 69] and accepts S-HMG, 
but as mentioned before, only in an ACP bound form. The ACP is necessarily a representative 
of the triplet ACP, located at the C-terminus of CurA. We were therefore interested in 
determining further molecular determants important for the specificity of the interaction. We 
expressed, purified and reconstituted hal anaerobe as described before [69][67] and proved by 
MALDI mass spectrometry its activity (Fig. 72). We attempted to map the specific interaction 
surface on ACPI using NMR titration experiments. Therefore (R,S)-HMG-[
15N]ACPI was titrated 
with active, unlabeled halogenase, but no chemical shift perturbations were observed. We 
repeated the same experiment with functional halogenase in non-reactive conditions: without Cl, 
α-KG, O2 or missing all components. Additionally we tried to manipulate the halogenase using 
the unfunctional mutant R241A [67] or Fe
3+ reconstituted, inactive halogenase. Finally we tried 
to use functional Halogenase but ACPI loaded with different and no substrates such as apo, 
holo, acetyl and malonyl. In all cases, despite using a high excess of Hal to ACP (8:1), no 
chemical shift perturbations or line broadening effects were observed which would indicate any 
formation of an ACP/Hal complex. This result might propose that interaction might be limited to 
the 4’-Ppant arm or acyl chain, similar to the TE-ACP interaction observed in the DEBS PKS 
[191]. We performed the activity assay using ACPI, CurB–ACP and TycB1 PCP as a substrate 
deliverer. Only in case of ACPI all S-HMG-ACPI (50% from R,S–HMG-ACPI) was chlorinated 
after 10 min into Cl-S-HMG (Fig. 72). Even after 1 hr HMG-CurB and HMG-PCP did not show 
any chlorinated form (Data not shown). This result demonstrates clearly that Cur Hal 
distinguishes between the ACPs (ACPI vs CurB), leading to the conclusion that an interface 
must be present, which can not be detected by NMR. In the assay the reaction is finished after 
10 min using 100 µM HMG-ACP and 5 µM Hal (20:1 ratio) in NMR of course we use even 
higher ratios (1:8). A reason for not observing any interaction in NMR might be due to the fact 
that the reaction is performed to fast and the product Cl-HMG-ACPI has too low affinity to Cur 
hal; too low affinity might also be the reason for all unreactive conditions/combinations tested. 
Presumably we have also too transient interactions to be detected by NMR. 
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Fig. 72: MALDI-MS of reactions of HMG-ACP/PCP with Hal a) HMG-ACPI b) HMG-ACPI with Hal c) HMG-TycB1 
PCP d) HMG-TycB1PCP with Hal e) HMG-CurB f) HMG-CurB with Hal 
Fluorescence anisotropy of Cur Hal and ACPI  
Despite the fact that pH 7-7.5 is recommended for the reaction of malemide with cyteines we 
obtained in these conditions proteins with 2-3 fluorescin attached to it. We screened the pH (6-
7.5) for one specific fluorescin labeling and obtained this in 20 mM MES, 100 mM NaCl at pH 6 
(App. 10). Different ACPI cysteine mutants (S10C, S87C, G89C, T90C) were prepared and 
evaluated using CD spectroscopy. They all showed melting curves with a transition from folded 
to unfolded giving melting temperatures at 54°C (S87C), 50.5°C (G89C), 52.1°C (T90C) 
indicating less stability then the wt protein (TM 62.8). We decidede to perform titration 
experiments with S10C and for a C-terminal fluorescin T90C, in both cases fluorescin should  Results 
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not disturb in any interactions due to the long distance from the active site (35 Ǻ). As a control, 
TycB1 PCP in its apo state was used, due to the fact that we showed via MS that the PCP 
loaded with HMG is not recognized as a substrate deliverer (Fig. 73). Fluorescence anisotropy 
measurements were done in the same conditions as the activity assay and each time the 
activity of the enzyme was proved in parallel by MS.  
 
Fig. 73: Fluorescence anisotropy measurements of ACP with Cur Hal. a) Blots of the normalized anisotropy of 
HMG- ACPIS10C (red) and apo (blue form) titrated with Hal b) Blots of the normalized anisotropy of HMG-ACPI T90C 
(red) and apo ACPIT90C (blue) and TycB1 PCP in apo (green) form titrated with Hal. Solid lines show the fit to a two-
binding-site model. Error bars show standard deviation. 
The experiments were repeated twice with different batches of Cur Hal. The concentration is the 
monomeric concentration with regard to the fact that each monomer has its own active site. 
Data were fit according to a two side-binding model giving the two binding constants K1 and K2, 
all fits have a correlation coefficient (R
2) higher than 0.98. The Binding constants resulting from 
the fluorescence anisotropy measurement are listed below (Table 16). 
Table 16: Summary table of the binding constants measured via fluorescence anisotropy 
Sample  K1 [µM]  Error [µM]  K2 [µM]  Error [µM] 
ACPIS10C HMG  0,105  0,033  2,4 * 10
16   
ACPIS10C apo  0,391  0,127  7,0 * 10
16   
ACPIT90C HMG  0,11  0,073  204,154  21,76 
ACPIT90C apo  0,037  0,211  314,71  145,87 
TycB1PCPapo  0,206  0,052  317,05  379, 18 
 
KD values for the second binding event were 2.4 * 10
16 , 7.0 * 10
16, 204.15± 21,76 µM, 314.71± 
145.87 µM , 317.05± 379.18 µM respectively, suggesting that they represent unspecific binding. 
The first Kd is unexpected high (0.03-0.4 µM) for both the apo version, the HMG version and 
PCP suggesting that these values are based on hydrophobic binding of Hal to the fluorophore 
fluorescin instead of specific binding to the protein.   Results 
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Activity assay and mutational analysis for Hal and ACPI 
To prove our hypothesis of the existence of a specific interaction surface, we went for 
mutational analysis. For the mutational approach we mutated solvent exposed, not conserved 
amino acids in HI, LI, HII, LII, HIII and HIV. Amino acids which are conserved between ACPI 
and ACPs (involved in other protein-protein interactions) were taken as essential for the 
structural stability and therefore excluded for a mutational approach. An alignment between 
CurB and ACPI highlights amino acids which might be important for a Hal-ACP interaction (App. 
11). All mutants were expressed and purified and the activity test performed as described 
before. Due to using (R,S)-HMG-ACPI as a substrate, activity was determined by assuming that 
a chlorination of 100% S-HMG, resulting in one peak unreacted R-HMG-ACP and one peak Cl-
(S)-HMG-ACP, separated by 34 Da and of equal intensities; this would then correspond to 
100% activity. This approach implies the assumption that both proteins display equal ionization 
capacities. The MALDI-MS raw data are presented in App. 14 and the derived activities are 
listed in Table 17.  
Table 17: Results from the activity test. 
1The activity is estimated based on the MALDI-MS results presented in 
App. 14. 
2 Impurities were estimated based on the SDS gel, some mutants were less pure. Based on the mutants 
E1978P, D1979T, Q1980D and Q2001E, T2002D, N2004S we can see that impurities do not decrease activity. The 
SDS gel is presented in App. 15. The melting temperature was determined by CD spectroscopy. The curves for CD 
spectroscopy are presented in App. 16.  
Mutation  Localization  Activity [%]
1  No of exp  Impurities [%]
2  TM
3 [°C] 
WT    85 ± 11  5  <5  64 ± 0,15 
Q1959A, Q1963A, E1967A  H I  91 ± 1  2  <5   
E1973D, E1975P, A1977E  L I  Not soluble       
E1978P, D1979T, Q1980D  L I  82 ± 8  3  ~15   
K1981S, V1982K, D1983K  L I  75 ± 5  3  <5   
D1988A  Active Site  29 ± 10  3  <5  57 ± 1,2 
I1990A  Active Site  18± 7  3  <5  64 ± 0,2 
V1993N, T1998M, T1999M  H II  70± 19  3  <5  65± 0,2 
Q2001E, T2002D, N2004S  C- H II  92± 2,5  3  ~30   
K2008P  L II  75± 7  3  <5   
A2009R  N- HIII  15± 12  3  <10  70 ± 2,5 
T2010A  H III  37± 7  3  <5  63 ± 0,26 
Y2013A  H III  35± 2,5  3  <5  61± 0,14 
D2014A  C- HIII  59± 2  3  <5  58 ± 1,35 
Y2015A  L IV  77  1  <10   
P2016K  L IV  90  1  <5   
L2019A, Q2027A, S2031A  H IV  37± 5  2  <5   
  Results 
  - 127 - 
The mutations D1988A, I1990A neighboring the active site S1989 and A2009R on helix III had 
the strongest impact on Hal activity (activity: 29% ± 10%; 18%± 7%; 15%± 12%, respectively). 
It is necessary to mention, that in these cases no product peaks were observed, which were in 
any way comparable with the other “active” proteins. Nevertheless, to ensure no 
underestimation of the activity we considered that a product peak might be covered by the first 
and second natrium peak (~+22 and ~+44 Da) leading to the assumption, that the peak at 34 
Da away from the educt might be product. This leads in general to an overestimation rather than 
an underestimation of the activity. The single point mutations T2010A, Y2013A, D2014A on 
helix III decrease the activity to 37%± 7%, 35%± 2%, 59%± 2%, respectively. CD curves of the 
less active mutants show that the mutations did not have any impact on the global fold. 
Whereas melting temperatures derived from CD melting curves show that some mutations lead 
to a less stable protein (Table 17, App. 16). To ensure that the mutations showing the strongest 
impact, are not related to structural perturbations we compared therefore [
1H,
15N]-TROSYs of 
the 
15N labeled mutants with the WT (Fig. 74).  
 
 
Fig. 74: Comparison of [
15N,
1H]-TROSY 
spectra of mutant ACPI and wild type. 
D1988A and I1990A show CSPs for 5-6 
amino acids located near the mutated 
amino acids, revealing no structural 
perturbations. The mutation A2009R 
shows stronger effects which might be 
due to a steric effect. The spectra of apo 
D1988A, apo I1990A and apo ACPI  were 
recorded at 500MHz, apo A2009R and a 
further apo ACPI spectra were recorded 
at 900MHz.  Results 
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Actually the comparison of [
1H,
15N]-TROSY apo mutant spectra with the apo WT spectra, 
reveals for D1988A and I1990A CSPs for 5-6 amino acids located near to the mutated amino 
acids, revealing that the mutation does not effect the structure. The mutation A2009 leads to 
stronger CSP which might be due to sterical reasons. We were interested in the question if 
these mutations might lead to a displacement of the cofactor which then in return effects the 
Hal/ACPI interaction. For clarification we loaded the mutants D1988A, I1990A and A2009R with 
the 4’-Ppant arm, acetyl and HMG, mapped the CSP against the sequence and compared these 
results with the WT (Fig. 75).  
 
Fig. 75: Comparison of the different chemical states of ACPI WT (green), A2009R (red), D1988A (light blue) 
and I1990A (yellow). a) CSP for the apo to holo conversion b) loaded with acetyl and c) HMG. In all cases the same 
regions such as helix II and III are affected. 
Interestingly, upon loading, the same amino acids undergo CSPs (around the active site 
Ser1989 and helix III), even for A2009R, supposing that the localization of the cofactor is not 
affected (Fig. 75). In the following we mapped the mutational effect according to the strength of 
activity decrease. Mutations which decreased the activity down to 0 to 30% are marked in red, 
this is the case for (D1988A and I1990A amino acids neighboring the active site Ser and 
A2009R located on helix III), mutations which decreased the activity to 30-70% were marked in 
magenta (e.g. the multiple mutant V1993N with T1998M and T1999M located on helix II, the 
single mutants T2010A, Y2013, D2014A all located on helix III) and mutants with minor to no 
effect and activities >70% were marked in yellow (Fig. 76). The mutations which affect the 
activity surround the substrate, building a nice, closed interface, which turned out to be 
important for Cur Hal recognition and selectivity.   Results 
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Fig. 76: Effect of ACPI mutation on activity. According to the strength of activity decrease we applied a color code. 
Mutations which decreased the activity to 0-30% are marked in red this is the case for (D1988A and I1990A amino 
acids neighboring the active site Ser and A2009R located on helix III), mutations which decreased the activity to 30-
70% were marked in magenta (e.g. the multiple mutant V1993N with T1998M and T1999M located on helix II, the 
single mutants T2010A, Y2013 D2014A all located on helix III) and minor to no effect with an activity of over 70% are 
marked in yellow. 
 Discussion 
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8 Discussion 
8.1  Optimization of constructs 
The biosynthetic origin of bacterial polyketides and non-ribosomal peptides has been studied 
extensively in the passing years. These biochemical studies unravelled the biochemical rules 
leading to the synthesis of complex polyketides and polypeptides. These biochemical rules 
dictate for example the polyketide starter unit selection or amino acid selection, chain length 
control, and post-PKS processing. Nevertheless the manipulation of these megasynthethases in 
their native organism or related hosts is still problematic. In the past years several X-ray and 
NMR structures of essential NRPS and PKS domains have been solved [7, 10, 40, 192]. 
Several bi-domain structures have been solved as well in recent years, such as the X-ray 
structures of the DEBS AT-KS didomains [21, 29], the X-ray structure of the SrfA-C termination 
modul [30] and the X-ray structure of the PCP-C domain [193]. These structures gave a good 
idea about how the domains are organized, but still, little structural informations are available on 
how domains interact and communicate. This may be because some of the crystallized 
molecules may not represent the active domain orientations. NMR as a structural technique has 
the advantage to be able to detect the proteins in there soluble, active states.  The drawback is 
that in solution, the large size and internal dynamics of multidomain fragments (> 35 kDa) make 
structure determination by nuclear magnetic resonance a challenge and require advanced 
technologies. The advances in NMR in recent years allowed working on increasing systems. 
Therefore the 37 kDa solution structure of the NRPS didomain PCP-TE from enterobactin 
synthase EntF gives insights into the interaction surface of those domains [194].  
One major bottleneck for structural investigations of PKS and NRPS systems is the high 
amount of protein needed. Therefore, a first major step in a structural project is the evaluation of 
putative protein targets for structural studies, meaning essentially the assessment of protein 
quality and in most cases the improvement or enhancement of the protein solubility. We faced 
this bottleneck during our work with the targets KS and AT (CurA), HCS (CurD) and KS (CurC) 
which displayed low solubility (7.1.1, 7.1.2). Solubility problems can be distinguished into two 
major fields, proteins that express insoluble and accumulat in so-called inclusion bodies (e.g 
HCS and KS) and proteins which can be expressed solubly but which either precipitate or build 
soluble aggregates after purification, the latter was encountered during the work with AT and KS 
from CurA (7.1.2).  
Several approaches are known to increase protein solubility, for example a) to reduce the 
rate of protein synthesis. This can be achieved by decreasing for example the temperature or 
the usage of a weaker promoter. b) To change the growth media by adding prosthetic groups, 
or glucose, or ethanol or polyols; c) To co-express chaperons or foldases e.g. by using Arctic 
Express cells; d) Using specific host strains with more oxidizing cytoplasmic environment such Discussion 
  - 131 - 
as AD494 and Origami; e) Addition of fusion partners; f) In vitro denaturation and refolding. 
Concerning the addition of a solubility tag, numerous solubility tags are reported in the literature, 
such as MBP (Maltose-binding protein), GST (Glutathione-S-transferase) [195], Trx 
(Thioredoxin), NusA (N-Utilization substance), SUMO (Small ubiquitin-modifier), SET (Solubility-
enhancing tag Synthetic),  DsbC (Disulfide bond C), Skp (Seventeen kilodalton protein), T7PK 
(Phage T7 protein kinase),  GB1 (Protein G B1 domain)) [196], but the majority of recent work 
has continued to focus on a few major players, notably the maltose-binding protein (MBP), the 
N-utilization substance A (NusA), thioredoxin (Trx) and glutathione-S-transferase (GST) [196]. 
GST, however, has turned out to be a bad solubility enhacer [197]. NusA and Trx have shown 
to be comparable to MBP in its capability of producing soluble proteins but without independent 
affinity functionality in case of NusA [196]. We decided in all cases where we encountered 
solubility problems to use MBP and Ub as a solubility tag. For AT and KS from CurA the N-
terminal MBP-tag increased the expression and helped to gain soluble protein. For HCS and KS 
both MBP and Ub N-terminally tagged constructs turned out to be insoluble in the conditions 
tested (low temperature, coexpression with chaperons). Due to the reasons mentioned before 
replacing MBP by other solubility tags might not increase the solubility of HCS and KS. Instead 
of trying other solubility tags, it might be better to check the influence of the tag at the C-
terminus. Further modification of the main construct by mutations and/or deletions of 
hydrophobic patches or unstructured regions might be even more promising in improving 
solubility. A drawback for this approach is, that mutations might have a negative impact on the 
interactions of these proteins. We did not try to modify the media (XYT) with prosthetic groups 
or additional glucose which might be worth trying. The expression of HCS (CurD) and KS 
(CurC) under a weaker promotor might also be worth a try (e.g trc instead of T7). Condsidering 
the biosynthesis of HCS and KS we assume that these proteins might build a complex, 
presumably with CurB as a third interplayer. An alternative approach to achieve the solubility of 
these proteins might be the co-expression of HCS and KS or HCS, KS and CurB. To achieve 
this, HCS and KS were cloned for example into the pstduet vector (Novagen). Such a construct 
would further surve for a co-expression with CurB. One main point to respect for co-expression 
is, that the vectors used, need two different Oris and antibiotic resistances and for more 
flexibility probably even different inducers. In case none of these options would help to express 
soluble protein refolding might be used. ACPs for example can be easily purified in denaturing 
conditions and followed by refolding without the 3D structure to be affected (Data not shown). 
We tried this approach in one shot by expressing Ub-HCS and Ub-KS in inclusion bodies. Then 
we separated soluble proteins from insoluble proteins and went directly for solubilization in urea 
followed by His6-tag purification in denaturing conditions. After purification the protein was 
refolded. The purity of the proteins was quite low (~30% impurities) (Fig. 28). For future work 
purity would be easy to improve by washing the inclusion bodies with buffers containing Discussion 
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increasing amounts of urea or guanidinimhydrochlorid. So far, refolding worked for several 
challenging proteins to gain enough material for further studies [198-201]. It is important to 
mention that the smaller the protein, the easier is the refolding. HCS and KS are both quite 
complex domains with 45 kDa in size, this makes in fact refolding attempts challenging. In 
addition the proteins have 10 cysteines in case of HCS and 8 cysteines in case of KS which 
sets a further challenge to any refolding attempt.  
As mentioned before AT and KS constructs from CurA was expressed solubly as MBP 
fusion proteins (Table 10), expect the construct L-AT-L (amino acids 974-1484 according to 
accession code entry AAT70096). But surprisingly in all cases the proteins showed soluble 
aggregation and no monomer peak on a gelfiltration column. To reduce the soluble aggregation 
of AT and KS constructs we tried altering the expression conditions by lowering the 
temperature, co-expressed the proteins with chaperones and added additives during protein 
isolation such as detergents (CHAPS), sugar (sucrose), arginine or glutamate. No one method 
has proven successful. The AT-L construct gives a surprising contradiction. AT-L was 
expressed and purified as MBP fusion protein but as well as a His6-tag fusion protein. 
Surprisingly AT-L fused N-terminally to MBP shows on the superose 6 gelfiltration column 
soluble aggregation and elutes in the void volume (App. 6b)). Instead, AT-L with a His6-tag was 
expressed -in little amounts- solubly and shows impoved behaviour versus the MBP fusion on a 
gelfiltration column by presenting a population of monomer to dimer, trimer and undefined 
multimers (App. 6c)). This result led to the hypothesis that MBP might promote in some cases 
soluble aggregation- a hypothesis which has not been checked. Furthermore, it might be of 
interest to see how the proteins behave without MBP. Due to the fact that all AT and KS 
constructs only express as MBP fusions an in vivo cleavage prior to purification might be 
reasonable. For this purpose, TEV protease would be co-expressed along with the fusion 
protein but in a time delayed manner as described by Kapust and Waugh [202]. Briefly, IPTG 
would be added to the log phase culture and the fusion protein would be allowed to accumulate 
for a period of time. Then, TEV protease expression (encoded on vector prk603) would be 
stimulated by adding anhydrotetracycline to the culture. For this purposes a special E. coli strain 
(e.g., DH5alphaPRO or BL21PRO cells from Clontech) producing the Tet repressor would be 
required.  
To summerize, for structural studies and interaction studies of the triplet ACPs we 
expressed and purified the triplet ACP as well as individual domains in high amounts and purity. 
For biochemical assays we could prepare ECH1, ECH2 as well as Cur Hal. For ECH2 and Cur 
Hal conditions were found in which NMR titration and fluorescence anisotropy were performed 
to investigate the interaction with ACPI. Discussion 
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8.2 Segmental  labeling 
We demonstrated a novel scheme for three fragment ligation by using only one robust split 
DnaE intein without any refolding steps. The use of only well characterized NpuDnaE intein for 
three-fragment ligation was of practical advantage for obtaining higher yields. From 2 L in vivo 
reaction giving H6-Smt3-NpuIntC15-ACPII-ACPIII and 1 L H6-Smt3-ACPI-NpuIntN∆C15 we 
obtained 1.7 mg final ACPI-[
15N]ACPII-ACPIII (7.2.7). Following the same protocol we produced 
ACPI-ACPII-[
15N]ACPIII and [
15N]ACPI-ACPII-ACPIII. The three fragment ligation was the only way 
to distinguish the different domains in ACPI-ACPII-ACPIII (Fig. 57), as a consequence allowing 
us to proceed in investigating the structural effect of the ACP repetion. Three fragment ligation 
is an excellent tool to investigate inter-domain NOEs for example by applying 3D 
13C-edited/
15N-separated NOESY-HSQC experiments to a [
15N]ACPI-[
13C]ACPII-ACPIII protein 
sample. In our case no inter-domain NOEs were observed. Of course the absence of NOEs 
itself do not exclude interactions between the domains but NMR titration experiments of ACPI 
with ACPII-ACPII did also not confirm any interaction between the domains (7.3). This taken 
together with the comparison of the chemical shifts of ACPI alone and in the triplet proves that 
the domains behave independent of each other (compare 7.3). In fact the inter-domain linkers 
are 30 aas long and unstructured as presented in Fig. 60, even if the linker would be α-helical 
this would still make a interdomain distance of 48 Ǻ. The NOE effect is sensitive to distances 
<5 Ǻ. 
The investigation of apoE3 is an example in which two fragment segmental labeling 
brought the break through for structure determination of this 299 aas long multi-domain protein. 
The full length backbone assignment was only possible due to segmental labeling [203, 204]. 
However for apoE3 NOE assignment was impossible due to severe peak overlap, only the 
application of segmental labeling, by preparing a sample in which the NT-domain was 
2H(99%)/
15N-labeled, whereas the CT-domain was only 
15N-labeled or 
13C/
15N-labeled allowed 
to distinguish NOEs by applying 3-D 
15N-edited NOESY experiments [205]. Another example for 
applying expressed protein ligation (EPL) to obtain interdomain NOEs is the study of the 40 kDa 
hHR23a protein with the purpose of studying the interaction between the N-terminal UBL 
domain and the C-terminal UBA and XPC domains [206, 207]. There, similar to us no inter-
domain NOEs were detected. But different to us, chemical shift perturbation analysis of 
individually expressed domains were performed and confirmed an interaction of the UBL 
domain with the UBA domain [206]. The authors suggested that its structure is not rigidly locked 
into one conformation, which would explain the lack of inter-domain NOEs.  
These examples show how powerful segmental labeling is especially for obtaining NOEs 
for multi-domain proteins for structure calculations, like in case of apoE3. The herein developed 
three fragment ligation is a tool to investigate the domain-domain interaction and the structure of 
even more complex proteins.  Discussion 
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In the studies of the triplet ACP (ACPI,II,III) we can exclude short range interactions 
between the domains, nevertheless based on our data, we can not exclude that there might be 
long range interactions between the ACPs. To exclude this, paramagnetic relaxation 
enhancement (PRE) experiments were performed which allow to measure distances up to 15 Ǻ 
[208, 209]. Unfortunately an evaluation of these PRE effects was for ACPI-ACPII-ACPIII not 
possible (data not shown). The high overlap of the peaks made it impossible to evaluate the 
decrease of intensity. To overcome this problem it might be interesting to attach a spin label to a 
segmentally labeled sample. In theory, this approach would solve the overlay problem. One 
drawback is that segmentally labeled proteins contain one cysteine; this is present in the flexible 
ligation site. Preferentially the spin label should be attached in rigid regions. To overcome this, 
one idea was to attach the spin label to the cofactor CoA and to load it then on one domain prior 
to the in vitro step of segmental labeling protocol. The drawback is, that the in vitro step was 
usually performed for 13 hours in reducing environment which has a strong impact on the spin 
label. It has been shown, for example, that nitroxide spin labels are reduced in reducing 
conditions, 1 mM DTT for example reduces spin labels after 3 hrs to 70% and after 48 hrs to 6% 
of its original activity, TCEP in contrast is less aggressive, 1 mM TCEP reduces spin labels after 
3 hrs to 86% and after 48 hrs to 53% of its original activity [210]. To sum up, results from PRE 
experiments would be of interest but these experiments were not interpretable for ACPI-ACPII-
ACPIII in the way performed. 
Our actual three fragment ligation protocol consists of an in vivo step and an in vitro step. 
A raising question was whether it is possible to further minimize the segmental labeling protocol 
by performing three fragment ligation in “one pot” (7.2.5). In theorie the “one pot” approach 
could be performed in vivo as well as in vitro. Both have pros and cons. As for the in vitro “one 
pot” approach two ligation steps required for three-fragment ligation can be performed in “one 
pot” by two orthogonal inteins, which could be convenient. However, considering the increased 
number of components that will be present in the “one pot” reaction, the purification steps by the 
“one pot” approach might be more labour-intensive as at least two spliced inteins, possible 
residual precursors, and by- products such as cleaved products have to be removed [140, 141]. 
In contrast, our stepwise approach with the combination of in vivo and in vitro ligation could 
simplify the purification step particularly when the ligation efficiency is very high.  
As for in vivo approach, a splicing system that would allow NMR spectroscopists to carry 
out three way ligations within E. coli in a “one pot” reaction would indeed provide advantages – 
but also disadvantages. Such a one pot system could in principle be constructed in two different 
ways: The first one uses three different plasmids with three different promoters and three 
different antibiotics (as presented in 7.2.5). In this system one would have to change from an 
unlabeled to a labeled and back to an unlabeled media, thus extending the expression time by 
additional ~4 hrs. This long expression time combined with the different antibiotics and further Discussion 
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stress from washing steps could easily reduce the overall yield of protein – if the bacteria would 
be able to survive and produce protein at all. For our “one pot” trial we co-expressed all proteins 
at the same time, only two of three proteins could be expressed (Fig. 52). This reveals that 
indeed three plasmids with three different antibiotics means at least in our case too much stress 
for the E. coli cells (7.2.5). To prevent the cells from this stress in a alternative approach one 
would place the DNA for the two unlabeled domains on one plasmid and thus reduce the 
number of plasmids, orthogonal promoters and antibiotics down to two. In this way the 
expression time will be reduced back to 8-9 hrs with only one media exchange and washing 
step as we used it in our current protocol. One major problem, however, would be the very high 
concentration of expressed proteins that would have to be stored before the splicing reaction 
could occur during the last phase of the expression protocol. This requirement could easily lead 
to intracellular aggregation, in particular for proteins that are not very soluble. We had to use 
additional solubility enhancement tags already in our two component in vivo ligation system with 
the ACPs (7.2.4). Finally, to obtain inter-domain contact information, NMR spectroscopists use 
NOE measurements between a 
15N- and a 
13C-labeled domain. In our ACPI-ACPII-ACPIII system 
we have produced for this purpose a sample with the ACPI domain 
15N labeled and the ACPII 
domain 
13C labeled while the ACPIII domain was unlabeled as initially mentioned (7.3.1). Such a 
labeling scheme could again only be realized with the three plasmid system and by changing 
the media twice. Overall, we believe, while conceptually and for some “easy” model systems a 
“one pot” reaction would be nice, the protocol that is presented here is more practical, more 
robust and also more flexible. 
Taken together we demonstrated a novel scheme for three fragment ligation by using only 
one robust split DnaE intein without any refolding steps. The use of only well characterized 
NpuDnaE intein for three-fragment ligation was of practical advantage for obtaining higher 
yields. This new strategy can be generally applicable to segmental isotopic labeling of an 
arbitrary region in many other multidomain proteins for NMR spectroscopic studies. This simple 
and robust scheme for a central-fragment labeling could become a valuable tool for elucidating 
structure–function relationships of a domain or a region in intact proteins by NMR spectroscopy. 
8.3  The ACP domains 
Taken together we show in 7.3.1 that the linker region is unstructured and that the ACP 
domains behave independent from each other in ACPI-ACPII-ACPIII as well as in the dimerized 
form of ACPI-ACPII-ACPIII -Cd. We can conclude that the structure of one representative ACP 
domain correspends with the structure of the other ACP domains, isolated as well as in the full 
length construct. The interaction between Cur Hal and ACP domains can be therefore as well 
studied using one representing ACP domain of the triplet, for example ACPI. 
Analysis of the NMR spectra showed that the apo to holo conversion of ACPI is 
accompanied by CSPs. The amino acids surrounding the active site Ser1989 show the Discussion 
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strongest perturbations between the apo and holo forms, including amino acids at the 
N-terminus of helix II and  on helix III (all >0.05 ppm CSP) (Fig. 62). In addition 
15N-NOESY-
HSQCs for apo and holo ACPI were measured, however, comparison of the NOE pattern of 
amino acids undergoing strong chemical shift perturbations revealed no differences between 
both states excluding major conformational changes upon formation of the holo state. This is a 
further example- in addition to the FAS ACP of Bacillus subtillis [34], FAS ACP of Escherichia 
Coli  [35] and the ACP of Type II FAS Mycobacterium tuberculosis [36]- of an ACP which 
contradicts the conformational switching model which has been proposed for enzymatic 
regulation for PCPs [7], the act ACP [33], the ACP from frenolicin [41] or the ACP from 
Plasmodium falciparum (PfACP) [43]. 
To calculate the structure of HMG-ACPI we combined the restraints obtained for holo-
ACPI with the NOE-based distance restraints obtained for HMG, assuming that no major 
conformational changes occur between the different states due to the negligeable CSP between 
both states (Fig. 64). Structural statistics for holo ACPI and HMG-ACPI are given in App. 9. 
X-ray studies of the E. coli FAS II ACP demonstrated that starting from C4 chain length the 
substrate and the 4’-Ppant arm is sequestered into a hydrophobic pocket [38]. These results 
were similar to the NMR findings for the PKS actinorhodin system of Streptomyces Coelicor 
[189]. For ACPI from Lyngbya majuscula HMG which has a chain length of C5 is clearly not 
bound to a hydrophobic cleft. Instead it seems to switch between solvent exposure and surface 
attachment (Fig. 68).  
8.4 Interactions  with  ACPI 
The curacin biosynthesis differs from other β-branching pathways in the introduction of a 
γ-chlorination step on (S)-3-hydroxy-3-methylglutaryl mediated by Cur Hal, a non-heme Fe(II), 
α-ketoglutarate-dependent enzyme [69]. Recent studies showed that the chlorination step takes 
place before the dehydration catalyzed by ECH1 and decarboxylation followed by ECH2 [69]. 
ECH1 and ECH2 are known to be promiscuous enzymes. ECH1 for example uses either S-HMG- 
or γ-Cl-(S)-HMG bound to one of the triplet ACPs or CurB or even in a CoA form [68, 70]. 
Interestingly ECH1 accepts CoA substrate but for example does not accept the substrate once 
presented by a PCP (as presented in 7.4.1). Also if direct interactions with the ACP are not 
important, the complete different surface charges of ACPs and PCPs most likely disrupt the 
interaction with ECH1. ECH1 was not soluble enough to further investigate these interactions 
using other biophysical methods, such as ITC, NMR or fluorescence anisotropy. Presumably 
ECH1 interacts with the 4’-Ppant arm as it has been the case for other enzymes that can 
effectively interact with multiple, noncognate ACP domains such as the DEBS TE domain [191]. 
In case of higher solubility of ECH1 this hypothesis could be checked by labeling isotopically the 
Ppant arm covalently linked to the ACP and performing titration experiments.  Discussion 
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For ECH2, the results from NMR titrations exclude direct interactions with the protein 
surface (7.4.2). We detected weak interactions (CSP~0.03 ppm) surrounding the 4’-Ppant arm 
but this negligeable effect was also observable for apo ACP and seems therefore to be more 
likely an artefact. It has been proposed that ECH1 and ECH2 , due to the fact that they accept 
CoA substrates, bind to the 4’-Ppant arm, thus facilitating rapid access and pairing of enzymes 
and substrates [70, 76]. Unfortunately this, at least for ECH2 could not be supported by 
fluorescence anisotropy measurements, there, unspecific presumably hydrophobic interactions 
was shown with Kd>200µM for HMG-ACPI and apo ACPI (App. 13).  
Overall our data demonstrate that Cur Hal interacts with ACPI specifically, suggesting that 
it will also interact with the other two ACPs of the triplet cluster. Cur Hal recognizes an interface 
consisting mainly of the N-terminus of helix II, the 4’-Ppant arm with its substrate, and helix III. 
Substrate attached to a different carrier domain (either the CurB ACP or TycB1 PCP) is not 
recognized by the halogenase and does not result in product formation (Fig. 72). The 
importance of presenting the substrate as part of an entire substrate-ACP complex is also 
demonstrated by the fact that the isolated HMG-CoA does not react with the halogenase.   
According to this example, we can clearly say that the carrier protein domain represents and 
architectural scaffold with an information-rich surface. It can be distinguished by distinct catalytic 
partner proteins such as Cur Hal. In contrast to this high specificity of the halogenase the other 
enzymes, e.g. ECH1 are less specific and also react with the isolated substrate-CoA. One 
reason for this specificity of the halogenase might be the radical mechanism used in the 
chlorination step which itself is most likely highly reactive and less specific. The requirement of 
presenting the correct substrate within a specific environment might be necessary to prevent 
unspecific chlorination or competitive hydroxylation reaction of substrates presented by other 
ACPs. Some of these ACPs, for example CurB, are stand alone ACPs, which can freely diffuse 
and should therefore be able to interact with the halogenase. Specificity of the other enzymes of 
the curacin assembly chain is most likely achieved in the standard way of specific substrate–
enzyme interaction, therefore not requiring a specific ACP surface.  
Surprisingly, it was not possible to directly detect the interactions between ACPI and Cur 
Hal by NMR spectroscopy. Weak or transient interactions are difficult to detect using the 
standard NMR experiments due to the low population of the complex. One technique for the 
investigation of such transient interactions that has recently emerged is paramagnetic relaxation 
enhancement (PRE) measurements. Spin labels attached to one partner result in relaxation 
enhancement in the other partner even when the contact time is short and the complex not 
stable [176, 177, 211]. Using this technique the unspecific interaction of a sequence specific 
transcription factor (the homeodomain of HOXD9) could be detected when sliding along the 
non-cognate DNA to its destination sequence [176]. In addition, it was possible to demonstrate 
the existence of an ensemble of transient, non-specific encounter complexes between the Discussion 
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amino-terminal domain of enzyme I and the phosphocarrier protein HPr [212]. We were 
interested in applying the same PRE experiments to our system, in order to visualize low 
populated states. Unfortunately no spin label was attached to Cur Hal because removing the 
WT cysteine (Cys19Ala) as well as the insertion of new cysteines into Cur Hal (Cys19Ser, 
Ile61Cys, His109Cys, Gly111Cys, Tyr274Cys, His168Cys and Ser178Cys) resulted in 
precipitation. 
Our results clearly show, that the individual triplet ACPs do not interact with each other. The 
question remains what is the biological function for this triplet assembly and its advantage over 
a single ACP copy. Previous studies have shown that the efficiency of the entire enzyme 
reaction increases with the number of ACP domains. It has been proposed that this clustering of 
ACP-linked substrates might result in binding of adjacent enzymes to corresponding substrates 
through non-specific enzyme–substrate interactions [76]. The reason for the existence of this 
triplet ACP cluster most likely has to be investigated at the level of the entire module by kinetic 
and enzymatic investigations and might be related to increasing the local concentration of 
potential substrate rather than distinct conformational and structural effects.  Outlook 
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9 Outlook 
The manipulation of PKS and/or NRPS systems for the production of new bioactive compounds 
is challenging. For this engineering approach it is important to decipher the degree of substrate 
promiscuity for enzymes that catalyze the transformation on the growing chain and even better 
to find ways to influence this substrate specificity. Additionally, it is important to understand the 
specificities of domain-domain or protein-domain interaction that occur during the biosynthesis.  
Almost all substrate precursors or intermediates are presented by ACPs or PCPs during the 
biosynthesis. To unravel the “rules” for recognition of these ACP or PCP domains is a major 
goal. Research in the past tried to identify the “rules” for recognition by structure determination 
using NMR or X-ray. Many insights could be obtained, especially in combination with 
biochemical approaches also using rational site-directed mutagenesis.  
In this work we showed that Cur Hal recognizes an interface consisting mainly of the N-
terminus of helix II, the 4’-Ppant arm with its substrate and helix III. The ACP represents an 
architectural scaffold with an information-rich surface and can be distinguished by Hal from 
other ACPs. Former publications support these findings by identifying amino acids surrounding 
the active site Ser and helix II as crucial for recognition leading to the name “recognition helix” 
[21, 45, 48-50, 54, 55]. We showed that helix III is essential for ACPI and Cur Hal interaction. In 
other systems helix III is involved in conformational switches for example in the NRPS PCP 
(TycB3) [7] or the ACP from frenolicin [41] and the ACP from Plasmodium falciparum (PfACP) 
[43]. It has been demonstrated that helix III is recognized during interactions for example 
between the aryl carrier protein ArcP (EntB) and the elongation modul EntF ([213, 214]). Taken 
together ACPs seem to share the same overall recognition hot spots. Furthermore not only helix 
II can be declared to be a “recognition helix”, but helix III as well. It is now of interest to 
transform the knowledge accumulated from previous structural and biochemical investigations 
into novel engineering approaches, for example mutating a non cognate ACP (e.g CurB) to an 
ACP of native-like recognition by Cur Hal. 
A further aspect which requires ongoing research is the dynamics of the NRPS and PKS 
systems. At present, publications about ACPs and PCPs are divided into two fields, with some 
ACPs/PCPs displaying conformational switches between apo and holo [41, 43, 213, 214] while 
others do not [34-36]. Certainly, dynamics and different conformations might play an important 
role in the recognition process and therefore the investigation of dynamics of PCPs and ACPs 
should be a goal of future research. In the past ACPs/ PCPs have been isolated from the full 
length protein for structural studies; interactions which natively take place in cis  were 
investigated in trans. Segmental labeling proved to be a valuable tool for investigating domain-
domain interactions in the native environment. It would be of great interest for the future 
research to study NRPS and PKS domains in their native environment focussing not only on 
interaction sites but also considering the importance and role of dynamics. References 
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11 Appendix 
11.1  Calibration curve for the Ferene S iron content determination  
 
App. 1: Calibration curve for the Ferene S iron content determination. Iron amounts were varied between 0 and 
20 nmol and measured versus Ferene S solution without added iron. 
11.2 Vector map: petM-60 from EMBL 
 
App. 2: petM- 60 vector from EMBL  
 The vector map was obtained from  
http://www.embl.de/pepcore/pepcore_services/cloning/choice_vector/ecoli/embl/) 
11.3 Open reading frame (ORF) of Ub-KS (CurC) in modified petM-60 
 
App. 3: Open reading frame (ORF) of Ub-KS (CurC) in modified petM-60 
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11.4 Open reading frame (ORF) of PolyN-TEV-KS (CurC) in modified pMAL-c2x 
 
App. 4: Open reading frame (ORF) of the MBP-PolyN-His6-TEV-KS (CurC) construct. The backbone of the 
vector is identical to pMAL-c2x 
11.5 Sequence alignment of different KS-AT didomains 
 
DEBS3           --------------------MELES-------------DPIAIVSMACRLPGGVNTPQRL 27 
DEBS5           MSGDNGMTEEKLRRYLKRTVTELDSVTARLREVEHRAGEPIAIVGMACRFPGDVDSPESF 60 
CurA            -----------------FSTAQLEN--------------GVAIIGMACRFPGDADSPQQY 29 
huFAS           -------------------------------------MEEVVIAGMSGKLP-ESENLQEF 22 
                                                        :.* .*: ::*   :. :   
 
DEBS3           WELLREGGETLSGFPTDRGWDLARLHHPDPDNPGTSYVDKGGFLDDAAGFDAEFFGVSPR 87 
DEBS5           WEFVSGGGDAIAEAPADRGWE------PDPD------ARLGGMLAAAGDFDAGFFGISPR 108 
CurA            WSLLHDGIDGITEVPPTR-WDIEQYYHPEKNQPGKIANRYGGFLTEVDKFEPDFFRISAR 88 
huFAS           WDNLIGGVDMVTD--DDRRWKAGLYGLPRRS----------GKLKDLSRFDASFFGVHPK 70 
                *. :  * : ::     * *.      *  .          * *     *:. ** : .: 
 
DEBS3           EAAAMDPQQRLLLETSWELVENAGIDPHSLRGTATGVFLGVAKFGYG-EDTAAAEDVEG- 145 
DEBS5           EALAMDPQQRIMLEISWEALERAGHDPVSLRGSATGVFTGVGTVDYGPRPDEAPDEVLG- 167 
CurA            EALYMDPQQRLLLEEHWKALEDAGINPESLSGTETGIFVGIAFHDYERLQDKYYQEQDLN 148 
huFAS           QAHTMDPQLRLLLEVTYEAIVDGGINPDSLRGTHTGVWVGVSGSETSEALSRDPETLVG- 129 
                :*  **** *::**  :: :  .* :* ** *: **:: *:.            :      
 
DEBS3           -YSVTGVAPAVASGRISYTMGLEGPSISVDTACSSSLVALHLAVESLRKGESSMAVVGGA 204 
DEBS5           -YVGTGTASSVASGRVAYCLGLEGPAMTVDTACSSGLTALHLAMESLRRDECGLALAGGV 226 
CurA            IYFATGSSTAIGAGRLSYFFQLNGPSITVDTACSSSLSAVHLACQSIRNGECQLALASGV 208 
huFAS           -YSMVGCQRAMMANRLSFFFDFRGPSIALDTACSSSLMALQNAYQAIHSGQCPAAIVGGI 188 
                 *  .*   :: :.*::: : :.**::::******.* *:: * :::: .:.  *:..*  
 
DEBS3           AVMATPGVFVDFSRQRALAADGRSKAFGAGADGFGFSEGVTLVLLERLSEARRNGHEVLA 264 
DEBS5           TVMSSPGAFTEFRSQGGLAADGRCKPFSKAADGFGLAEGAGVLVLQRLSAARREGRPVLA 286 
CurA            NLLLSPELSISFSQAGMLSPDGRCKTFDAAANGYVRSEGCGVVVLKSLKQAIADNDRILA 268 
huFAS           NVLLKPNTSVQFLRLGMLSPEGTCKAFDTAGNGYCRSEGVVAVLLTKKSLARR----VYA 244 
                 :: .*    .*     *:.:* .*.*. ..:*:  :**   ::*   . *      : * 
 
DEBS3           VVRGSALNQDGASN-GLSAPSGPAQRRVIRQALESCGLEPGDVDAVEAHGTGTALGDPIE 323 
DEBS5           VLRGSAVNQDGASN-GLTAPSGPAQQRVIRRALENAGVRAGDVDYVEAHGTGTRLGDPIE 345 
CurA            VVRGTAINQDGASN-GLTAPNQSAQEAVLKRALSVAGVSANQISYVEAHGTGTSLGDPVE 327 
huFAS           TILNAGTNTDGFKEQGVTFPSGDIQEQLIRSLYQSAGVAPESFEYIEAHGTGTKVGDPQE 304 
                .: .:. * ** .: *:: *.   *. :::   . .*: . ... :******* :*** * 
 
DEBS3           ANALLDTYGRDRDADRPLWLGSVKSNIGHTQAAAGVTGLLKVVLALRNGELPATLHVEEP 383 
DEBS5           VHALLSTYGAERDPDDPLWIGSVKSNIGHTQAAAGVAGVMKAVLALRHGEMPRTLHFDEP 405 
CurA            IKAIEAVYGKDRSADRPLMIGSVKTNIGHTEAAAGIAGLIKVVLSLQNQYIPPHLHWKQL 387 
huFAS           LNGITRALCATR--QEPLLIGSTKSNMGHPEPASGLAALAKVLLSLEHGLWAPNLHFHSP 362 
                 :.:  .    *  : ** :**.*:*:**.:.*:*::.: *.:*:*.:   .  ** ..  
 
DEBS3           TPHVDWSSGGVALLAGNQPWRR--GERTRRAAVSAFGISGTNAHVIVEEAPEREHRETTA 441 
DEBS5           SPQIEWDLGAVSVVSQARSWPA--GERPRRAGVSSFGISGTNAHVIVEEAPEADEPEPAP 463 
CurA            NPYISLAGIPGVIPTEGKVWEQYEGDETRVAALSSFGFSGTNSHAIVEEAPEGRSQEPGA 447 
huFAS           NPEIPALLDGRLQVVDQPLPVR-----GGNVGINSFGFGGSNVHIILRPNTQPPPAPAPH 417 
                .* :                          ..:.:**:.*:* * *:.  .:     .   
 
DEBS3           HDGR--------PVPLVVSARSTAALRAQAAQIAELLER-PDADLAGVGLGLATTRARHE 492 
DEBS5           DSG---------PVPLVLSGRDEQAMRAQAGRLADHLAREPRNSLRDTGFTLATRRSAWE 514 
CurA            RSQEPGARSQEPPYLLTVSAKKEQALKELVSSYQHHLETNPELELADVCYTANTGRADFN 507 
huFAS           ATL---------PRLLRASGRTPEAVQKLLEQGLRHSQDLAFLSMLNDIAAVPATAMPFR 468 
                            *  *  *.:   *::             .  .: .      :     . 
 
DEBS3           HRAAVVASTREEAVRGLREIAAGAATADAVVEGVTEVDG-RNVVFLFPGQGSQWAGMGAE 551 
DEBS5           HRAVVVG-DRDEALAGLRAVADG-RIADRTATGQARTR--RGVAMVFPGQGAQWQGMARD 570 
CurA            HRLAIIATNPQQLTNKLRQYQAGEEESGVFSGQLSHSSSPAKVAFLFTGQGSQYVQMGRQ 567 
huFAS           GYAVLGG---ERGGPEVQQVPAG----------------ERPLWFICSGMGTQWRGMGLS 509 
                   .: .   :.    ::    *                   : :: .* *:*:  *. . Appendix 
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DEBS3           LLSSSPVFAGKIRACDESMAPMQDWKVSDVLRQAP----GAPGLDRVDVVQPVLFAVMVS 607 
DEBS5           LLRESQVFADSIRDCERALAPHVDWSLTDLLS-------GARPLDRVDVVQPALFAVMVS 623 
CurA            LYQTQPVFRQVLDQCDELLRPYLERPLLEVLYPQDTPNSNSYLLDQTAYTQPTLFALEYA 627 
huFAS           LMR-LDRFRDSILRSDEAVKPFGLKVSQLLLS------TDESTFDDIVHSFVSLTAIQIG 562 
                *      *   :  .:. : *        :*        .   :*        * *:  . 
 
DEBS3           LAELWRSYGVEPAAVVGHSQGEIAAAHVAGALTLEDAAKLVVGRSRLMRSLSGE-GGMAA 666 
DEBS5           LAALWRSHGVEPAAVVGHSQGEIAAAHVAGALTLEDAAKLVAVRSRVLRRLGGQ-GGMAS 682 
CurA            LCKLWESWGIKPQVVMGHSVGEYVAATIAGVLSLEDGLKLIALRGRLMQQLPAG-GEMVS 686 
huFAS           LIDLLSCMGLRPDGIVGHSLGEVACGYADGCLSQEEAVLAAYWRGQCIKEAHLPPGAMAA 622 
                *  *  . *:.*  ::*** ** ...   * *: *:.      *.: ::      * *.: 
 
DEBS3           VALGEAAVRERLRPWQDRLSVAAVNGPRSVVVSGEPGALRAFSEDCAAEGIRVRDIDVD- 725 
DEBS5           FGLGTEQAAERIGRFAGALSIASVNGPRSVVVAGESGPLDELIAECEAEAHKARRIPVD- 741 
CurA            VMASKSQVKDAIANHTKQVTIAAINGPESVVISGEAGAIQAIVTKLESKLIKTKQLQVS- 745 
huFAS           VGLSWEECKQRCP---PGVVPACHNSKDTVTISGPQAPVFEFVEQLRKEGVFAKEVRTGG 679 
                .  .     :        :  *. *.  :*.::*  ..:  :  .   :   .: : ..  
 
DEBS3           YASHSPQIERVREELLETTGDIAPRPAR------VTFHSTVESRSMDGTELDARYWYRNL 779 
DEBS5           YASHSPQVESLREELLTELAGISPVSAD------VALYSTTTGQPIDTATMDTAYWYANL 795 
CurA            HAFHSPLMTPMLAEFAAVAQQITYHQPR------IPVISNVTGTIADKSIATADYWVEHV 799 
huFAS           MAFHSYFMEAIAPPLLQELKKVIREPKPRSARWLSTSIPEAQWHSSLARTSSAEYNVNNL 739 
                 * **  :  :   :      :             .  . .           : *   :: 
 
DEBS3           RETVRFADAVTRLAESGYDAFIEVSPHPVVVQAVEEAVEEADGAED-AVVVGSLHRDGGD 838 
DEBS5           REQVRFQDATRQLAEAGFDAFVEVSPHPVLTVGIEATLDSALPADAGACVVGTLRRDRGG 855 
CurA            VKPVRFVAGIKTLAEQDIRIFLEIGPKPVLLVMGRECLIGSK-----KIWLPSLRPGKPD 854 
huFAS           VSPVLFQEALWHVPEH--AVVLEIAPHALLQAVLKRGLKPSC-----TIIPLMKKDHRDN 792 
                 . * *  .   :.*     .:*:.*:.::    .  :  :             :    . 
 
DEBS3           LSAFLRSMATAHVSGVDIRWDVALPGAAP-------FALPTYPFQRKRYWLQPAAPAAAS 891 
DEBS5           LADFHTALGEAYAQGVEVDWSPAFADARP-------VELPVYPFQRQRYWLPIPTGGRAR 908 
CurA            WLQMLQSLGQLYVQGVKVDWLGFYPDDAPQK-----VVLPTYPWQRKRYWISDLQQYKNK 909 
huFAS           LEFFLAGIGRLHLSGIDANPNALFPPVEFPAPRGTPLISPLIKWDHSLAWDVPAAEDFPN 852 
                   :  .:.  : .*:.       .           .  *   :::.  *           
 
DEBS3           DELAYRSSSVDKLAAALEHHHHHH----------------------------------- 915 
DEBS5           DE---------------DDDWRYQ----------------------------------- 917 
CurA            GK--------------------------------------------------------- 911 
huFAS           GSGSPSAAIYNIDTSSESPDHYLVDHTLDGRVLFPATGYLSIVWKTLARALGLGVEQLP 911 
 
App. 5: Sequence alignment of different KS- AT didomains. The sequence alignment of CurA KS-AT, DEBS3 KS-
AT, DEBS5 KS-AT, huFAS KS-AT didomain was performed using ClustalW. The beginning and end points of the 
domains are colored. KS in red and AT in yellow. 
11.6 Gelfiltration profile for some constructs of the Cur KS-AT didomain  
 
App. 6: Gelfiltration profile for some constructs of the Cur KS-AT didomain. All gelfiltrations were performed 
at 16°c on a superose 6 column. a) Overlay of gelfiltration profiles of MBP-KS, the proteinconcentration was 3 
mg/ml with 10 mM DTT (blue) and without DTT (red). DTT has no impact on aggregation. b) Overlay of gelfiltration 
profiles of MBP-AT-L at a concentration of 1.3 mg/ml with 10 mM DTT (red) and without DTT (blue) c) gelfiltration 
profile of AT. The peak at 17.55 and 17.5 ml in a) and b) is isolated MBP which was proven by MALDI-MS. 
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11.7 Open reading frame of His6-TEV-TycB1 PCP in pBH4 
 
App. 7: Open reading frame (ORF) of the His6-TEV-TycB1 PCP. The backbone of the vector is identical to pBH4 
 
11.8 TycB1 PCP 
 
 
 
 
 
 
 
App. 8: Assessment of the 
difference between the two 
populations of the TycB1 Protein. 
a) MALDI-MS spectra of the Protein 
from Fractions 18-22 in red b) 
MALDI-MS spectra of the Protein 
from Fractions 33-36 in black c) 
Overlay of two [
1H,
15N]-TROSY 
spectra recorded at 500 MHz. In red 
fraction 18-22 and in black fraction 
33-36. The red circle indicates two 
peaks which are not present in the 
smaller protein. 
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11.9 Structural statistics 
App. 9: Statistics derived from Cyana for the structure of holo and (S)-hydroxyl-methylglutaryl (HMG)-ACPI 
NMR restraints  Holo  HMG  Structural statistics  Holo  HMG 
Number of peaks      Restraint violations     
13C NOESY-HSQC  5260  5078  Max. Dihedral angle restraint violations (˚)  /  / 
15N NOESY-HSQC  1557  1557  Max. distance restraint violations (A)  0.12  0.21 
13C
Arom NOESY-HSQC  58  57  Cyana target function value (Å
2)  2.42  1.56 
Hydroxy-methyl-glutaryl           
  Intramolecular NOEs  -  86       
  Intermolecular NOEs  -  37       
 
Distance restraints 
    Precision for residues 1950-2033 
Total NOE  2866  2923  R.m.s.d to mean coordinates (Ǻ)    
  Short range |i-j|<=1  1307  1349  Heavy atoms  0.54 ± 0.06  1.01± 0.29 
  Medium-range 1<|i-j|<5  826  819  Backbone  0.24 ± 0.04  0.11± 0.02 
  Long range |i-j|>=5  734  755  Ramachandran plot staistics (%)    
Hydrogen bonds  -    most favored  88.6  87.1 
      additionally allowed  11.4  12.9 
Dihedral angle restraints      generously allowed  0  0 
Talos+ Φ/ Ψ  162  162  disallowed  0  0 
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11.10  Results of the optimization of the fluorescence labeling of ACPI 
 
 
 
 
 
 
 
 
App. 10:  Maldi-MS of fluoreszence labeled 
ACPI S10C at different conditions. For 
fluorescence labeleing: Protein was reduced 
with 0.5 mM TCEP at least two hoUrs on ice. 
Then 10 molar excess of fluorophore was 
added and the protein incubated for 1 hr at RT. 
Then the protein was purified via a PD10 
collumn. The reaction was performed in different 
buffer conditions leading to the following MS 
reults a) control ACPI S10C without fluorescin b) 
at pH 6 one fluorescin is attached c) pH 6.5 
mainly one fluorescin is attched and some 
fractions of the protein have a 2
nd fluorescin 
attached d) pH 7; one, two and three fluorescins 
are attached e) pH 7.5 one, mainly two and 
three fluorescins are attached. Appendix 
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11.11  Basis for the rational mutation of ACPI 
 
App. 11: Basis for the rational mutation of ACPI. The alignement of ACPI with ACP with complete other function 
indicates regions which are conserved between ACPs (cyan). The alignment between CurB and ACPI shows further 
amino acids which might be relevant for the general ACP stability (orange). Amino acids which are solvent exposed 
(calculated with Get Area) and therefore target for mutations are indicate in grey. On the top and bottom of the 
alignement are indicated the structural elements from the calculated ACPI structure and the modeled CurB structure. 
Arrows indicate the AA which underly CSP for the apo to holo switch with CSP > 0.05 ppm (black) or the holo to HMG 
conversion with CSP> 0.02 ppm (red). 
11.12  NMR titration of HMG-ACPI with ECH2 
 
 
 
 
 
 
 
 
App. 12: Titration of HMG-ACPI 
with ECH2. a) Overlay of different 
titration steps. HMG-ACPI is 
coloured in red, HMG-ACPI: ECH2 
1:1 in green and HMG-ACPI: ECH2 
1:4 in blue. The spectra match with 
high similarity. Two peaks which 
show the highest CSP are shown in 
the inlets b) G1992 and c) D1988. 
Both show a growing CSP with 
higher amount of ECH2 added. Appendix 
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11.13  Fluorescence anisotropy of ACPI with ECH2 
 
App. 13: Fluorescence anisotropy measurements of ACP with ECH2. Blot of the normalized anisotropy of HMG- 
ACPI S90C (black) and apo (red) both titrated with ECH2. In both cases no saturation was reached. The binding 
constants (247µM for apo ACPI and ECH2 and 209µM for HMG-ACPI and ECH2) were derived by fitting a one-site-
binding model present more likely unspecific hydrophobic interaction and no specific interaction for HMG-ACPI with 
ECH2.  
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11.14  Data for the activity test for different ACPI mutants and Cur Hal 
 Appendix 
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App. 15: Tricine gel of ACPI mutants. 1: WT- ACPI; 2: Q1958A, 
Q1963A, E1967A  ; 3: E1978P, D1979T, Q1980D 4:K1981S, 
V1982K, D19835K;5: D1988A; 6: I1990A; 7: V1993N,T1998M, 
T1999M; 8: Q2001E, T2002D, N2004S; 9: K2008P; 10: A2009R; 
11: T2010A; 12: Y2013A; 13: D2014A; 14: Y2015A; 15: L2019A,
App. 14: MALDI-MS for the activity test for the different mutants. In 
case product occurred the MW is marked in red. In case of e) f) j) 
corresponding to the mutants D1988A, I1990A and A2009R no clear 
peak is visible for a chlorination product. In these cases a dotted line 
according to the expected molecular weight of the products is set. The 
corresponding intensity was used for residual activity calculation, also 
when it derives from the Na adducts, to avoid underestimation of activity. Appendix 
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App. 16: CD melting curves of the mutants displaying a decrease in activity. 
 
 Acknowledgements 
  - 163 - 
Acknowledgements 
First of all, I like to thank Prof. Volker Dötsch for being an excellent supervisor, his scientific 
guidance and constant generous support during my PhD thesis. I gratefully acknowledge his 
open‐minded character and his support of new ideas. Paired with his enthusiasm about science, 
he generated an atmosphere of inspiration, which was of great benefit for my work. Most of all, I 
am grateful for the opportunity to spend a very inspiring time in Helsinki at the Institute of 
Biotechnology and got the chance to participate in several conference and the EMBO summer 
school. 
I want to especially thank Dr. Frank Löhr. He introduced me into the field of NMR, I am 
grateful for his patience, explanations and all the NMR measurements he performed for me. 
This was a highly productive collaboration which made my PhD thesis possible. 
I am much indebted to Dr. Hideo Iwai for welcoming me in his laboratory and for the 
constant support during my research stay in his group at the Institute of Biotechnology in 
Helsinki. The collaboration about segmental labeling was highly productive and I could highly 
benefit from his knowledge. In this context I want to thank as well Sesilja Aranko who was a 
helping hand in Hideo Iwai’s lab in Helsinki. Together with Jesper Oemig, both created a highly 
productive and enjoyable atmosphere in the lab. 
My ACPI project was based on a close collaboration with Prof. Dr. Peter Güntert and 
Daniel Gottstein. I would like to thank them for their cooperativeness and many fruitful 
discussions.  
Especially I am grateful to Prof. Dr. Clemens Glaubitz for introducing me into solid state 
NMR and for co-examining this thesis. I want to thank him for his support and helpful advice.  
Furthermore I wanna thank my students Nina Ripin, Christopher Hein, Irina Pader and 
Florian Sochor who contributed to this work during their diploma thesis or long term internships. 
For a productive teamwork in the lab and helpful discussions I would like to thank Sina Reckel, 
Robert Hänsel, Jan Heering and Gregor Deutsch as well as the rest of the Dötsch lab. I could 
benefit a lot from their knowledge. In addition I want to thank them and the rest of the Dötsch 
group for creating an enjoyable and friendly atmosphere in the lab.  
Further I am thankful to Robert Hänsel, Gregor Deutsch, Dr. Aisha Laguerre and 
Sebastian Kehrlößer for proof-reading this thesis. Also I would like to thank Birgit Schäfer, 
Manfred Strupf, Natalja Rogova and Sigrid Oguzer-Fachinger who are all responsible for the 
smooth flow in the lab. Together with all the other lab members they contributed significantly to 
a good working atmosphere. Many thanks also to my parents and family for their moral support 
throughout my education. I would like to thank my friends, my roommates and T7 for their 
encouragement and support outside the lab. I want to thank as well my fiancé Charbel for his 
encouragement and for being a delightful partner.  
  - 164 -  
  - 165 - 
 
Eidesstattliche Versicherung 
 
Ich erkläre hiermit an Eides Statt, dass ich die vorliegende Dissertation über „ Structural and 
functional characterization of the ACP triplet in the curacin cluster and its interaction partners “ 
selbstständig angefertigt und mich anderer Hilfsmittel als der in der Dissertation angegebenen 
nicht bedient habe. Alle Entlehnungen aus anderen Schriften sind mit Angabe der betreffenden 
Schrift gekennzeichnet. Ich erkläre weiterhin, dass ich mich bisher keiner Doktorprüfung 
unterzogen habe. 
 
 
 
 
Frankfurt, den 
 
         ___________________________________  
  - 166 - Alena Busche, Teichstraße 7, 60594 Frankfurt am Main 
Cellphone: 0049 (0)176- 20496644, Email: alenabusche@gmx.de 
  
Curiculum vitae 
 
Personal details 
Date of birth:   06. Decembre 1982 
Place of birth:  Oldenburg 
Nationality: German 
 
Education 
11/2007- 11/2011  Goethe University of Frankfurt      Frankfurt, Germany 
pHD at the Institute of Biophysical Chemistry 
Supervisor: Prof. Dr. V. Dötsch 
 
01/2007 – 09/2007  Harvard  Medical  School     Boston,  USA 
        Diploma thesis in the Department of Cell Biology,  
Supervisor: Prof. Dr. Frank McKeon 
 
09/2004 – 10/2007  École Superieure de Biotechnologie     Strasbourg, France 
Strasbourg (ESBS) 
        Master’s degree in Biotechnology 
        Grade: 15.07 (‘very good’) 
 
10/2002 – 07/2004  Leibnitz  University        Hanover,  Germany 
    Intermediate  examen  in  Chemistry 
    Grade:  1.0  (‘excellent’) 
 
09/1994 - 10/2002  Gymnasium Lehrte, grammar school    Lehrte, Germany 
        German university entrance level 
 
Professional experience 
Since 11/2007    University of Frankfurt, PhD      Frankfurt, Germany 
    Institute of biophysical chemistry, Prof. Dr. V. Dötsch 
Thesis: “Structural and functional characterization of the acyl carrier  
protein triplet in the curacin cluster and its interaction partners” 
 
11/2009-12/2009   University of Helsinki          Helsinki, Finland 
        Research stay at the Department of Biotechnology, Dr. H. Iwai 
        Collaboration on segemntal labeling 
 
01/2007– 10/2007  Harvard  Medical  School     Boston,  USA 
        Diploma thesis in the Department of Cell Biology, Prof. Dr. F. McKeon 
        Thesis: “Characterization of Astrotactin2 as p73 target” Alena Busche, Teichstraße 7, 60594 Frankfurt am Main 
Cellphone: 0049 (0)176- 20496644, Email: alenabusche@gmx.de 
  
 
 
06/2005 – 07/2005  University of Amsterdam       Amsterdam, Netherlands 
    Internship at Swamerdame Institute for Life Science (SILS), 
Dr. Remco Kort 
        Subject: Molecular Biology and Microbiology in Yeast 
 
09/2004 - 12/2006  University of Strasbourg       Strasbourg, France 
University  of  Basel     Basel,  Switzerland 
University of Freiburg      Freiburg, Germany 
University of Karlsruhe      Karlsruhe, Germany 
        Internships of two months each, in 
-  Plant-biotechnology in Freiburg (Germany) 
-  Microbiology in Basel (Switzerland) 
-  Bio-engineering in Karlsruhe (Germany) 
-  Cell biology in Strasbourg (France) 
Scholarships 
08/2011      Conference scholarship, “XXIVth International Conference on Magnetic  
Resonance in Biological Systems (ICRMBS)” 
01/2007 – 09/2007  Bourse d’Alsace 
01/2007 – 09/2007  City of Strasbourg “bourse jumelles” 
09/2005 – 09/2006  Baden Württemberg Fond 
09/2004 - 09/2005  Erasmus 
Additional Information 
Languages  German  (native) 
French (fluent) 
English (fluent) 
 
Hobbies:    Climbing   
Traveling (Europe, South-America, North-America, Lebanon, Australia) 
Diving 
List of publications 
Busche AE, Aranko AS, Talebzadeh-Farooji M, Bernhard F, Doetsch V, Iwai H: Segmental 
isotopic labeling of a central domain in a multidomain protein by protein trans-splicing using only 
one robust DnaE intein. Angewandte Chemie (International ed 2009, 48(33):6128-6131. 
 
Busche AE, Gottstein D, Hein C, Ripin N, Pader I, Gu L, Walsh CT, Sherman DH, Löhr F, 
Güntert P, Dötsch V: Characterization of the interaction between an ACP domain and a 
halogenase in the curacin A polyketide synthetase. submitted 
 
Structure of holo- ACP I  from Lyngbya majuscula, submitted     accession code: 2liu 
Structure of HMG- ACP I  from Lyngbya majuscula, submitted    accession code: 2liw 
 Alena Busche, Teichstraße 7, 60594 Frankfurt am Main 
Cellphone: 0049 (0)176- 20496644, Email: alenabusche@gmx.de 
  
 
Talks 
08/2010  XXIVth International Conference on Magnetic           Cairns, Australia 
Resonance in Biological Systems (ICRMBS) 
Talk: “Segmental Isotopic Labeling of a central domain in a multidomain Protein” 
Alena E.L. Busche, S.A. Aranko, F. Bernhard, V. Doetsch, H. Iwai 
 
04/2010  4th Center for Biomolecular Magnetic Resonance        Frankfurt, Germany 
(BMRZ)- Cluster of Excellence (CEF) symposium 
Chair: „Magnetic resonance on Biomolecular complexes” 
 
05/2008  2nd Center for Biomolecular Magnetic Resonance        Frankfurt, Germany 
(BMRZ)- Cluster of Excellence (CEF) symposium 
Talk: “Structural Dynamics of Peptidyl Carrier Domains in Nonribosomal Peptide S
 ynthetases  (NRPS)”   
Posters 
08/2010  Annual meeting of the European magnetic resonance       Frankfurt, Germany 
Community (Euromar) 
Poster:”Characterization of the interaction between an ACP domain and a 
halogenase in the curacin A polyketide synthetase” 
 
07/2009  VIII European Symposium of the Protein Society            Zuerich, Switzerland 
  Poster:“Segmental Isotopic Labeling of a central domain by protein trans-splicing” 
Alena E.L. Busche, S.A. Aranko, C. Hein, M. Talebzadeh-Faroji, F. Bernhard, A.  
Koglin, C. T. Walsh,V. Doetsch, H. Iwai 
 
08/2008  EMBO course on Multidimensional NMR in          Il Ciocco, Italy 
Structural Biology 
Poster: „Structural Dynamics of Peptidyl Carrier Domains in Nonribosomal Peptide 
Synthetases“  Alexander Koglin, Mehdi Talebzadeh, Alena Busche, Frank Löhr, 
Frank Bernhard, Gerhard Wagner, Christopher T. Walsh , Mohamed A. Marahiel 
and Volker Dötsch 
 